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General Introduction 11
BAckground
The maximum chance of a clinically recognised pregnancy given a menstrual cycle is 
only 10-15%, even when conditions are optimal. Increasing evidence points to implanta-
tion failure rather than conception failure as the reason for the relatively low fecundity 
observed in human species [Coulham 1991; Dickey et al., 1994; Macklon et al., 2002; 
Simpson et al., 1994; Wang et al., 2003; Wilcox et al., 1988]. The success of implantation 
and of the embryo-maternal interaction depends on a well vascularised, receptive endo-
metrium [Zygmunt et al., 2003]. The generation of receptive endometrium starts during 
the secretory phase of the menstrual cycle, continues throughout the first-trimester and 
includes decidualisation, angiogenesis, and immune cell invasion. [Bulmer et al., 1991; 
Giudice 1999; Lessey 2000; Salamonsen et al.,2002/2003; Smith 2000]. The invasion 
of immune cells is enormous: from 8% of total stromal cells during the menstrual cycle 
up to 30% during the first-trimester. [Bulmer et al.,1991]. Vascular adaptation includes 
(pseudo-) vasculogenesis, arterial remodelling, and angiogenesis, the formation of new 
vessels out of existing ones [Burton et al., 1999, Pijnenborg et al., 1983].
Disturbances in vascular development may play a role in the pathogenesis of pregnancy 
complications, such as miscarriage, pre-eclampsia, intrauterine growth restriction, and 
even during adulthood, i.e. cardiovascular disease [Barker et al., 1993; Torry et al., 2004; 
Vailhe et al., 1999; Vuorela et 2000; Zygmunt et al., 2003]. This thesis assessed the role 
of angiogenesis in cycling endometrium and during human implantation.
the inception of pregnAncy
endometrium
The uterine mucosa, or endometrium, goes through cyclic breakdown and regeneration 
throughout reproductive life. It is composed of two distinct layers; the functionalis layer, 
the upper two third layer which is shed and renewed monthly during reproductive life, 
and the basalis layer, the lower one third layer representing the germinal layer from 
which renewal occurs [Li et al., 1994].
The cyclical process is regulated by changes in circulating levels of oestradiol and proges-
terone. Morphologic alterations are particularly evident in the functionalis layer and only 
minimal in the basalis layer [Mutter, Ferenczy 2002]. After menstruation, the functionalis 
layer is regenerated by proliferation of endometrial glands, stromal and endothelial cells 
in response to oestradiol. This phase is called the proliferation phase and will last for 
approximately 14 days. Once the ovarian follicle has matured, ovulation occurs and this 
preludes the post ovulation period or secretory phase. Progesterone, mainly produced 
by the corpus luteum, will cause precisely controlled changes in the oestradiol -primed 
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endometrium in preparation for blastocyst implantation. For instance, the glands dis-
play increased lumen and change secrete production. In addition, the stromal compart-
ment becomes more prominent and is characterised by oedema, invasion of leucocytes, 
and cuffing of vessels. These morphological changes are known as pre-decidualisation 
and even occur in the absence of fertilisation [Aplin 2000; Lessey 2003]. When fertilisa-
tion fails, the corpus luteum degenerates and progesterone levels diminish. This causes 
breakdown and shedding of the functionalis layer during the menstrual phase [Li et al., 
1994; Mutter, Ferenczy 2002].
decidua
Additional decidualisation occurs in the presence of pregnancy and slowly converts se-
cretory endometrium into decidua. Several subtypes of decidua are described in the 
first-trimester. Decidual secretory endometrium (DSE) is only pre-decidualised and will 
develop into decidua parietalis (DP) under influence of pregnancy-induced hormones, 
i.e. progesterone, oestradiol and hCG. Decidua basalis (DB) will arise in the additional 
presence of the extravillous trophoblast (EVT, Figure 1).
The additional decidualisation results in further tissue remodelling, increased vascu-
lar permeability, oedema, proliferation and differentiation of stromal cells, invasion of 
leukocytes, and vascular remodelling [Aplin 2000; Salamonsen et al., 2003]. Stromal 
cells transform from small spindle-shaped cells into large decidual round cells and dis-
play an increased production of secreted proteins and extra cellular matrix proteins. 
This may function in facilitating migration of EVTs towards spiral arteries [King 2000; 
Trundley,Moffett 2004]. Epithelial glands decrease in density, generate smaller amounts 
of secrete and have a more silent appearance. Furthermore, arteries become extensively 
remodelled and the length and size increase because of proliferation of endothelial and 
elongation rather then conventional sprouting angiogenesis [King 2000; Trundley, Mof-
fett 2004].
implantation and trophoblast invasion
Implantation is only facilitated during the narrow window of 7 to 10 days after ovulation, 
the “implantation window” . Initiation of implantation is due to an active biochemical 
process that requires interaction between the implanting blastocyst and the endometrial 
epithelium [Aplin 2000]. A variety of different molecules, e.g. prostaglandins, proteases, 
cytokines and growth factors, secreted by human trophoblast as well as endometrial cells 
regulate this “crosstalk” and allow apposition, attachment and invasion of the blastocyst 
[Guidice 1999; Krussel et al., 2003; Nardo et al., 2003; Salamonsen 2002; van der Weiden 
et al., 1991]. Moreover, hCG production by the conceptus announces the presence of 
fertilisation to the maternal system [Reshef et al., 1990].
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Several days after fertilisation the embryo differentiates into a blastocyst, which contains 
an inner cell mass that will from the embryo and an outer trophectoderm that will be-
come placenta and chorion. Attachment of the blastocyst to the uterine wall triggers the 
differentiation of trophectoderm into two layers: an inner cytotrophoblast layer and an 
outer syncytiotrophoblast layer. After attachment, the cytotrophoblast proliferates into 
buds which protrude through the syncytium. These protruding cytotrophoblasts become 
either villous or extra-villous trophoblasts (EVT). The first covers the chorionic villi and 
interacts with maternal blood in the intervillous space thus providing an exchange bar-
rier between mother and foetus. The later invades into the decidua. Some EVT’s, called 
endovascular trophoblasts, migrate into maternal capillaries to replace the endothelium 
[Burrows et al., 1996; Norwitz et al., 2001; Red-Horse et al., 2004]. EVTs invade up to the 
myometrium; far enough to access a viable maternal blood supply but not so far that the 
mother is endangered.
immune cell invasion
Immune cells infiltrate post-ovulatory endometrium. In the absence of pregnancy their 
number declines during menstruation, whereas in the presence of fertilisation, their 
number increases up to the 20th week of gestation [van den Heuvel et al., 2005a]. In the 
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figure 1. Schematic representation of the different types of decidua in first-trimester pregnancy.
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first-trimester 30% of stromal cells are leucocytes; 75% of these leucocytes are uterine 
natural killer (uNK) cells and 10% are macrophages [Bulmer et al., 1991].
Migration of uterine natural killer (uNK) cells is thought to be regulated both directly and 
indirectly by hormones, via oestrogen receptor ERβ1 and via chemo-attractants produced 
by hormone-stimulated stromal cells [Henderson 2003; King et al.,1996]. Various growth 
factors and cytokines are expressed by uterine natural killer (uNK) cells, including angio-
genic factors and proteases [Al-Atrash et al., 2001; Albertsson et al., 2000; Hanna et al., 
2006; Lash et al., 2006; Li et al., 2001a].
Possible functions of uterine natural killer (uNK) cells include controlling the invasion 
of trophoblast cells, regulate vessel stability (via IFNγ), decidualisation of endometrium, 
induce EVT apoptosis, regulate angiogenesis and immunomodulation [Bulmer, Lash 
2005; Dosiou, Giudice 2005; Hanna et al., 2006; King et al., 1998; Quenby, Farquharson 
2006]. A correlation with failure of implantation is inconsistently described. Women 
with recurrent miscarriages were shown to have elevated numbers of uterine natural 
killer (uNK) cells in peri-implantation endometrium compared to controls [Clifford et 
al., 1999; Quenby et al., 1999; Tuckerman et al., 2007]. However, others have shown 
comparable numbers of uterine natural killer (uNK) cells in the same setting and in 
decidua of missed abortions compared to controls [Michimata et al., 2002; Shimada et 
al., 2004/2006].
Macrophages are immunosuppressive cells in human first-trimester decidua, probably 
mediated by prostaglandin E2 production [Parhar et al., 1989] and play a role in con-
trolling placenta growth. Their content of lysosomal enzymes could indicate phagocytic 
functions [Bulmer et al., 1988].
Miscarriage
Only 30-50% of conceptions result in the birth of a child. Most pregnancies fail even 
before the next menstrual date is due [Macklon et al., 2002; Rai, Regan 2006]. About 
10-15% of the recognised pregnancies end in a miscarriage, 90-95% of which will oc-
cur before foetal cardiac activity has been detected [Kavalier 2005; Wang et al., 2003]. 
Approximately half of all miscarriages will evacuate spontaneously as a spontaneous 
abortion. The other miscarriages remain in utero until noticed by ultra sound, the 
so-called missed abortions. Aetiological categories of miscarriages can be divided in 
embryo-related and maternal-related causes. The most likely cause of the first category 
are the chromosomal abnormalities. Maternal-related causes include uterine, endocri-
nological, immunological or thrombotic disorders [Coulham 1991; Kutteh 1999]. Few 
studies have addressed decidual and placental vascularisation in relation to miscarriage. 
Deficient villous vascularisation, differential decidual vascularisation, increased blood 
flow, and differential VEGF-A expression have been shown to be correlated with miscar-
riage [Greenwold et al., 2003; Jauniaux, Burton 2005; Lisman et al., 2004; Meegdes et 
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al., 1988; Vailhe et al., 1999; Vuorela et al., 2000]. Even abnormal uterine circulation in 
receptive phase of non-conception cycles has been shown in recurrent abortion patients 
[Habara et al., 2002].
Angiogenesis
general Angiogenesis
Under certain circumstances, the vascular network needs to adapt, expand and remodel 
to adjust to changing conditions. To that end, angiogenesis is induced. This process 
occurs only in few physiological conditions, i.e. the ovary, endometrium and placenta, 
and in various pathological conditions, such as tumour growth. Angiogenesis involves 
activation and proliferation of endothelial cells, degradation of their basal membrane, 
migration through the surrounding extracellular matrix (ECM), and finally stabilisation 
and maturation of vessels. Angiogenesis is a complex process, which is tightly regulated 
by angiogenic promoters and inhibitors. In quiescent tissue, promoters and inhibitors 
are in balance. During an episode of vessel growth, the balance tips in favour of the 
promoters.
endometrial angiogenesis
Uterine blood supply is facilitated by the uterine arteries, which give rise to arcuate and 
radial arteries supplying the basal layer of the endometrium. Endometrial angiogenesis 
is mandatory to support the reconstruction of the endometrium after menstruation and 
to provide a vascularised, receptive endometrium for implantation and placentation 
[Gargett, Rogers 2001; Weston, Rogers 2000].
Endometrial angiogenesis appears spatially and transiently regulated during the cycle. 
Endothelium in the superficial layer of the endometrium shows cyclical variation in pro-
liferation and angiogenic activity. However, due to the lack of correlation between vascu-
lar events, e.g. endothelial cell migration and proliferation, the timing of angiogenesis 
during the cycle remains unclear [Goodger, Rogers 1995]. Despite these reservations, 
previous studies have described the existence of three angiogenic episodes during the 
cycle.
The first episode occurs during the early proliferative phase representing post-menstrual 
repair; the second occurs during the late-proliferative phase under the influence of oe-
strogen; and the third during the secretory phase under the influence of progesterone 
[Ferenczy et al., 1979; Goodger, Rogers 1995; Maas et al., 2001; Rogers, Gargett 1998; 
Smith 2000]. However, no significant differences in endothelial cell proliferation were 
detected throughout the cycle [Goodger, Rogers 1994]. Furthermore, proliferating en-
dothelial cells were mainly present in existing vessels rather than in vascular sprouts. 
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These findings suggest that endometrial angiogenesis is a continuing process through-
out the cycle and that it proceeds by elongation and intussusceptions rather than by 
classical angiogenesis via sprout formation (Figure 2) [Gambino et al., 2002; Rogers, 
Gargett 1998].
Although the overall control of endometrial growth and regression is regulated primarily 
by oestrogen and progesterone, the role of sex steroids in endometrial angiogenesis is 
less clear. Several reports describe the expression of progesterone and oestrogen recep-
tors in endometrial cells, including endothelial cells, but their conclusions have not been 
decisive [Critchley et al., 2001; Iruela-Arispe et al., 1999; Krikun et al., 2005; Rey et al., 
1998]. The general idea is that oestradiol and progesterone are able to regulate endome-
trial angiogenesis probably both directly and indirectly via locally produced angiogenic 
factors [Bausero et al., 1998; Iruela-Arispe et al., 1999; Kapiteijn et al., 2001; Kayisli et al., 
2004; Perrot-Applanat et al., 2000; Salamonsen 1994; Shifren et al., 1996].
Overall, neither the timing of vascular growth during the menstrual cycle nor the mecha-
nisms by which endometrial vessels are formed are currently understood, thus placing 
major limitations on our understanding of how angiogenesis promoters and inhibitors 
may act in the endometrium [Rogers, Gargett 1998].
decidual angiogenesis
Successful pregnancy requires the development of a complex network that facilitates the 
maternal-foetal exchange. Human maternal vascular adaptation to implantation starts 
during the secretory phase and continues throughout the first-trimester. This process 
includes the induction of angiogenesis, vasculogenesis, vascular permeability, and arte-
rial remodelling [Burton et al., 1999; Pijnenborg et al., 1983; Smith 2000]. These complex 
processes involve various cell types, including immune cells and stromal fibroblasts, 
which locally regulate the expression of mitogenic and angiogenic growth factors and 
cytokines [Sherer, Abulafia 2001]. Furthermore, oestradiol, progesterone and hCG also 
play a role. For example, hCG produced by the blastocyst has been shown to be an 
angiogenic factor itself [Zygmunt et al., 2002].
Arterial remodelling involves swelling of endothelial cells, arterial dilatation and remod-
elling of the muscular walls. Regulation of arterial remodelling is poorly understood. 
Craven et al., described these modifications to be a maternal response to pregnancy, 
since this remodelling occurred independently of the presence of trophoblast invasion, 
[Craven et al., 1998]. In contrast, others have stated that the true physiological change, 
which involves medial necrosis and replacement with fibrinoid material, only occurs in 
the presence of interstitial trophoblast, thus in the deciduas basalis [Kam et al., 1999; 
Pijnenborg 1998]. In addition, veins appear to be remodelled as well during early preg-
nancy, resulting in dilatation and intravenous fibrin depositions in association with tro-
phoblasts [Craven et al., 2002].
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An important feature during vascular development in the first-trimester is the invasion 
of maternal vessels by endovascular trophoblasts. This invasion results in replacement 
of maternal endothelial cells and plugging of spiral arteries [Pijnenborg et al., 1983]. 
Partly because of these plugs, the maternal circulation to the placenta is restricted before 
the 8th week of pregnancy. Maternal blood flow will gradually extend over the next few 
weeks and by the 12th week blood flow to the inter-villous space is completely established 
[Burton et al., 1999; Jaffe, Woods 1993; Jauniaux et al., 2000]. Before the 10th week the 
uterine glands provide nutrition to the embryo. As a result, the human uteroplacental 
unit development takes place in a relatively low-oxygen environment during most of 
the first-trimester. Also a burst of oxidative stress occurs after establishment of mater-
nal circulation [Burton et al., 1999; Charnock-Jones et al., 2004; Jauniaux et al., 2000]. 
Moreover, the arterial plugging may protect the embryo from forceful maternal blood 
flows and oxygen overload [Burton et al., 1999; Jaffe, Woods 1993; Jauniaux et al., 2000; 
Kingdom, Kaufmann 1997].
Placental and uterine oxygen levels are spatially regulated as gestation progresses and 
regulate placental and decidual vascularisation by influencing the production of angio-
genic factors [Charnock-Jones et al., 2004; Jauniaux et al., 2000; Sharkey et al., 2000; 
Shore et al., 1997]. Several reports state that first-trimester is characterised by both 
vasculogenesis and branching angiogenesis, while the second-trimester mainly displays 
branching angiogenesis and the third-trimester non-branching angiogenesis and that 
these series of events are probably regulated by oxygen [Charnock-Jones et al., 2004; 
Geva et al., 2002].
The low resistance arteriolar system results in pouch-like vessels, which are unrespon-
sive to maternal vasomotor control. The lack of autoregulation of placental blood flow 
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Sprouting
Intussusception
Elongation
figure 2. Endometrial angiogenesis proceeds by elongation and intussusception rather than by classical 
sprout formation. Adapted from Rogers 1998. 
See colour figures supplement
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allows dramatic increase in blood supply required to serve the growing demands of 
the foetus [Brosens et al., 1967; Greiss et al., 1976]. Limitations of this blood supply 
may have adverse clinical effects, like intra uterine growth restriction and pre-eclampsia 
[Khong et al., 1986].
Angiogenic fActors
Vegf family
The best known group of angiogenic factors is the vascular endothelial growth factor 
(VEGF) family, which consists of five mammalian members: placental growth factor 
(PlGF) and VEGF-A, VEGF-B, VEGF-C, VEGF-D. VEGF-A and PlGF are the most interest-
ing factors of this family with regard to endometrium and decidua (Figure 3).
VEGF-A modulates the expression of many genes, enhances vascular permeability, in-
duces endothelial cell proliferation, regulates apoptosis and plays an important role in 
the regulation of angiogenesis [Ferrara 2004; Hoeben et al., 2004]. There are two recep-
tors for VEGF-A; VEGF-R1 (flt-1) and VEGF-R2 (KDR) (Figure 3). Binding of VEGF-A to 
KDR induces proliferation and migration of endothelial whereas binding to flt-1 causes 
migration but not proliferation. In this way, VEGF-A induced endothelial proliferation 
and apoptosis can be regulated by changes in endothelial expression levels of KDR and 
flt-1 [Hoeben et al., 2004].
Regulators of VEGF-A expression are the steroid hormones oestrogen and progesterone 
[Classen-Linke et al., 2000; Hyder,Stancel 1999; Perrot-Applanat et al., 2000]. Especially 
VEGF-A mRNA expression by endometrial carcinoma cell lines and stromal cells were 
found to be sensitive to steroidal stimulation [Charnock-Jones et al., 1993; Shifren et al., 
1996]. Another stimulator of VEGF expression is hypoxia [Ferrara 2004; Sharkey et al., 
2000].
VEGF-A expression has been studied recurrently in endometrium. Various splice variants 
were detected, namely VEGF
206
, VEGF
189,
 VEGF
183, 
VEGF
165
, VEGF
145
 and VEGF
121
, of which 
VEGF
165 , 
VEGF
145 
and VEGF
121 
are dominantly present in endometrium (Figure 3) [Krikun 
et al., 2004a; Sherer,Abulafia 2001]. Data regarding the cyclical expression of VEGF-A 
were not always in agreement [smith 1998]. Several reports describe an increased glan-
dular expression in the secretory phase and an increased stromal expression during the 
proliferative phase [Charnock-Jones et al., 1993; Moller et al., 2001; Shifren et al., 1996]. 
Others did not detect variations in epithelial or stromal VEGF expression or in VEGF-A 
secretion by endometrial explants throughout the cycle [Gargett et al., 1999; Sugino et 
al., 2002]. Strongest immunoreactivity of VEGF-A on endothelial cells was detected in 
late proliferative and secretory phases and correlated with the presence of KDR and flt-1 
[Bausero et al., 1998].
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KDR and flt-1 were mainly found in endometrial endothelial cells and KDR also in glands 
throughout the cycle [Krussel et al., 1999; Meduri et al., 2000; Moller et al., 2001; Sugino 
et al., 2002]. Although the abundant VEGF-A expression and the endothelial expression 
of VEGF-A receptors suggest a role in endometrial angiogenesis, the relation between 
VEGF, receptor activation and endothelial cell proliferation during the cycle is poorly 
understood.
Several studies have reported expression of VEGF-A and its receptors in early pregnancy 
decidua. Abundant levels of VEGF mRNA were detected at the site of implantation and 
lower levels elsewhere in the decidua [Clark et al., 1996; Sharkey et al., 1993]. VEGF-A, flt-1 
and KDR proteins have been detected in maternal decidual, epithelial and endothelial 
cells [Clark et al., 1996/1998a; Sharkey et al., 1993; Sugino et al., 2002]. VEGF-A proteins 
were also expressed by maternal macrophages, (syn)cytotrophoblast, and extravillous 
trophoblasts [Clark et al., 1996; Cooper et al., 1995; Jackson et al., 1994]. VEGF, via its 
receptor flt-1, appears to play an active role in trophoblast invasion and angiogenesis 
during human and rhesus monkey implantation [Ahmed et al., 1995; Clark et al., 1996; 
Cooper et al., 1995; Krikun et al., 2004a; Sharkey et al., 1993; Sengupta et al., 2007; 
Sugino et al., 2002; Torry,Torry 1997].
PlGF shares biochemical and functional features with VEGF and interacts with VEGFR-1 
(Flt-1). PlGF and VEGF-A have synergistic effects regarding angiogenesis, but PlGF-in-
duced vessels are more mature and stable than VEGF-induced vessels [Carmeliet et al., 
2001; Luttun et al., 2002]. In contrast with VEGF, low oxygen tension results in reduced 
PlGF expression in trophoblasts in vitro [Shore et al., 1997].
PlGF is abundantly expressed in human placenta, rising from the first-trimester to the 
late second-trimester and subsequently declining from 30 weeks of gestation to delivery 
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PlGF VEGF-A VEGF-B VEGF-C VEGF-D VEGF-E
figure 3. The VEGF family members and their receptors. Adapted from http://ethesis.helsinki.fi/ julkaisut/
mat/bioti/vk/jeltsch/14revie7.html.
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[Torry et al., 1998]. PlGF mRNA is expressed in villous and extra-villous trophoblast cells 
while the protein is detected in vascular endothelium of term placental tissue [Clark et 
al., 1998a; Jackson et al., 1994; Vuorela et al., 1997]. In addition, intense staining for 
PlGF antigens is detected in decidual stromal cells [Khalig et al., 1996]. The receptor 
of PlGF, flt-1, is expressed on endothelial cells, perivascular smooth muscle cells and 
(extravillous) trophoblast during pregnancy [Athanassiades, Lala 1998; Torry et al., 2004; 
Vuorela et al., 1997]. PlGF may, via flt-1, act as a regulator of decidual angiogenesis and 
an autocrine mediator of trophoblast function [Khalig et al., 1996; Sherer,Abulafia 2001; 
Torry et al., 2004].
Angiopoietin family
Angiopoietin-1 (Ang-1), Angiopoitein-2 (Ang-2) and their receptor TIE-2 are known for 
their involvement in angiogenesis. The two ligands bind with equal affinity to TIE-2 but 
have different functions. Ang-1maintains vessel integrity, decreases vascular permeabil-
ity and plays a role in endothelial and vascular maturation after VEGF-induced neovas-
cularisation [Geva,Jaffe 2000]. Transgenic overexpression of Ang-1 in mice results in the 
development of more complex vascular networks [Suri et al., 1998]. Ang-2 is a functional 
antagonist of Ang-1 and is only expressed at sites of vascular remodelling. Ang-2 leads 
to loosening of cell/cell interactions and allows access to angiogenic inducers like VEGF 
[Maisonpierre et al., 1997]. Co-expression of VEGF and Ang-2 induces angiogenesis and 
increased vascular permeability, but Ang-2 results in vascular regression in the absence 
of angiogenic signals [Asahara et al., 1998]. Hypoxia regulates both Ang-1 and Ang-2, i.e 
upregulates Ang-2 and destabilises Ang-1 [Geva,Jaffe 2000; Zhang et al., 2001].
Ang-1 is widely expressed in the adult, whereas Ang-2 is selectively expressed at sites of 
active angiogenesis, like the uterus and placenta [Maisonpierre et al., 1997]. In endome-
trium, both Ang-1 and Ang-2 were detected in glands, stromal cells, and endothelium 
[Hewett et al., 2002; Krikun et al., 2000]. A significant upregulation in the late secretory 
phase has been described for Ang-1, whereas Ang-2 and TIE-2 showed only minor varia-
tions during the cycle [Hirchenhain et al., 2003]. TIE-2 was mainly detected in endothe-
lium and glands and only small amounts were found in stromal cells [Hewett et al., 
2002; Krikun et al., 2000].
Ang-1 and -2 and TIE-2 are detected in human first-trimester decidua; TIE-2 mainly in 
maternal endothelial cells, endovascular trophoblasts, and (syn-) cytotrophoblasts and 
Ang-1 and -2 mainly in the latter. These findings suggest an additional role for angiopoi-
etins, besides their role in angiogenesis, in regulating trophoblast behaviour in the de-
velopment of uteroplacental circulation [Dunk et al., 2000; Goldman-Wohl et al., 2000; 
Zhou et al., 2003]. The angiopoietins are regulated as gestation progresses: Ang-2 is 
maximally present in the first-trimester and declines thereafter, whereas Ang-1 increases 
from first- to third-trimester. This suggests that Ang-2 is mainly involved in first-trimester 
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vasculogenesis and branching angiogenesis and Ang-1 in third-trimester non-branching 
angiogenesis [Geva et al., 2002]. An association of the angiopoietins with miscarriage 
has not been described but reduced endothelial TIE-2 expression has been linked to the 
occurrence of miscarriage [Vuorela et al., 2000].
periceLLuLAr proteAses
Proteolysis plays a pivotal role in the regulation of angiogenesis and placental develop-
ment [Heymans et al., 1999; Pepper 2001a/2001b; Salamonsen 1999; Solberg et al., 
2003; Stetler-Stevenson 1999]. Key players in pericellular proteolysis are the uPA/plasmi-
nogen system and the membrane-type matrix metalloproteinases (MT-MMPs) [Alfano et 
al., 2005; Kindzelskii et al., 2004; Koolwijk et al., 2001; Reuning et al., 2003].
upA/plasminogen system
The plasminogen activator (PA) system is based on the protease plasmin, which cleaves 
most ECM components. The circulating plasminogen is converted into the active 
protease plasmin by either tissue-type plasminogen activator (tPA) or urokinase-type 
plasminogen activator (uPA). tPA is mainly involved in clot dissolution, whereas uPA 
mediates pericellular proteolysis during cell migration, tissue remodelling and angio-
genesis [van Hinsbergh et al., 2006]. uPA binds a specific cell-surface receptor, uPAR, 
which restricts the uPA-activity to the cell environment and enables activation of plasmin 
directly on the cell surface.
The activity of uPA is regulated by at least two specific serine proteinase inhibitors, plas-
minogen activator inhibitor type-1 and -2 (PAI-1 and 2), of which PAI-1 is expressed on 
endothelium and PAI-2 on monocytes and trophoblasts [Spengers, Kluft 1987]. Further-
more, the presence of uPA is not only determined by the ability of the cells to produce 
uPA, but also by their content of uPAR, which binds and internalises uPA in complex with 
its inhibitor PAI-1 [Blasi, Carmeliet 2002; Kroon et al., 1999].
The role of uPA mediated plasminogen activation in cell migration has been studied 
for a variety of cells and for endothelial cells, leucocytes, and trophoblasts in particular 
[Blasi et al.,1987; Heymans et al., 1999; Hu et al., 1999; Pepper 2001a; Reuning et al., 
2003; Salamonsen et al., 2003]. The uPA expression is low in resting endothelial cells, 
whereas its expression is more abundant during angiogenesis and inflammation. This 
may explain the rich expression of uPA in endometrium endothelial cells [Koolwijk et al., 
2001]. Furthermore, also stromal cells contained uPA antigen, but glandular epithelium 
did not [Koolwijk et al., 2001]. Both uPA and uPAR expression has been detected in the 
invasive trophoblast cells, which indicates a role for uPA and uPAR play in trophoblast 
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invasion [Floridon et al., 1999; Hofmann et al.,1994; Hu et al., 1999; Multhaupt et al., 
1994; Pierleoni et al., 1998; Salamonsen 1999].
Membrane-type Matrix metalloproteinases
The matrix metalloproteinases are a still expanding family of zinc-requiring enzymes that 
play a role in matrix remodelling and cell-matrix interactions. The membrane-type MMPs 
consist of six proteolytic enzymes which are particularly suited to function in pericel-
lular proteolysis because of their membrane-associated localization [Hotary et al., 2000; 
Visse,Nagase 2003]. The MT-MMPs incorporated unique domains which anchor them 
into the cell membrane. Four MT-MMPs are transmembrane proteins, namely MT1-, 
MT2-, MT3- and MT5-MMP (MMP-14, -15, -16 and 24) and two are GPI-anchored, MT4- 
and MT6-MMP (MMP-17 and -25) [Visse,Nagase 2003]. We studied the transmembrane-
spanning MT-MMPs, MT1- (MMP-14), MT2- (MMP-15), MT3- (MMP-16) and MT5-MMP 
(MMP-24), since these MT-MMPs induce capillary tube formation and their GPI-an-
chored counterpart MT4- and MT6-MMP was unable to do so [Hotary et al., 2000].
MT1-MMP is the best known MT-MMP and is involved in degradation of ECM compo-
nents, cell migration, and generating bioavailability of growth factors [Collen et al., 2003; 
Galvez et al., 2001; Hiraoka et al., 1998]. MT1-MMP facilitates MMP activity by activation 
of pro-MMP-2 and pro-MMP-13. MT1-MMP has received considerable attention as being 
involved in tumour angiogenesis and has been shown to be able to induce angiogenesis 
[Hotary et al., 2000; Seiki,Yana 2003; Sounni et al., 2002]. MT2-MMP and MT3-MMP 
are also involved in cell migration and invasion. Furthermore, their overexpression in 
endothelial cells can induce capillary-tube formation, similar to MT1-MMP. MT1-, MT2- 
and MT3-MMP mRNA levels increase during tube formation in vitro [Hotary et al., 2000; 
Lafleur et al., 2002; Shofuda et al., 2001]. The function of MT5-MMP is less well studied. 
MT5-MMP has a gelatinolytic effect and influences axonal growth and embryonic brain 
development [Llano et al., 1999; Pei et al., 1999].
MMP activity is modulated by growth factors, cytokines, plasmin, steroid hormones and 
several activated MMPs [Visse,Nagase 2003]. Specific inhibitors are four tissue inhibitors 
of metalloproteinases (TIMPs) [Gomez et al., 1997; Greene et al., 1996]. TIMP-1 inhibits 
the activity of all MMPs except MT1-MMP. TIMP-2 acts specifically on MMP-2 and its 
expression usually follows that of MMP-2. TIMP-3 is anchored in the matrix and inhibits 
all MMPs, including MT1-MMP, and has additional properties of stimulating cell growth 
and inducing apoptosis [Will et al., 1996; Woessner 2001]. Finally, TIMP-4 functions in 
a more tissue specific manner as it is highly expressed in cardiac tissue [Greene et al., 
1996]. TIMP-1, -2 and -3 mRNA has been detected in humane endometrium, cytotro-
phoblasts and decidual endothelium and glandular epithelium during the first-trimester 
[Hurskainen et al., 1996; Maatta et al., 2000].
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Members of the MMP family are widely expressed in the cycling endometrium and their 
expression and activity are sensitive to regulation by cytokines and to downregulation 
by progesterone [Freitas et al., 1999; Lockwood et al., 1998; Salamonsen et al., 1997; 
Singer et al., 1999; Zhang et al., 2000]. Progesterone withdrawal during the late secretory 
phase leads to increased MMP levels, focal tissue degradation and menstrual bleeding 
[Lockwood et al., 1998; Salamonsen et al., 1997; Zhang et al., 2000; Zhang, Salamonsen 
2002]. The expression, regulation and function of MT-MMPs are studied in less detail. 
The expression of MT1-, MT2- and MT3-MMP mRNAs and proteins in endometrial tis-
sue has been described in various cycle phases [Chung et al., 2002; Goffin et al., 2003; 
Maatta et al., 2000; Nakano et al., 2001; Zhang et al., 2000]. Suggested functions of 
endometrial MT-MMPs include tissue remodelling during the proliferative phase and 
tissue degradation during menstruation [Curry,Osteen 2003]. The involvement of MT-
MMPs in regulating endometrial angiogenesis is not clear, although the expression of 
MT2-MMP, and to a lesser extent of MT1-MMP, has been described in endometrium 
endothelium in vivo [Maatta et al., 2000; Zhang et al., 2000].
With regard to MT-MMPs in decidua, only MT1- and MT2-MMP have been studied. MT1- 
and MT2-MMP RNA and protein expression are described in decidual extracts, stromal 
cells, and the extra-villous trophoblast [Bjorn et al., 1997/2000; Hurskainen et al., 1998; 
Nakano et al., 2001; Nawrocki et al., 1996]. These MT-MMPs are assumed to regulate 
trophoblast invasion during implantation. Whether migration of other cell types, e.g. 
immune and endothelial cells, is also regulated by MT-MMPs remains to be seen [Sala-
monsen 1999].
outLine of this thesis
The principal aim of this thesis is to assess the role of angiogenesis in cycling endo-
metrium and during implantation. We hypothesise that angiogenesis is of paramount 
importance for the development of a receptive endometrium for implantation and there-
fore is a crucial contributor to the inception of pregnancy.
Pericellular proteolysis plays an important role in angiogenesis being required for en-
dothelial cell migration, invasion and tube formation. chapter 2 focussed on regulation 
of in vitro endometrial angiogenesis by pericellular proteases, in particular MT1-MMP 
and MT3-MMP because of their demonstrated role in angiogenesis. We studied the ex-
pression of proteases by human endometrial microvascular endothelial cells (hEMVEC) 
and their involvement in the formation of capillary tubes. In chapter 3 we analysed the 
presence of MT-MMPs in human endometrium in vivo and their correlation with endo-
metrial neovascularisation.
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These first chapters provide data on angiogenesis in human endometrium, whereas the 
following chapters focus on angiogenesis in human decidua. The involvement of cytok-
ines and angiogenic growth factors in angiogenesis during implantation was studied in 
chapter 4, by determining the effect of IVF supernatants on angiogenesis by endometrial 
endothelial cells (hEMVEC) in vitro.
The vascularisation pattern and the decidual expression of angiogenic factors in human 
first-trimester pregnancies in vivo are described in chapter 5. This study was performed 
in three first-trimester decidual tissues: decidual secretory endometrium (DSE), decidua 
basalis (DB) and parietalis (DP). By comparing these decidual tissues within subjects, 
the influences on vascularisation and expression of growth factors that occur indepen-
dently of trophoblast invasion, i.e. induced by pregnancy-induced hormones, were sepa-
rated from the influence of the invasive extra-villous trophoblast.
The presence of pericellular proteases in human first-trimester decidua was studied in 
chapter 6. This study, like chapter 5, is performed in three decidual tissues, DSE, DP and 
DB, to be able to determine the regulation of decidual pericellular proteases as well.
The hypothesized involvement of angiogenesis in the pathogenesis of a miscarriage was 
addressed in chapter 7. First-trimester decidual tissues of miscarriages and matched 
controls were compared with regard to vascularisation and the expression of angiogenic 
growth factors and proteases.
chapter 8, a preliminary report, focused on the role of first-trimester angiogenesis in the 
pathogenesis of pre-eclampsia and/or intrauterine growth retardation. First-trimester 
decidua obtained during chorion villous biopsies. The included patients were followed 
throughout their pregnancy to be able to relate the expression of the angiogenic fac-
tors to the pregnancy outcome, ie uncomplicated, pre-eclampsia or intrauterine growth 
retardation.
In chapter 9, results from above mentioned studies are discussed and future perspec-
tives presented. chapter 10 provides the conclusions of the thesis. Finally, chapter 11 
summarises all presented studies and provides a dutch summary.
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ABstrAct
objective: In the endometrium angiogenesis is a physiologically process, while in 
most adult tissues angiogenesis is initiated only during tissue-repair or pathologi-
cal conditions. Pericellular proteolysis plays an important role in angiogenesis being 
required for endothelial cell migration, invasion and tube formation.
Materials and Methods: We studied the expression of proteases by human endome-
trial microvascular endothelial cells (hEMVEC) and their involvement in the forma-
tion of capillary tubes and compared these requirements with those of foreskin MVEC 
(hFMVEC).
results: Inhibition of urokinase and matrix-metalloproteinase (MMPs) both reduced 
tube formation in a fibrin or fibrin/collagen matrix. hEMVEC expressed various MMPs 
mRNAs and proteins; in particular MMP-1, MMP-2, MT1-, MT3- and MT4-MMP. 
MT3- and MT4-MMP mRNA expressions were significantly higher in hEMVEC than in 
hFMVEC. Other MT-MMP mRNAs and MMP-9 were hardly detectable. Immunohis-
tochemistry confirmed the presence of MT3-MMP in endothelial cells of endometrial 
tissue. Overexpression of TIMP-1 or TIMP-3 by adenoviral transduction of hEMVEC 
reduced tube formation to the same extent, while only TIMP-3 was able to inhibit 
tube formation by hFMVEC. Tube formation by hEMVEC was partly inhibited by the 
presence of anti-MT-3-MMP IgG.
conclusion: Thus, in contrast to tube formation by hFMVEC, which largely depends 
on MT1-MMP, capillary-like tube formation by hEMVEC is, at least in part, regulated 
by MT3-MMP. 
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introduction
In the adult, angiogenesis plays a role in many pathological conditions, such as the 
growth of solid tumours, diabetic retinopathy, rheumatoid arthritis, and wound healing 
[Carmeliet 2003; Folkman 1995]. Physiological angiogenesis during adulthood is limited 
to the female reproductive tissue, namely in the ovary and endometrium. Endometrial 
angiogenesis plays a role in endometrial remodelling during the menstrual cycle and 
after conception during the implantation of the embryo [Bacharach et al., 1992; Rogers, 
Gargett 1998; Smith 1998].
Angiogenesis is initiated by a shift in the balance between pro-angiogenic and anti-
angiogenic factors [Bergers, Benjamin 2003; Hanahan, Folkman 1996]. It involves the 
sprouting of new capillary-like structures from existing vasculature and may involve 
blood-born cells that intussuscepts in and around the new vascular structures [Carmeliet 
2003]. These newly formed tubes are subsequently stabilised, often by interaction with 
pericytes. While the general mechanisms of angiogenesis are probably rather similar in 
various tissues, the individual players, such as growth factors, integrins and proteases, 
may vary in different tissues. Endothelial cells from different tissues and vessel types 
have specific properties [Chi et al., 2003], many of which are conserved in vitro [Chi et al., 
2003; Defilippi et al., 1991; Koolwijk et al., 2001]. We previously observed that different 
types of human microvascular endothelial cells (hMVEC) have different requirements 
for proliferation and capillary tube formation in vitro. While endometrial MVEC (hEM-
VEC) are highly sensitive to VEGF-A (VEGF) and form capillary tubules after exposure to 
VEGF-A, foreskin MVEC (hFMVEC) are more sensitive to bFGF and only form capillary 
tubes in a fibrin matrix after simultaneous exposure to bFGF or VEGF-A and the inflam-
matory cytokine TNFα [Koolwijk et al., 1996; Koolwijk et al., 2001; Kroon et al., 1999].
Among the various processes that regulate angiogenesis, the generation of proteolytic 
activity is thought to be pivotal in the regulation of cell migration and capillary tube 
formation [Pepper 2001a]. Key regulators of pericellular proteolysis and capillary-like 
tubule formation by endothelial cells are cell-bound urokinase-type plasminogen activa-
tor (u-PA) and plasmin as well as matrix metalloproteinases (MMPs) [Bacharach et al., 
1992; Collen et al., 2003; Galvez et al., 2001; Hotary et al., 2000; Koolwijjk et al., 1996; 
Kroon et al., 1999; Lafleur et al., 2002; Pepper 2001a; Pepper et al., 1990; Pepper 1997; 
Werb 1997]. Initial data on the formation of tubular structures by hEMVEC indicated 
that cell-bound u-PA and plasmin contribute to this process [Koolwijk et al., 2001]. In 
addition to the u-PA/plasmin cascade, the rapidly expanding family of MMPs [Visse, 
Nagase 2003] plays an important role in cell migration and invasion, and in angiogen-
esis in vivo [Heymans et al., 1999; Pepper et al., 1990; Stetler-Stevenson 1999]. MMPs 
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are widely expressed in the endometrium and play a role in tissue degradation and 
menstrual bleeding [Salamonsen, Woodley 1996]. Furthermore, a number of them are 
also detected during the proliferative and early secretory phase [Tabibzadeh, Babaknia 
1996], which suggests a role in endometrial remodelling and angiogenesis [Rodgers et 
al., 1994; Smith 2001]. However, the exact role of MMPs in endometrial angiogenesis in 
vivo and tube formation by hEMVEC in vitro is unknown.
Membrane-type MMPs (MT-MMPs) have been suggested to play a key role in angiogen-
esis, in addition to the gelatinases MMP-2 and -9 [Hotary et al., 2000/2002; Zhou et al., 
2000]. The membrane-associated localisation of membrane-type MMPs (MT-MMPs) 
makes this group of MMPs particularly suited to function in pericellular proteolysis 
[Hotary et al., 2000]. Six MT-MMPs have been described: four transmembrane proteins 
and two GPI-anchored ones. Recently, MT1-MMP (MMP-14) received considerable at-
tention as being involved in endothelial cell migration and invasion [Collen et al., 2003; 
Galvez et al., 2001; Lafleur et al., 2002]. MT1-MMP contributes to angiogenesis by its 
capacity to degrade ECM components, thereby promoting cell migration, invasion and 
possibly the bioavailability of growth factors. Furthermore, it activates pro-MMP-2 (via 
the TIMP-2-MT1-MMP complex), pro-MMP-13, and αvβ3-integrin, an important integrin 
in angiogenesis [Deryugina et al., 2000; Galvez et al., 2001; Sounni et al., 2002; Zhou et 
al., 2000]. MT1-MMP as well as MMP-2 are able to stimulate angiogenesis [Taraboletti 
et al., 2002; Vagnoni et al., 1998]. In hFMVEC, MT1-MMP becomes a key factor in capil-
lary tube formation when collagen is present in the fibrinous matrix [Collen et al., 2003; 
Hotary et al., 2000]. MT2-MMP (MMP-15) and MT3-MMP (MMP-16) are also involved 
in cell migration and invasion, depending on the cell type [Hotary et al., 2000; Shofuda 
et al., 2001]. Their overexpression in endothelial cells can induce capillary-tube forma-
tion, similar to MT1-MMP [Hotary et al., 2002]. MT1-MMP and MT2-MMP are present 
in endometrial tissue during various stages of the menstrual cycle; MT3-MMP mRNA is 
increased during the proliferative phase of the endometrium [Chung et al., 2002; Goffin 
et al., 2003; Maatta et al., 2000; Zhang et al., 2000]. It is generally believed that these 
MMPs also play a role in endometrial angiogenesis [Salamonsen 1994], but except for 
the expression and immunolocalisation of specific MMPs in endometrial tissue little 
information is available.
The activity of MMPs and MT-MMPs is regulated by activation of the pro-enzymes and 
by specific inhibitors, the tissue inhibitors of MMPs (TIMPs) and α-macroglobulins. The 
TIMP family consists of four members, which differ in expression patterns, regulation 
and ability to interact specifically with latent MMPs and members of the related metal-
loproteinases of the ADAMs and TACE group [Woessner 2001]. TIMP-1 is secreted as a 
soluble protein and has a general inhibiting activity on many MMPs, but does not inhibit 
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MT1-MMP. TIMP-3 is associated with the matrix components and has a similar inhibi-
tory spectrum, but also inhibits MT1-MMP [Li et al., 2001b]. Furthermore, TIMP-3 can 
induce apoptosis in various cell types [Woessner 2001].
In this study we report on the expression of MMPs and MT-MMPs by hEMVEC and 
the requirement of these proteases for capillary-like tube formation by these cells. By 
overexpressing TIMP-1 and TIMP-3 we could demonstrate that different MMPs act as key 
regulators for tube formation by hEMVEC and hFMVEC.
MAteriALs And Methods
Materials
Penicillin/streptomycin, L-glutamine and tissue culture medium 199 (M199) with 20 mM 
HEPES with or without phenol red were obtained from BioWhittaker (Verviers, Belgium). 
Newborn calf serum (NBCS) was obtained from Life Technologies (Grand Island, NY, 
USA). Human serum (HS), prepared from fresh blood from 10-20 healthy donors, was 
obtained from a local blood bank and was pooled and stored at 4°C. NBCS and HS were 
heat-inactivated before use. Pyrogen-free human serum albumin (HSA) was obtained 
from Sanquin (Amsterdam, The Netherlands). Tissue culture plastics and microtiter 
plates were obtained from Costar/Corning (Cambridge, MA, USA) and Falcon® (Becton 
Dickinson (BD) Biosciences), Bedford, MA, USA). A crude preparation of endothelial cell 
growth factor (ECGF) was prepared from bovine brain as described previously [Maciag 
et al., 1979]. Heparin and thrombin were obtained from Leo Pharmaceutics Products 
(Weesp, the Netherlands). Human fibrinogen was obtained from Chromogenics AB 
(Mölndal, Sweden). Dr. H. Metzner and Dr. G. Seeman (Aventis Behring GmbH, Mar-
burg, Germany) generously provided factor XIII. Fibronectin was a gift from Dr. J. van 
Mourik (CLB, Amsterdam, the Netherlands). Rat tail collagen type-I was obtained from 
BD Biosciences. Human recombinant vascular endothelial growth factor-A (VEGF-A) was 
obtained from RELIATech (Braunschweig, Germany) and tumour necrosis factor alpha 
(TNFα) was a gift from Dr. J. Travernier (Biogent, Gent, Belgium). Phorbol 12-myristate 
13-acetate (PMA) was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Adeno-
viral vectors containing LacZ, TIMP-1 and TIMP-3 were previously described [Lamfers et 
al., 2002; Quax et al., 2001; Van der Laan et al., 2003]. Aprotinin was purchased from Pen-
tapharm Ltd (Basel, Switzerland). BB94 (Batimastat) was a kind gift from Dr. E.A. Bone 
(British Biotech, Oxford, UK). Rabbit-anti-human polyclonal antibodies against u-PA, 
MMP-9 and MT1-MMP were produced in our laboratory. Mouse-anti-human monoclo-
nal antibody against MT3-MMP was obtained from Oncogene Research Products (Bos-
ton, USA). Human recombinant MT1-MMP (pro-domain-catalytic domain-hemopexin 
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domain) was purchased from Chemicon (Temecula, CA, USA) and recombinant pro-
MMP-9 from Invitek (Berlin, Germany). PBS/T concentrate was obtained from Organon 
Teknika (Boxtel, Holland). GAPDH control reagents (VIC-labeled) were purchased from 
Applied Biosystems (Nieuwerkerk a/d/ IJssel, the Netherlands). For western blotting, 
protease inhibitors from Roche Diagnostics (Almere, the Netherlands), Immobilon-P 
polyvinylidene fluoride transfer membranes from Milipore (Bedford, USA), skim milk 
powder from Merck (Amsterdam, the Netherlands), goat anti-β-actin antibody (sc-1615) 
and horseradish peroxidase-conjugated secondary antibodies from Santa Cruz (Heer-
hugowaard, The Netherlands) were used. The Super Signal West Dura Extended Dura-
tion Substrate (Pierce, St. Augustin, Germany) and the luminescent image workstation 
(Roche Diagnostics, Almere, the Netherlands) were used for visualisation.
cells
Human endometrial microvascular endothelial cells (hEMVEC) were isolated from en-
dometrial tissue from pre-menopausal women and cultured and characterised as previ-
ously described [Koolwijk et al., 2001]. hEMVEC were maintained in hEMVEC culture 
medium: M199 without phenol-red supplemented with 20 mM HEPES (pH 7.3), 20% 
HS, 10% NBCS, 150 µg/mL ECGF, 5 U/mL heparin, 100 IU/mL penicillin and 100 mg/
mL streptomycin. The cells were cultured on fibronectin-coated dishes under humidified 
5% CO
2
 / 95% air atmosphere. VEGF-A (5 ng/mL) was added to the culture medium of 
the primary isolates to facilitate the initial growth of the endothelial cells. Human fore-
skin microvascular endothelial cells (hFMVEC) were isolated, characterised and cultured 
as previously described [Defilippi et al., 1991; Van Hinsbergh et al., 1987].
in vitro capillary-like tube formation assay
Human fibrin matrices were prepared as described before [Koolwijk et al., 2001]. For the 
collagen gels, 7 volumes of rat tail collagen type-I (3 mg/mL) were mixed with 1 volume 
of 10x M199 with phenol red and 2 volumes of 2% (w/v) Na
2
CO
3
 (final pH 7.4). 300µl 
Aliquots were added to each well of a 48-wells plate and allowed to gelate at 37 °C in the 
absence of CO
2
.
Confluent hEMVEC were detached and seeded at a split ratio of 2:1 on top of the fibrin 
and/or collagen matrices and cultured for 24 h hEMVEC culture medium without ECGF 
and heparin. Subsequently, the endothelial cells were cultured with the mediators in-
dicated for 2 - 5 days. Invading cells and the formation of capillary-like structures of 
endothelial cells in the three-dimensional fibrin and/or collagen matrix were analysed by 
phase contrast microscopy. The total length of the structures formed was measured in 6 
randomly chosen microscopic fields (7.3 mm2/field) by computer-equipped Optimas im-
age analysis software (Bioscan, Demons, WA) connected to a monochrome CCD camera 
(MX5) and expressed as mm/cm2.
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gelatin zymography
Gelatinolytic activities of MMPs secreted by hEMVEC were analysed by zymography 
on gelatin-containing polyacrylamide gels as described [Birkedal-Hansen, Taylor 1982]. 
Using this technique both active and latent species can be visualised. Samples were 
applied to a 10% (w/v) acrylamide gel co-polymerised with 0.2% (w/v) gelatin. After 
electrophoresis the gels were washed three times for 10 min in 50 mmol/L Tris/HCl, pH 
8.0, containing 5 mmol/L CaCl
2
, 1µmol/L ZnCl
2
 and 2.5% (w/v) Triton X-100 to remove 
the SDS, followed by three washes of 5 min in 50 mmol/L Tris/HCl, pH 8.0, containing 
5 mmol/L CaCl
2
, 1µmol/L ZnCl
2
 and incubated overnight at 37ºC. The gels were stained 
with Coomassie Brilliant Blue R-250.
immunohistochemistry
Immunohistochemical staining of MT3-MMP was performed in paraffin-embedded 
sections of human endometrium using a monoclonal mouse anti-MT3-MMP and a 
horseradish peroxidase-conjugated horse-anti-mouse antibody. Specificity of the immu-
nohistochemical reaction was verified by omission of the first antibody as wells as using 
normal mouse serum in stead of the first antibody.
Western blotting
Total cellular extracts were prepared in the presence of protease inhibitors and applied 
to SDS-PAGE electrophoresis essentially as described [Kleemann et al., 2003]. After pro-
teins were blotted onto Immobilon-P polyvinylidene fluoride transfer membranes, the 
blots were blocked with 5% (w/v) skim milk powder diluted in 20 mM Tris (pH 7.4), 
55 mM NaCl, and 0.1% (v/v) Tween-20. Then, blots were incubated with a mouse anti-
MT3-MMP antibody or a goat anti-β-actin antibody followed by horseradish peroxidase-
conjugated secondary antibodies. All antibodies were diluted in 20 mM Tris (pH 7.4), 
55 mM NaCl, 0.1% (v/v) Tween-20, and 5% (w/w) bovine serum. The Super Signal West 
Dura Extended Duration Substrate and the luminescent image workstation were used 
for visualization.
rnA isolation and real-time rt-pcr
Total RNA from hEMVEC and hFMVEC was isolated as described previously [Chomc-
zynski, Sacchi 1987]. Reverse transcription (RT) was carried out in 20 µl volumes using 
random primers and a cDNA synthesis kit purchased from Promega. MMP and MT-
MMP expression was quantified using real-time PCR according to the Taqman method 
of Applied Biosystems (Perkin Elmer) using a forward and reverse primer combined 
with a specific (6-carboxy-fluorescein/6-carboxy-tetramethyl-rhodamine [FAM/TAMRA]) 
double-labelled probe. The following sequences were used for MT3-MMP (MMP-16): 
forward primer, 5’-GGC TCG TGT GGG AAA TGG TA-3’; reverse primer, 5’-AGA ACT CTT 
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CCC CCT CAA GTG-3’; and probe, 5’-ACA GCT GGC TCT ACT TCC CCA TGG C-3’. Primers 
and probes for MT1-MMP were described previously [Collen et al., 2003]. All data were 
controlled for quantity of RNA input by performing measurements on the endogenous 
reference gene GAPDH (VIC-labelled) as follows. For each RNA sample, a difference in Ct 
values (dCT) was calculated for each mRNA by taking the mean Ct of duplicate wells and 
subtracting the mean Ct of the duplicate wells for the reference RNA GAPDH measured 
in the same RT reaction. All RT reactions were carried out in quadruplicate. As positive 
controls were used: cDNA of human endometrial stromal cells for MMP-12, cDNA of 
HT1080 cells for MMP-13 and ds cDNA encoding for MMP-3, MMP-7 and MMP-8.
Adenoviral gene transfer of tiMp-1 and tiMp-3 to heMVec and hfMVec
Replication-deficient adenoviral vectors (E1-deleted, transcriptional control via the CMV 
promotor) encoding human TIMP-1 (AdTIMP-1), human TIMP-3 (AdTIMP-3) and a 
β-galactosidase-encoding adenoviral vector (AdLacZ), as a control, were used for the 
experiments [Quax et al., 2001]. Confluent hEMVEC and hFMVEC were washed twice 
with M199 supplemented with 0.1% HSA to remove human serum components, subse-
quently the hEMVEC were incubated with the adenoviral constructs in M199 containing 
0.1% HSA for 2 hours. After transduction the medium was replaced with hEMVEC culture 
medium without VEGF-A. 24 h later the cells were seeded on top of a three-dimensional 
fibrin/fibrin-collagen matrix and stimulation was started 6 h after seeding.
tiMp-1 eLisA and MMp Bioactivity Assays
TIMP-1 antigen was assayed by enzyme-linked immunosorbent assay (ELISA; R&D Sys-
tems, Oxon, United Kingdom). MT1-MMP and MMP-9 activity were determined by MMP 
activity assays (Biotrak; Amersham, Biosciences, Buckingshamshire, UK) as previously 
indicated [Collen et al., 2003; Hanemaaijer et al., 1998]. Selective TIMP-3 activity over 
that of TIMP-1 was assayed by determination of active MT1-MMP in extracts of hEM-
VEC transduced with AdLacZ, AdTIMP-1, and AdTIMP-3. Inhibition of MMP-9 activity 
by TIMP-1 and TIMP-3 was determined by addition of serial dilutions of 48-hour condi-
tioned media of hEMVEC transduced with AdLacZ, AdTIMP-1, and AdTIMP-3 to APMA 
activated recombinant pro-MMP-9.
statistics
Experiments were performed with duplicate wells and expressed as mean ± SEM. For 
statistical evaluation the analysis of variance (ANOVA) was used, followed by a modified 
t-test according to Bonferroni. Statistical significance was accepted at p<0.05.
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resuLts
capillary-like tube formation by heMVec is inhibited by collagen type-i
Three-dimensional matrices were prepared consisting of pure fibrin, collagen or mix-
tures of fibrin and collagen. As previously reported [Koolwijk et al., 2001], hEMVEC form 
spontaneously capillary-like tubular structures in a fibrin matrix, a process that is mark-
edly enhanced by VEGF-A (Figure 1A, C). When hEMVEC were seeded on top of matrices 
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figure 1. Capillary-like tube formation by hEMVEC in a fibrin or collagen matrix depends on u-PA and MMP 
activities.
hEMVEC were cultured on top of a three-dimensional fibrin matrix (A,C,D) or 50-50% fibrin/collagen-type-1 
matrix (B,E) and stimulated with VEGF-A (10 ng/mL). A and B: Micrographs taken after 4 days of culturing; 
insets in A and B show details of capillary-like structures. Bar = 300 µm, Bar insets = 100 µm. C: Cross 
section perpendicular to the matrix surface and stained with Hematoxylin-Phloxine-Safran (bar = 50 µm). 
D and E: hEMVEC were cultured with 10 ng/mL VEGF-A (control) in the absence or presence of polyclonal 
anti-u-PA (αuPA, 100 µg/mL), BB94 (5 µg/mL) or a combination of BB94 and anti-u-PA. After 3-5 days 
of culturing, mean tube length was measured by image analysis. The data in panel D are expressed as a 
percentage of VEGF-A-induced tube formation ± SEM of 6 independent experiments of duplicate wells 
performed with 3 different hEMVEC isolations. Panel E represents 3 experiments. ∗: P<0.05 vs. control, #: 
P<0.05 vs. αuPA.
(see colour figures supplement)
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containing 0-50% type-I collagen homogeneously mixed with fibrin, a concentration-
dependent decrease in the extent of tube formation was seen. In a mixed collagen-fibrin 
matrix (50/50), the decrease was 55±4% under basal conditions (n = 3, not shown) and 
53±2% in the presence of VEGF-A (Figure 1B) as compared to the tube formation in a 
pure fibrin matrix (Figure 1A). In a pure collagen type-I matrix, capillary-like structure 
formation by hEMVEC was hardly detectable, even after stimulation with VEGF-A (data 
not shown).
u-pA/plasmin and MMps are involved in tube formation by heMVec in matrices 
composed of fibrin and/or collagen
To establish the involvement of u-PA/plasmin and MMPs in the formation of capillary-
like structures by hEMVEC, u-PA-blocking antibodies, the plasmin inhibitor aprotinin, 
or the broadly acting metalloproteinase inhibitor BB94 were used (Figure 1C and D). 
The VEGF-A-enhanced tube formation in a fibrin matrix was reduced by 55±11% by u-PA-
blocking antibodies (Figure 1D), and by 54±7% by the plasmin inhibitor aprotinin (data 
not shown). In a matrix consisting of an equal mixture of fibrin and collagen anti-u-PA 
antibodies reduced tube formation only by 17±0% (Figure 1E). The inhibiting effect of 
BB94 was increased by adding collagen, since tube formation in pure fibrin was inhib-
ited by 31±5% and in collagen-fibrin matrices by 64±3%. An almost complete inhibition 
(84±6% and 82±2%, respectively) of capillary-like structure formation was seen after the 
simultaneous addition of BB94 and anti-u-PA antibodies (Figure 1D and E).
Table 1. mRNA level of MT-MMPs in hEMVEC and hFMVEC.
heMVec hfMVec
CT dCT CT dCT
transmembrane Mt-MMps Mt1-MMp  27.8 ± 0.4  9.0 ± 0.4  27.3± 0.9  8.4 ± 0.4
Mt2-MMp  33.7 ± 1.2  14.1 ± 1.2  35.9 ± 1.6  16.6 ± 1.3
Mt3-MMp  26.4 ± 0.2  7.4 ± 0.4*  27.8 ± 0.8  9.1 ± 0.4
Mt6-MMp  36.3 ± 1.0  17.7 ± 0.8  34.5 ± 1.1  15.6 ± 1.8
gpi-anchored Mt-MMps Mt4-MMp  26.9 ± 0.2  7.3 ± 0.3 *  30.2 ± 1.2  10.6 ± 0.6
Mt5-MMp  31.6 ± 0.3  12.8 ± 0.3  33.8 ± 2.1  14.6 ± 1.4
table 1. Analysis of MT-MMP mRNA expression in VEGF-A-stimulated hEMVEC and hFMVEC.
Confluent hEMVEC and hFMVEC were stimulated with 10 ng/ml VEGF-A for 24 hours. After stimulation, 
RNA was isolated and cDNA was synthesized as described. Real-time RT-PCR for MT-MMP/GAPDH pairs 
were performed as described and expressed as the number of cycles (CT ± SEM). The housekeeping gene 
GAPDH was used to correct for the total mRNA content of the samples. The dCT values were calculated as 
the difference in number of cycles required for the PCR reaction to enter logarithmic phase and expressed as 
dCT ± SEM. The gene expression of MT3-MMP and MT4-MMP mRNA was significantly higher in hEMVEC 
compared to the expression in hFMVEC (*: P<0.01). The gene expression of the other MT-MMPs was 
comparable between the two cell types.
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heMVec express various MMps and Mt-MMps
To study which MMPs are expressed by hEMVEC, real-time RT-PCR was used to as-
sess the expression and regulation of MMP mRNA levels in hEMVEC. Real-time RT-PCR 
revealed that hEMVEC express considerable amounts of MMP-1, MMP-2, MT1-MMP, 
MT3-MMP and MT4-MMP mRNAs (i.e. less than 30 cycles and dCT< 9) under basal as 
well as VEGF-A-stimulated conditions. The data for the MT-MMPs are given in Table 1. 
hFMVEC had a similar expression pattern as hEMVEC, except for MMP-1, which was 
poorly expressed by hFMVEC under basal conditions (not shown), and MT3-MMP 
and MT4-MMP, which were expressed to a higher degree in hEMVEC (Table 1). Under 
basal and VEGF-A-stimulated conditions hEMVEC expressed relatively small amounts of 
MMP-9 (mean CT = 35.3 ± 1.5 cycles; mean dCT 14.4 ± 1.3 (± SEM)) and MT2-, MT5- and 
MT6-MMP (Table 1). The MMP-9 mRNA expression increased markedly when the cells 
were stimulated with 10-8 M phorbol ester PMA (mean CT 27.4 ± 1.0; dCT 8.4 ± 0.7 (± 
SEM)). No mRNA of MMP-3, MMP-7, MMP-8, MMP-12 and MMP-13 was detected in  
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figure 2. hEMVEC express various MMPs and MT-MMPs.
hEMVEC were cultured for 24 h in M199 supplemented with 0.5% HSA (A) or 20% HS (B,C) and were 
not stimulated (control) or stimulated with TNFα (2.5 ng/mL), VEGF-A (10 ng/mL) or PMA (10-8 M), 
as indicated. A: Gelatin zymography of 24 h conditioned medium. (M = ladder) B: MT1-MMP activity in 
cell lysates (mean ± range of two experiments performed in duplicate wells with two different isolations; 
detection limit of the assay 0.2 ng/mL). C: Western blot of MT3-MMP in 24 h conditioned medium. D and 
E: Immunohistochemical analysis of MT3-MMP in endometrial tissue shows the presence of MT3-MMP in 
endothelial cells (D, arrows) and myometrium (E, stars).
(see colour figures supplement)
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hEMVEC. Positive controls resulted in abundant signals: ds cDNA encoding for MMP-3, 
MMP-7 and MMP-8, cDNA of human endometrial stromal cells for MMP-12 and cDNA 
of HT1080 cells for MMP-13.
The expression of active MMPs was confirmed by gelatin zymography and activity as-
says. Gelatin zymography of serum-free hEMVEC-conditioned media (24 h) showed ex-
pression of latent MMP-2 (72 kDa) and a 55kDa band that represents MMP-1 or MMP-3. 
From the mRNA data we assume that the 55kDa band represents MMP-1 rather than 
MMP-3. Stimulation with 10-8 M PMA induced MMP-9 (92kDa) protein synthesis and ac-
tivation of MMP-2 (64 kDa, Figure 2A). The presence of MT1-MMP was demonstrated by 
activity assay (Figure 2B). Both VEGF-A and TNFα exposure doubled the activity of MT1-
MMP, while phorbol ester caused a dramatic increase in MT1-MMP activity in hEMVEC 
(Figure 2B). The presence of MT3-MMP protein was confirmed by Western blotting. The 
production of MT3-MMP was not affected by TNFα and increased slightly after VEGF-A 
exposure (Figure 2C). MT3-MMP was detectable in endothelial cells of proliferative hu-
man endometrial tissue, as well as in endometrial epithelial cells and myometrial cells 
(Figure 2D and E).
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figure 3. hEMVEC overexpress active TIMP-1 and -3 after transduction.
Confluent hEMVEC were transduced with 1.25⋅106, 2.5⋅106 and 1.0⋅108 pfu/mL AdLacZ, AdTIMP-1 or 
AdTIMP-3 as described in the Methods section. After 2 h the medium was removed and the cells were 
incubated for 6 h with hEMVEC culture medium and incubated for 48 h in M199 supplemented with 0.5 % 
HSA, 10 ng/mL VEGF-A with or without PMA (10-8 M). A: TIMP-1 levels were determined in the hEMVEC-
conditioned medium by ELISA following the manufacturers’ descriptions. B: MT1-MMP activity in the 
lysates of PMA-stimulated transduced hEMVEC was inhibited by TIMP-3 and not by TIMP-1. MT1-MMP 
activity was analysed as indicated in the Methods section. C: MMP-9 activity was assayed using a bioactivity 
assay as described in the Material and Methods. The ability of TIMP-1 and TIMP-3 to inhibit MMP-9 activity 
was measured in 100- (black bars) and 25-fold (gray bars) dilutions of the conditioned media of hEMVEC 
overexpressing TIMP-1 orTIMP-3.
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figure 4. Both TIMP-1 and TIMP-3 inhibit capillary-like tube formation by hEMVEC.
hEMVEC were transduced with 2.5⋅106 pfu/mL AdLacZ, AdTIMP-1 and AdTIMP-3 and were cultured on 
top of a three-dimensional fibrin matrix or a fibrin-10% collagen matrix and stimulated with VEGF-A (10 
ng/mL) with or without BB94 (5 µg/mL). A: Phase contrast micrographs after 3 days of culturing showing 
tube formation in the fibrin matrix, Bar = 300 µm. B: Mean tube length was measured and expressed 
as a percentage of the tube formation by the AdLacZ-transduced cells ± SEM/range of 5 (fibrin matrix, 
black bars) and 2 (fibrin-collagen matrix, striped bars) independent experiments performed in duplicate 
wells. The mean tube length of the AdLacZ-transduced hEMVEC was 239±13 mm/cm2 on the fibrin-collagen 
matrix. ∗ P<0.03 vs LacZ transduced cells.
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Adenoviral gene transfer of both tiMp-1 and tiMp-3 impairs Vegf-A-induced tube 
formation by heMVec
As the general metalloproteinase inhibitor BB94 inhibited tube formation by hEMVEC, 
the effects of TIMP-1 and TIMP-3, two physiological tissue inhibitors of MMPs, on this 
process were studied. hEMVEC were infected for 2h with replication-deficient adeno-
viruses expressing human TIMP-1 (AdTIMP-1), TIMP-3 (AdTIMP-3) or a control LacZ 
(AdLacZ). Transduction of hEMVEC with AdTIMP-1 caused a concentration-dependent 
increase in TIMP-1 antigen production, while AdLacZ or AdTIMP-3 did not affect TIMP-1 
production (Figure 3A). To verify whether the overexpressed TIMP-1 and -3 were func-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2, Figure 5.  
hEMVEC hFMVEC
A
dL
ac
Z
A
dT
IM
P-
1
A
dT
IM
P-
3
A
dL
ac
Z+
B
B
94
A
dL
ac
Z
A
dT
IM
P-
1
A
dT
IM
P-
3
A
dL
ac
Z+
B
B
94
0
25
50
75
100
m
ea
n
tu
be
 le
ng
th
(%
 o
f c
on
tr
ol
)
∗ ∗ ∗
∗
∗
A
dL
ac
Z
A
dT
IM
P-
1
A
dT
IM
P-
3
A
dL
ac
Z+
B
B
94
A
dL
ac
Z
A
dT
IM
P-
1
A
dT
IM
P-
3
A
dL
ac
Z+
B
B
94
m
ea
n
tu
be
 le
ng
th
(%
 o
f c
on
tr
ol
)
figure 5. TIMP-1 inhibits capillary-like tube formation by hEMVEC but not by hFMVEC.
hEMVEC and hFMVEC were transduced with 2.5⋅106 pfu/mL AdLacZ, AdTIMP-1 and AdTIMP-3. Subsequently 
the cells were cultured on top of a three-dimensional fibrin matrix or a fibrin-10% collagen matrix in M199 
supplemented with 10% HS and 10% NBCS and stimulated with VEGF-A (10 ng/mL) and TNFα (10 ng/
mL) with or without BB94 (5 µg/mL). Mean tube length was measured and expressed as a percentage of 
the tube formation by the AdLacZ-transduced cells ± SEM/range of 2-3 independent experiments performed 
in duplicate or triplicate wells (fibrin matrix; black bars, fibrin-collagen matrix; striped bars). The mean tube 
length of the AdLacZ-transduced hEMVEC was 270±80 mm/cm2 on the fibrin matrix and 266±83 mm/cm2 
on the fibrin-collagen matrix, ∗ P<0.05 vs. LacZ transduced cells.
MT3-MMP in endometrial angiogenesis in vitro 39
tional and active, their effect on MT1-MMP and MMP-9 activity was analysed. In con-
trast to cell extracts of AdLacZ- or AdTIMP-1-transduced-hEMVEC, in which MT1-MMP 
remained active, MT1-MMP activity was completely inhibited in cell extracts of AdTIMP-
3-transduced-hEMVEC (Figure 3B). AdTIMP-1- and AdTIMP-3-transduced hEMVEC in-
hibited exogenous active MMP-9 comparably (Figure 3C).
Previous studies on HUVEC and hFMVEC have shown that TIMP-3 was a more potent 
inhibitor of capillary-tube formation than TIMP-1 [Lafleur et al., 2002; Collen et al., 2003; 
Anand-Apte et al., 1997]. Unexpectedly, in hEMVEC both TIMP-1 and TIMP-3 overexpres-
sion inhibited VEGF-A-induced tube formation, to an extent similar as BB94 (Figure 4A 
and B). This was found both in fibrin and in fibrin-collagen matrices (Figure 4B). No 
apparent cell death or morphological changes were observed either in the AdTIMP-1- or 
AdTIMP-3-transduced hEMVEC.
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figure 6. Inhibition of MT3-MMP reduces tube formation by hEMVEC.
hEMVEC were cultured on top of a three-dimensional fibrin matrix in M199 supplemented with 10% HS and 
10% NBCS. Cells were cultured under control conditions in the presence of 0.5 ng/ml VEGF or stimulated 
with VEGF-A (10 ng/mL), VEGF-A (10 ng/mL) and anti-FITC IgG (25 µg/ml), VEGF-A (10 ng/mL) and anti 
MT3-MMP IgG (αMT3; 25 µg/ml) or VEGF-A (10 ng/mL) and BB94 (5 µg/mL). Mean tube length was 
measured and expressed as the mean tube length ± SEM of 2 experiments performed in duplicate wells. ∗ 
P<0.02 vs VEGF stimulated hEMVEC; P<0.05 vs VEGF /anti-FITC IgG treated hEMVEC.
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comparison of the effect of tiMp-1 and tiMp-3 overexpression on tube formation by 
heMVec and hfMVec
Because of the lack of effect of TIMP-1 on tube formation in our previous experiments 
with VEGF/TNFα-stimulated hFMVEC [Collen et al., 2003], we compared the effects of 
TIMP-1 and TIMP-3 overexpression on capillary-like tube formation by hEMVEC and hF-
MVEC under identical culture conditions. Both cells types were grown on a fibrin-10% 
collagen matrix and stimulated by the simultaneous addition of VEGF and TNFα, which 
is required to induce tubules by hFMVEC [Koolwijk et al., 1996]. Like in VEGF-stimulated 
hEMVEC, both TIMP-1 and TIMP-3 reduced capillary-like tube formation in VEGF/TNFα-
stimulated hEMVEC to the same extent as BB94 (Figure 5, stripped bars). In contrast, 
only TIMP-3 inhibited tube formation by hFMVEC to a significant extent. Similar data 
were obtained with fibrin matrices (Figure 5, black bars). No significant cell detachment 
was observed in the AdTIMP-1- or AdTIMP-3-transduced hFMVEC and hEMVEC grown 
on the fibrin matrix, neither under control conditions nor in cells stimulated with VEGF/
TNFα or TNFα alone (data not shown). This indicates that the overexpression of TIMP-1 
or TIMP-3 did not induce a visible degree of apoptosis or cell death under our experi-
mental conditions.
inhibition of Mt3-MMp reduces tube formation by heMVec
The inhibition of tube formation by both TIMP-1 and TIMP-3 overexpression indicates 
that other MMPs than MT1-MMP play a role in the regulation of tube formation by 
hEMVEC. To obtain evidence for the involvement of MT3-MMP in the regulation of this 
process, tube formation by hEMVEC was induced in the presence of anti-MT3-MMP 
IgG. Inhibition of MT3-MMP significantly reduced the VEGF-A-enhanced capillary-like 
tube formation by hEMVEC, while non-specific anti-FITC IgG had no effect (Figure 6). 
The inhibition of VEGF-enhanced tube formation by MT3-MMP IgG was 48.8% of the 
inhibition achieved by BB94, suggesting that other metalloproteinases may contribute 
additionally.
discussion
The present study demonstrates that both the u-PA/plasmin system and MMPs contrib-
ute to the invasion and tubular structure formation by endothelial cells in a 3D-fibrin-
collagen matrix. Since TIMP-1 and TIMP-3 overexpression reduced capillary-like tube 
formation by hEMVEC to the same extent, not primarily MT1-MMP, but other MMPs play 
a regulatory role in this process in hEMVEC. Major MMPs expressed by hEMVEC were 
MMP-1, MMP-2, MT1-MMP (MMP-14) MT3-MMP (MMP-16) and MT4-MMP (MMP-17) 
under basal and VEGF-A-stimulated conditions. Our data suggest that MT3-MMP is in-
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volved in the regulation of tube formation by hEMVEC, because tube formation by hEM-
VEC was inhibited of by anti-MT3-MMP IgG in vitro, and MT3-MMP was encountered in 
endothelial cells of proliferative endometrium in vivo.
Our data on the expression of MMPs by hEMVEC in vitro are in agreement with observa-
tions reported from immunohistochemical studies in endometrial tissue sections. Frei-
tas et al found MMP-1, MMP-2, MMP-3 and MMP-9 in endometrial vascular structures, 
which might include endothelial cells, and MMP-2 was demonstrated in newly formed 
capillary strands [Freitas et al., 1999]. Skinner et al only found MMP-9 on endometrial 
endothelial cells after exposure to high progestagen levels [Skinner et al., 1999]. MT1-
MMP was detected at low levels on endothelial cells in proliferative and secretory endo-
metrium [Maatta et al., 2000; Zhang et al., 2000]. MT2-MMP was observed at a constant 
low level throughout the menstrual cycle [Goffin et al., 2003; Zhang et al., 2000]. In 
addition, TIMP-1, -2, and -3 were demonstrated in endometrial endothelial cells by in situ 
hybridization [Chegini et al., 2003; Maatta et al., 2000; Rodgers et al., 1994]. Recently 
Goffin et al also reported the presence of MMP-19 mRNA in endometrial tissue through-
out the cycle and the mRNAs of MMP-7, MMP-26 and MT3-MMP in this tissue during 
the proliferative phase of the cycle [Goffin et al., 2003]. However, no information on their 
expression by specific cells is currently available.
Within the large group of MMPs the MT-MMPs attract specific attention, because of 
their membrane localisation that enables them to regulate localised proteolytic activities 
directly at the cell-matrix interaction sites. Hotary et al showed that overexpression of the 
transmembrane MT1-MMP, MT2-MMP or MT3-MMP induced endothelial invasion and 
tube formation in fibrin, while the GPI-anchored MT4-MMP was unable to do so [Hotary 
et al., 2002]. MT1-MMP and MT3-MMP are involved in the migration and invasion of 
various mesenchymal cells, such as fibroblasts and smooth muscle cells [Vernon et al., 
1995], while other cells, such as leukocytes and trophoblasts, use MT2-MMP [Eeckhout, 
Vaes 1977; Giavazzi et al., 2000]. Our data indicate that human endometrial endothe-
lial cells in vitro largely express MT1-MMP, MT3-MMP and MT4-MMP while only tiny 
amounts of MT2- and MT5-MMP mRNA are present. Previous studies on HUVEC and 
hFMVEC indicated that invasion and tube formation of endothelial cells was inhibited by 
TIMP-3 and not by TIMP-1, suggesting that MT1-MMP has a dominant role among the 
MMPs in regulating endothelial migration and invasion [Anand-Apte et al., 1997; Collen 
et al., 2003; Galvez et al., 2001; Hotary et al., 2002; Lafleur et al., 2002]. The present data 
confirm our previous data for hFMVEC, but also show consistently that both TIMP-1 and 
TIMP-3 inhibited tube formation by endometrial endothelial cells. Although these data 
do not exclude the involvement of MT1-MMP, they strongly suggest that other MMPs 
than MT1-MMP may contribute more dominantly to endometrial angiogenesis.
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The expression of MMP-1 differed markedly between hEMVEC and hFMVEC, however 
a role for MMP-1 is less likely since MMP-1 is only upregulated in the secretory phase 
of the menstrual cycle and not in the proliferative phase. However, data on cell-specific 
expression are required before definitive conclusions can be drawn. A second possible 
explanation of the comparable inhibition by TIMP-1 and TIMP-3 might be that MT1-MMP 
acts in concert with other MMPs, in particular MMP-2, and that inhibition of the other 
MMPs is rate-limiting. However, the comparable expressions of MMP-2 and MT1-MMP 
in hEMVEC and hFMVEC do not favor this suggestion. Finally, a more likely candidate 
may be MT3-MMP, which like MT1-MMP can contribute potently to angiogenesis in a fi-
brinous matrix [Hotary et al., 2002]. The recent finding that the expression of MT3-MMP 
mRNA is elevated in endometrial tissue during the proliferative phase of the menstrual 
cycle suggests such a role [Goffin et al., 2003]. Furthermore, our data on the relative 
expressions of MT3-MMP mRNAs in hEMVEC and hFMVEC, the presence of MT3-MMP 
protein on endometrial endothelial cells and the inhibition of capillary tube formation by 
inhibiting MT3-MMP are strongly in favor of a contribution of MT3-MMP in capillary-like 
tube formation by hEMVEC.
To summarise, MMPs contribute to in vitro capillary tube formation by human endome-
trial endothelial cells. Whereas capillary tube formation by hFMVEC depends largely on 
MT1-MMP, the described data for hEMVEC suggest that other MMPs than MT1–MMP, 
in particular MT3-MMP, play an important role in tube formation by human endometrial 
endothelial cells.
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ABstrAct
objective: Endometrial angiogenesis is necessary for the formation of a vascularized 
receptive endometrium. Previously we described that membrane-type-3 metallopro-
teinase (MT3-MMP) is associated with endometrial capillary-like tube formation in 
vitro. However, the association of MT-MMPs with endometrial angiogenesis in vivo is 
unknown. Therefore, this study analysed the presence of MT-MMPs in human endo-
metrium and their correlation with endometrial neovascularisation. 
Materials & Methods: Expressions of the six MT-MMPs were determined in cultured 
human endometrial endothelial, epithelial and stromal cells by immunohistochem-
istry and RT-PCR. Vascularisation parameters and MT-MMP expressions in vivo were 
evaluated by immunohistochemistry in serial sections from human endometrium 
samples.
results: Mainly MT1-, MT2-, MT3- and MT4-MMP antigens were expressed in cultured 
endometrial endothelial cells. All MT-MMP antigens were expressed in various cell 
types of the endometrium, with decreased expression levels during the early secretory 
phase. Only MT2-, MT3- and MT4-MMP antigens were expressed by endothelial cells 
during the early-late proliferative and mid-late secretory phase. Strikingly, these phas-
es also showed elevated vascularisation parameters; elevated total vascular surface 
in proliferative phases, elevated number of vessels in proliferative and late secretory 
phases and increased luminal surface in the proliferative phases.
conclusions: All MT-MMP antigens are expressed in endometrium in a cycle-depen-
dent pattern. The vascular expression of MT2- MT3- and MT4-MMP correlated with 
angiogenic episodes of the cycle. Since MT2- and MT3-MMP are known to regulate 
capillary-like tube formation, these findings support earlier in vitro data on the regula-
tory role of MT3-MMP in endometrial angiogenesis. Additionally, MT2-MMP appears 
to be associated with endometrial neovascularisation as well.
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introduction
Angiogenesis, the sprouting of new capillaries from existing vasculature, is essential to 
support endometrial reconstruction after menstruation and to provide a vascularized, 
receptive endometrium for implantation. Endometrial angiogenesis occurs periodically 
at three separate episodes during each cycle; during the early proliferative phase repre-
senting post-menstrual repair, during the mid-proliferative phase under the influence of 
oestrogen and during the secretory phase under the influence of mainly progesterone 
[Ferenczy et al., 1979; Goodger, Rogers, 1995; Rogers, Gargett, 1998; Smith, 2001]. Most 
work to date concerning the regulation of endometrial angiogenesis has focused on ste-
roidal hormones and vascular endothelial growth factor (VEGF). The steroidal hormones 
regulate endometrial growth and probably also endometrial angiogenesis either directly 
or indirectly through locally produced factors like VEGF and proteases [Bausero et al., 
1998; Iruela-Arispe et al., 1999; Perrot-applanat et al., 2000; Shifren et al., 1996].
Angiogenesis is facilitated by proteolysis, since endothelial cells require proteolytic activ-
ity to be able to degrade their basal membrane, to migrate, and to invade the underlying 
extra-cellular matrix [Heymans et al., 1999; Pepper, 2001a; Stetler-Stevenson, 1999]. Key 
regulators of proteolysis belong to the family of matrix metalloproteinases (MMPs) and 
in particular to the subgroup of membrane-type matrix metalloproteinases (MT-MMPs). 
Their membrane-associated localisation makes them particularly suited to function-
ing in pericellular proteolysis [Hotary et al., 2000; Visse, Nagase 2003]. MT1-, MT2-, 
MT3- and MT5-MMPs are trans-membrane proteins, whereas MT4- and MT6-MMP are 
GPI-anchored. MT-MMPs are inhibited by tissue inhibitors of matrix metalloproteinases 
(TIMPs); TIMP-1 inhibits all MT-MMPs, except MT1-MMP, while TIMP-2 and -3 inhibit 
all MT-MMPs [Hernandez-Barrantes et al., 2002; Visse, Nagase 2003]. MT1-MMP is also 
inhibited by TIMP-4 [Bigg et al., 2001].
Previous reports showed that MT-MMPs play an important role in angiogenesis [Hotary 
et al., 2000/2002; Zhou et al., 2000]. MT1-MMP has received considerable attention as 
being involved in tumour angiogenesis [Seiki, Yana, 2003; Sounni et al., 2002]. Further-
more, MT1-, MT2- and MT3-MMP have been shown to be able to induce capillary-like 
tube formation in vitro [Collen et al., 2003; Galvez et al., 2001; Hiraoka et al., 1998; 
Hotary et al., 2000/2002; Lafleur et al., 2002]. Capillary formation by human foreskin 
microvascular endothelial cells is mediated by MT1-MMP [Collen et al., 2003; Plaisier et 
al., 2004]. However, we recently showed that capillary-like tube formation by human en-
dometrial microvascular endothelial cells (hEMVEC) is mediated by MT3-MMP, suggest-
ing that MT3-MMP may be a potential regulator of endometrial angiogenesis [Plaisier 
et al., 2004].
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Whether MT-MMPs are associated with endothelial cells during endometrial angiogene-
sis in vivo is not clear. Furthermore, also the role of MT-MMPs in endometrial receptivity 
and remodelling is still indistinct. Several MT-MMPs have been demonstrated in whole 
endometrial extracts at mRNA level [Chung et al., 2002; Goffin et al., 2003] and MT1- and 
MT2-MMP antigens have been demonstrated in various endometrial cell types [Määttä 
et al., 2000; Zhang et al., 2000]. However, little information is available regarding the 
expression of the six MT-MMPs in endothelium and their relationship to endometrial 
angiogenesis. Therefore this study aims to analyse the expression of MT-MMPs by endo-
metrial cells, including endothelium, to assess their endometrial expression during the 
menstrual cycle, and to correlate these findings to the angiogenic status of the cycling 
endometrium.
MAteriALs And Methods
collection of human endometrium samples
Endometrial samples were collected from 26 pre-menopausal and 5 post-menopausal 
women undergoing hysterectomy for benign gynecological pathologies (leiomyoma 
(n=23), uterine prolapse (n=1), dysmenorrhoea (n=1), menorrhagia (n=2)). Tissue was 
collected according to the guidelines of the Institutional Review Board and informed 
consent was obtained from each patient. None of the subjects had received steroid hor-
mone therapy, i.e. OAC, IUD or HRT, for at least three months prior to surgery. Total 
donors with an irregular cycle n=4; n=1 in EP, n=1 in LP, n=1 in ES, n=1 in LS. Endometrial 
tissue (0.5-1.0 grams) was scraped off the fundus uteri, using a surgical knife, immedi-
ately after surgery. When leiomyoma was present, tissue was obtained from the opposite 
site of the uterus. Tissue was either stored at 4°C or fixed in formaldehyde.
All pre-menopausal samples were dated by an independent pathologist using the endo-
metrial dating criteria of Noyes et al [Noyes et al., 1975]. The histological appearance of 
the endometrium was classified as menstrual (day 28-3; M; n=2), early proliferative (day 
4-10; EP; n=5), late proliferative (day 11-14; LP; n=7), early secretory (day 15-20; ES; n=6), 
and late secretory (day 21-28; LS; n=6) phase. Samples were excluded when containing 
endometritis, leiomyoma, adenomyosis or when dating was inconsistent with known 
last day of the menstrual cycle. The mean age of the pre-menopausal group was 42.4 
years (range 31-48) and of the post-menopausal group 59.7 years (range 57-63). Age, 
pre-operative diagnosis and menstrual irregularity were equally distributed among the 
groups M, EP, LP, ES, and LS.
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cell isolation and culture
Human endometrial microvascular endothelial cells (hEMVEC), epithelial (hEEC) and 
stromal (hESC) were isolated from pre-menopausal endometrium and cultured as previ-
ously described [Koolwijk et al., 2001]. Cells were extracted from minced tissue using 
0.2% collagenase and further separated using gravity sedimentation as follows. After 
setting for 5 minutes, the supernatant was separated from the epithelium-rich settled 
pellet. The heterogeneous supernatant, containing mainly stromal and endothelial cells, 
was further separated into hEMVEC and hESC by repeated selections with anti-CD31-
coated Dynabeads (Dynal Biotech, Oslo, Norway). The pellet was resuspended in M199 
with 10% new born calf serum (NBCS) and placed in culture dishes. During the fol-
lowing 15 minutes, remaining stromal and endothelial cells attached to the dish, while 
epithelial structures remained in the media. By transferring the media and repeating 
this, an epithelial cell culture was derived. Cells were characterised by morphology and 
immunohistochemical markers; hEMVEC were positive for CD31 and von Willebrand 
factor and negative for cytokeratin-8 and -18. hEEC were positive for cytokeratin-8 and 
-18, and hESC were negative for these markers.
hEMVEC were cultured in M199 with 20% human serum (HS), 10% NBCS, 37.5 µg/
ml endothelial cell growth factor (ECGF), 5 U/ml heparin, 100 IU/ml penicillin and 100 
mg/ml streptomycin. hESC and hEEC were cultured in M199 with 10% HS, 10% NBCS, 
75 µg/ml ECGF, 5 U/ml heparin, 100 IU/ml penicillin and 100 mg/ml streptomycin. 
The cells were cultured on fibronectin-coated dishes under humidified 5% CO
2
/95% air 
atmosphere. Human recombinant VEGF-A (5 ng/ml, RELIAtech, Germany) was added to 
the culture of primary isolates of endothelial cells to facilitate initial growth.
reverse transcription and real-time quantitative rt-pcr
Total RNA from cultured cells was isolated as described previously [Chomzynski, Sacchi 
1987). RNA quantity and quality were determined in a spectrophotometer (Nanodrop 
ND-1000, OD
260
/OD
280
 between 1.8 and 2.0) Reverse transcription was performed with 1 
µg total RNA, random primers and a cDNA synthesis kit (Promega Corporations, Madi-
son, USA).
RNA expression was quantified according to the Taqman real-time PCR method (Ap-
plied Biosystems, Perkin Elmer, Wellesley, USA) using primers combined with a specific 
(FAM/TAMRA) double-labelled probe. Sequences of the primers and probes used to 
detect MT-MMPs were described previously [Collen et al., 2003; Plaisier et al., 2004]. The 
endogenous reference gene GAPDH, (primers/VIC-labelled probe, Applied Biosystems, 
Foster City, USA) was used to correct for the total mRNA content of the samples. Other 
genes, β-actin and cyclophilin, were also used as reference genes and showed compa-
rable results (data not shown). The primer efficiencies were verified by determining a 
standard curve using serial dilutions of hESC cDNA. Primers were considered efficient 
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when the calculated efficiency ranged between 90%-110%. RT-PCR reactions for MT-
MMP/GAPDH pairs were performed in duplicate and expressed in cycle times (Ct), the 
number of cycles required for the PCR reaction to enter the logarithmic phase. dCt’s 
were calculated as the difference in Ct of the target gene and the reference gene GAPDH. 
Water and “-RT samples”, obtained by the omission of the RT-enzyme in the cDNA reac-
tion, were used as negative controls.
immunohistochemistry on cultured cells
Cultured cells were fixed for 10 minutes with cold 2% para-formaldehyde followed by 
1 minute with cold acetone. After three washes with PBS, the cells were incubated for 
15 minutes with 5% human serum and 5% goat serum in PBS to reduce aspecific bind-
ing. Subsequently, the cells were incubated with a first antibody overnight at 4°C. The 
following commercially available first antibodies were used: monoclonal mouse anti-
MT2-MMP, monoclonal mouse anti-MT3-MMP (162-22G5 and 117-10C6, Oncogene, San 
Diego, USA), polyclonal rabbit anti-MT4-MMP, polyclonal rabbit anti-MT5-MMP (M3684 
and M6684, Sigma, St Louis, USA) and polyclonal rabbit anti-von Willebrand Factor (A 
0082, Dakocytomation, Glostrup, Denmark). Anti-MT1-MMP antibodies were produced 
and characterised as previously described [Collen et al., 2003; Koolwijk et al., 1996; 
Plaisier et al., 2004; Van Boheemen et al., 1995] and polyclonal goat anti-MT6-MMP was 
a generous gift from W. English (Cambridge, UK). After three washes with PBS, the cells 
were incubated with a FITC-labelled secondary antibody for 1 hour at room temperature 
and finally washed three times with PBS. The DAPI (Vector laboratories, Burlingame, 
USA) was added and cells were mounted and evaluated using a Zeiss Axiovert 200 M 
inverted microscope. To detect lysosomes, a acidic organelle-selective probe was used, 
which accumulates in lysosomes and is linked to a fluorescence label. This Lysotracker 
Red DND-991µM (L-7528, Molecular Probes, Invitrogen, Breda, Netherlands) was added 
to unfixed cultured cells and visualised.
immunohistochemistry on paraffin sections
Tissue samples were processed into paraffin sections as previously described [Kroon 
et al., 1999]. Besides the above described first antibodies, monoclonal mouse CD34 
(QBend/10, Novocastra, Newcastle upon Tyne, UK) was also used on the tissue samples. 
Endogenous peroxidase was quenched with 3% H
2
O
2
/ methanol and aspecific binding 
was reduced by incubation with 5% bovine serum albumin. Antigen retrieval in trypsin 
was used for the detection of MT2- and MT4-MMP. Primary antibodies were applied 
overnight at 4°C followed by incubation with a biotinylated secondary antibody. Anti-
body binding was visualised using avidin-biotin and streptovidin-horseradish peroxidase 
conjugates. Sections were counterstained with Mayer’s hematoxylin. Specificity of the 
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reaction was verified by the omission of the first antibody or using mouse, goat or rabbit 
serum as first antibody.
evaluation of the vascularisation pattern
CD34-stained sections were used to scan six fields, randomly taken throughout the 
stained sections, at x100 magnification. CD34-positive vessels were counted and their 
luminal surface was measured using image analysis software (Qwin) developed by Leica 
Microsystems. The total vascular surface (mm2/mm2), the number of vessels per mm2 
and the luminal surface (µm2/vessel) were calculated using the same software.
evaluation of immunohistochemical staining
Immunostaining in all samples was evaluated, at 100x magnification, by calculating a 
staining index according to the following equation: proportion of stained cells x staining 
intensity. The proportion of stained cells was expressed as 0, 1, 2 or 3 (positive staining 
signal in 0%, <10%, 10-50% or >50% of cells, respectively) and intensity of staining as 1, 
2 or 3 (weak, moderate or strong staining, respectively). The minimum score was 0 and 
the maximum score was 9 [Nap et al., 2004]. The average of the scores of two indepen-
dent observers was used to calculate the mean staining index, which represents the pro-
tein expression per cell type, namely glandular epithelial cells, stromal cells, endothelial 
cells and perivascular smooth muscle cells (PSMCs). The inter-observer variability was 
4% for MT1-MMP, 14 % for MT2-MMP, 8 % for MT3-MMP, 10 % for MT4-MMP, 9 % 
for MT5-MMP and 5 % for MT6-MMP (mean variability 8%). Total mean staining indices 
(Total SI) were calculated as the sum of mean staining indices in each tissue sample and 
represent the total protein expression per tissue.
statistical analysis
The one-way analysis of variance (ANOVA) and the Bonferroni post hoc test were used to 
examine the MT-MMP expression levels in endometrial cells in vitro. The Kruskal-Wallis 
test, a non-parametrical test for more than two independent samples, was used to exam-
ine the differences between the stages of the menstrual cycle. Results were considered 
statistically significant when p<0.05 (SPSS, version 11.5).
resuLts
Vascularisation pattern in endometrium during the cycle
Analysis of the endometrial vascularisation parameters, using CD34-stained paraffin 
sections (Fig. 1A), showed that the total vascular surface was elevated in the late prolif-
erative phase, 0.05 mm2/mm2, compared to the other phases (p<0.01, Fig. 1B). Vessel 
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density ranged between 132 and 195 vessels per mm2 (mean 168/mm2) during the cycle. 
LP, LS and M endometrium showed an increased number of vessels compared to EP and 
ES (p<0.02, Fig. 1C). Finally, the luminal surface was raised in the first half of the cycle, 
331-398 µm2/vessel, compared to the second half, 178-193 µm2/vessel (p<0.05, Fig. 1D).
Mt-MMp expression in endometrial cells in vitro
To screen which MT-MMPs are expressed by endometrial cells, we first determined the 
expression of the MT-MMPs by human endometrial microvascular endothelial (hEM-
VEC), stromal (hESC) and epithelial (hEEC) cells in vitro using RT-PCR. hEMVEC mainly 
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figure 1. Vascularisation pattern in cycling human endometrium.
The vascularisation pattern in human endometrium was determined by image analysis of anti-CD34-
stained sections. Six fields per biopsy were scanned at 100x magnification. A CD34 antigen expression in 
endothelial cells in late proliferative endometrium (bar = 50 µm). B The total vascular surface (mm2/mm2), 
c the number of vessels per mm2 and d the luminal surface (µm2/vessel) were calculated for each sample 
and expressed as mean ± SEM. EP = Early proliferative phase (n=6), LP = Late proliferative phase (n=7), ES 
= Early secretory phase (n=6), LS = Late secretory phase (n=6), M = menstrual phase (n=2); • p<0.01 versus 
EP, ES and LS; # p <0.02 versus EP, ES; ∗ p<0.01 versus ES, LS and M; and $ p<0.05 versus ES, LS and M.
(see colour figures supplement)
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expressed MT1-, MT3-, and MT4-MMP mRNAs (dCt <9.0, Table 1), whereas MT2-, MT5- 
and MT6-MMP mRNA were weakly expressed (Table 1).
Strikingly, MT1-MMP mRNA expression was considerably lower in endothelial cells com-
pared to both stromal and epithelial cells (ΔdCt 6.1 and 6.1, p<0.01). Epithelial cells 
expressed most MT-MMPs more abundant than the other cell types (p<0.01, Table 1).
At protein level, all MT-MMPs were expressed by hEMVEC, but were rather located in 
the cell than on the cell membrane (Fig. 2). MT1-, MT2-, MT3- and MT4-MMP were 
clearly and consistently detectable (Fig. 2 A-G), whereas MT5- and MT6-MMP antigens 
were only weakly present (not shown). The MT-MMPs showed a perinuclear staining 
(compare its localisation with the cortical F-actin of the cells in Figs 2B, D and F), often 
in a granular pattern. This granular pattern was distinct of that of von Willebrand factor 
in Weibel Palade bodies (Fig 2H), but, in part, resembled the lysosomal compartment as 
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A. MT1-MMP 
E. MT3-MMP 
G. MT4-MMP 
H. v WF
I. Lysotracker 
C. MT2-MMP 
B. MT1-MMP + actin
F. MT3-MMP + actin
D. MT2-MMP + actin
figure 2. MT-MMP antigen expressions in hEMVEC.
Endothelial MT-MMP expression was determined by fluorescence microscopy (magnification 40x). The 
expression of MT1-MMP (± actin A, B), MT2-MMP (± actin c,d), MT3-MMP (± actin e,f), MT4-MMP (g), 
von Willebrand Factor in Weibel Palade bodies (h) and lysotracker in lysosomes (i) in cultured endometrial 
endo helial cells (hEMVEC). The negative control only showed blue staining of the nuclei (not shown). Blue 
= DAPI in nuclei, green = target protein, red = actin or lysotracker.
(see colour figures supplement)
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visualised by lysotracker, an acidic-organelle-selective fluorescent probe (Fig. 2I). Unex-
pectedly, MT2-MMP antigen was also encountered in the nuclei.
Mt-MMp antigen expressions in cycling human endometrium
Subsequently, we investigated the presence of the six MT-MMP antigens in cycling endo-
metrium by immunohistochemistry in serial paraffin sections of the samples that were 
also used for the evaluation of the vascularisation pattern.
MT-MMP antigen expressions in vascular cells
Endometrial endothelium exhibited weak expression of MT-MMP antigens with a maxi-
mal staining index of 2.2 (Fig. 3A, Table 2). MT2-MMP was most abundantly expressed 
by endothelium during the early proliferative, late proliferative and late secretory phase, 
in a similar way to MT4-MMP (p>0.05, Fig. 3A, C and E). Vascular MT3-MMP antigens 
were only detected during the early and late proliferative phase (Fig. 3A and D). MT5- and 
MT6-MMP antigens were not detected in endothelium. Surprisingly, MT1-MMP was also 
not detected in endothelium, while it was clearly present in other cell types (Fig. 3B). 
MT1-MMP was also clearly present in cervix carcinoma endothelium in a parallel experi-
ment (data not shown).
Perivascular smooth muscle cells (PSMCs) expressed all MT-MMPs abundantly through-
out the cycle, with a mean staining index of 4.2 (range 1.0-7.9, Table 2, Fig. 3B).
Table 1. MT-MMP mRNA expression in human endometrial cells in vitro.
heMVec hesc heec
Ct dCt Ct dCt Ct dCt
Mt1-MMp 27.8±0.4  9.0±0.4 22.8±1.5  2.9±1.5* 22.7±0.5  2.9±0.1*
Mt2-MMp 33.7±1.2 14.1±1.2 35.6±1.8 15.6±0.6 29.0±0.3  9.2±0.3*
Mt3-MMp 26.4±0.2  7.4±0.4 30.5±0.4 10.6±1.2* 25.0±0.6 6.3±0.4
Mt4-MMp 26.9±0.2  7.3±0.3 28.3±1.1  9.0±0.4* 29.8±0.1 10.1±0.1*
Mt5-MMp 31.6±0.3 12.8±0.3 33.5±1.4 14.6±0.5* 27.7±0.6  7.9±0.4*
Mt6-MMp 36.3±1.0 17.7±0.8 35.2±1.6 14.4±2.5 32.4±0.6  12.2±0.7
table 1. RNA was isolated from cultured hEMVEC (3 donors), hESC (5 donors) and hEEC (3 donors) and 
cDNA was synthesised as described. Donors were pre-menopausal and of proliferative phases. RT-PCR for 
MT-MMP/GAPDH pairs were performed in duplicate and expressed as the number of cycles (Ct ± SEM). 
GAPDH was used to correct for the total mRNA content of the samples (mean GAPDH Ct 19.3 ± 0.3). The 
dCt values were calculated as the difference in the number of cycles required for the PCR reaction of the 
target gene and of the reference gene to enter the logarithmic phase and expressed as dCt ± SEM.
* p<0.01 versus hEMVEC.
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figure 3. MT-MMP antigen expressions in endometrial endothelium and other cell types.
The expression of MT-MMP antigens by endometrial endothelial cells was determined by 
immunohistochemistry. A. MT-MMP antigen expressions in endothelial cells expressed per cycle phase as 
mean staining index ± SEM (all p>0.05). The staining index is minimally 0 (no stained cells) and maximally 
9 (>50% strongly stained cells). B. MT1-MMP antigen detected in PSMCs (open arrow) but not in endothelial 
cells (arrows) in late proliferative (LP) endometrium. c. MT2-MMP antigen expression in endothelium in LP 
endometrium (arrow). d. MT3-MMP expression in endothelial cells (arrows) and stromal cells (open arrow) 
in LP endometrium. e. MT4-MMP expression in endothelial cells (arrow) in LP endometrium. f. Negative 
control. Bar = 50 µm.
   = Early proliferative phase (n=6),  = Late proliferative phase (n=7),  = Early secretory phase (n=6), 
= Late secretory phase (n=6), = menstrual phase (n=6).
(see colour figures supplement)
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Table 2. MT-MMP antigen expression during the menstrual cycle.
ec psMc ge sc total si
Mt1-MMp ep 0.0 4.1 5.2 0.6  9.9
Lp 0.0 5.0 5.0 1.3  11.3
es 0.0 4.2 4.8 2.2  11.2
Ls 0.0 5.6 4.0 1.8  11.4
M 0.0 4.5 4.5 0.0  9.0
Mt2-MMp ep 1.6 7.0 4.8 5.2  18.6
Lp 1.6 5.7 7.3 4.9  19.6
es 0.2 5.8 4.4 3.6  14.0 *
Ls 2.2 6.2 5.0 5.8  19.2
M 0.0 2.0 1.5 1.5  5.0
Mt3-MMp ep 1.0 5.3 4.4 2.2 12.9
Lp 1.0 4.6 3.6 1.9 11.0
es 0.0 3.0 1.3 1.3  5.5 #
Ls 0.0 4.0 3.4 1.8  9.2
M 0.0 3.0 5.0 0.0  8.0
Mt4-MMp ep 0.6 5.0 3.6 1.8 11.0
Lp 1.7 4.9 5.3 3.7 15.6
es 0.0 5.0 5.3 1.3  11.5 *
Ls 1.4 7.8 4.2 5.4 18.8
M 0.0 2.5 1.5 1.5  5.5
Mt5-MMp ep 0.0 1.0 1.8 0.2  3.0
Lp 0.0 4.7 3.1 0.7  8.6
es 0.0 3.0 3.5 0.3  6.8
Ls 0.0 3.6 3.0 0.8  7.4
M 0.0 4.0 3.5 1.5  9.0
Mt6-MMp ep 0.0 3.0 2.0 0.5  5.5
Lp 0.0 3.9 3.9 1.0  8.7
es 0.0 3.0 3.0 0.8  6.8 $
Ls 0.0 5.0 3.0 2.3  10.3
M 0.0 0.0 3.0 0.0  3.0
table 2. The MT-MMP antigen expressions are expressed as the mean staining indices per cell type per 
phase, which is minimally 0 (no stained cells) and maximally 9 (>50% strongly stained cells). The total 
staining indices (total SI) per phase is calculated as the sum of the mean staining indices of endothelial 
cells (=EC), perivascular smooth muscle cells (=PSMC), glandular epithelium (=GE) and stromal cells 
(=SC). EP = early proliferative (n=6), LP = late proliferative (n=7), ES = early secretory (n=6), LS = late 
secretory (n=6), M = menstruation (n=2), * = p<0.05 versus LP and LS, # = p<0.05 versus EP and LP, $ = 
p<0.05 versus LS.
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MT-MMP antigen expressions in endometrial cells other than vascular cells
All MT-MMPs were expressed by epithelial and to a lesser extent by stromal cells (Table 
2). Both cell types expressed higher amounts of MT1-, MT2-, MT3- and MT4-MMP than 
of MT5 and MT6-MMP. All MT-MMPs were highly expressed in smooth muscle cells of 
the myometrium (data not shown).
Mt-MMp regulation during the menstrual cycle and the post-menopause
MT-MMP antigen expressions during the menstrual cycle
First, total MT-MMP antigen expressions in proliferative phase were compared to those 
in early secretory phase, showing that MT2-, MT3-, and MT4-MMP expressions were 
markedly lower in ES endometrium (total SI differences 5.3, 8.8 and 4.3 respectively, 
p<0.05, Table 2). The expression of MT1-, MT5- and MT6-MMP only slightly decreased in 
the ES phase compared to the proliferative phases (Table 2).
Subsequently, early secretory phase were compared to the late secretory phase, demon-
strating that total MT2-, MT3-, MT4-, and MT6-MMP expressions were elevated during 
the LS phase compared to the ES phases (MT2-, MT4- and MT6-MMP p<0.05, MT3-
MMP p>0.05, Table 2). The total staining index of MT1-and MT5-MMP remained rather 
constant during the cycle phases (Table 2).
All MT-MMPs were expressed in considerable amounts during the menstrual phase. 
Unfortunately only two biopsies of menstrual phase endometrium were available and 
therefore the staining patterns can only be indicative.
MT-MMP antigen expressions in post-menopausal endometrium
Post-menopausal endometrial biopsies showed less abundant amounts of MT-MMP 
antigens as compared to the MT-MMP expressions in pre-menopausal endometrium. 
Nevertheless, all MT-MMPs, except MT5-MMP, were present in postmenopausal en-
dometrium. In post-menopausal tissues the total staining index (total SI) of MT1-MMP 
was 4.3, that of MT2-MMP was 4.5, that of MT3-MMP 3.3, that of MT4-MMP 3.0, that of 
MT5-MMP 0.0, and that of MT6-MMP was 1.0. Post-menopausal MT-MMPs were mainly 
expressed by epithelial cells and not by endothelium or PSMCs
discussion
The present study showed that all MT-MMPs are expressed in human endometrium, of 
which most expressions show a cycle-dependent pattern. Furthermore, vascular MT2-, 
MT3- and MT4-MMP expression correlates with angiogenic episodes of the menstrual 
cycle. Since MT2- and MT3-MMP are known stimulators of angiogenesis in vitro [Hotary 
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et al., 2000; Plaisier et al., 2004], these findings suggest that MT2- and MT3-MMPs are 
associated with endometrial angiogenesis.
MT-MMPs act at the cell surface where they can locally facilitate degradation of extra- cel-
lular matrix, cell migration, invasion and angiogenesis. The abundance of all MT-MMP 
in cycling endometrium and the relatively weak MT-MMP expressions in the postmeno-
pausal endometrium suggest that endometrial MT-MMPs play a role in remodelling of 
cycling endometrium.
A possible function of MT-MMPs may be associated with the shedding process, since 
their antigens were highly expressed during the late secretory and menstrual phase and 
other MMPs have been shown to be associated with menstruation as well [Lockwood et 
al., 1998; Salamonsen, Woolley 1996; Zhang et al.,2000]. Alternatively MT-MMPs may 
play a role in endometrial remodelling in preparation for implantation. Most MT-MMP 
expressions were reduced during the receptive window, probably under the influence of 
steroidal hormones. The low amount of MT-MMPs during the generation of receptive 
endometrium may be essential for the establishment of a stable environment in prepara-
tion for embryonic implantation. However, whether MT-MMPs play a role during implan-
tation remains yet unresolved and this should be assessed in first-trimester decidua.
Another function of MT-MMPs may be the regulation of angiogenesis. Assuming the 
participation of MT-MMPs in angiogenesis, their antigens must be expressed by en-
dothelium during phases of the menstrual cycle with high angiogenic activity. Therefore 
the present study did not only analyse the expression of MT-MMPs in cultured endo-
metrial endothelial cells and in endometrial tissue samples but also determined their 
association with vascularisation in these samples.
MT2-, MT3-, and MT4-MMP were expressed by both in vitro and in vivo endothelial cells. 
Endometrial endothelium in vivo expressed MT3-MMP during the proliferative phase, 
whereas MT2- and MT4-MMP were expressed during both proliferative and late secre-
tory phases. Strikingly, the endothelial MT-MMP expressions were expressed during 
phases with high angiogenic activity. The proliferative, and to a lesser extent the late 
secretory phase, showed an elevated endometrial angiogenesis, since respectively three 
and one vascularisation parameter(s) were raised in these phases. Previous studies have 
described these angiogenic episodes as well [Ferenczy et al., 1979; Goodger, Rogers 1995; 
Rogers, Gargett 1998; Smith 2001; Morgan et al., 1996].
MT1-MMP is expressed by endothelium in vitro whereas its endothelial expression in vivo 
was consistently not detectable. This difference may be explained by translational regula-
tion or culture-induced changes in in vitro cell metabolism. MT1-MMP expression is reg-
ulated by several signal transduction pathways, including the MAPK and PI3K pathways, 
which are influenced by cytokines and growth factors [Boyd et al., 2004; Chakraborti et 
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al., 2003; Galvez et al., 2005]. Since human serum, ECGF (containing acidic FGF) and 
VEGF were used in the culture system, signalling pathways could have been activated 
and influenced MT1-MMP expression by endometrial cells [Plaisier et al., 2004].
The endothelial expression of MT2-MMP in both phases and the consistent absence 
of endothelial MT1-MMP is in accordance with previous work by Zhang et al [Zhang et 
al., 2000]. They showed that MT1-MMP antigens were present in all endometrial cell 
types, but were ‘virtually absent’ in endothelial cells. Määttä et al detected weak MT1-
MMP mRNA expression in endothelium, but did not study MT1-MMP protein expression 
[Määttä et al., 2000]. No data regarding the cellular expression of MT3- and MT4-MMP 
have been reported.
Although MT1-MMP is generally accepted to contribute to angiogenesis, MT2- and MT3-
MMP are also described as stimulators of angiogenesis in vitro [Galvez et al., 2001; 
Hotary et al., 2000/2002; Lafleur et al., 2002; Zhou et al., 2000]. MT4-MMP is not able 
to induce capillary tube formation in 3D-matrices in vitro [Hotary et al., 2002]. In a recent 
in vitro-study regarding endometrial angiogenesis, we showed that capillary-like tube 
formation by endometrial endothelial cells is not predominantly regulated by MT1-MMP 
but rather by MT3-MMP [Plaisier et al., 2004]. These in vitro findings are supported by 
the absence of endothelial MT1-MMP in vivo and the presence of MT3-MMP antigens 
in endothelium in vivo during the angiogenic proliferative phase. Moreover, the detec-
tion of endothelial MT2-MMP expression during the angiogenic proliferative and late 
secretory phase suggests MT2-MMP to be an additional regulator of angiogenesis to 
consider [Hiraoka et al., 1998; Hotary et al., 2000; Lafleur et al., 2002]. Future research 
should clarify their involvement in endometrial angiogenesis and the role of MT4-MMP 
in endothelium.
A remark should be made about the analysed endometrium samples, which were mainly 
obtained from women diagnosed with leiomyoma. Although the samples were obtained 
distant of the lesions and were microscopically “normal”, it is noteworthy that recently a 
relation between MMPs and myoma has been described. An altered level of MMP-9 was 
found in uterine cavities of leiomyoma patients [Inagaki et al., 2003a], but whether this, 
or myoma themselves, can affect MT-MMP production by endothelial or other endome-
trial cells, remains unclear.
The present study showed that all MT-MMPs were expressed at protein level in hu-
man endometrium in a cycle-dependent pattern, with decreased expression levels in 
hormone-dependent secretory phases. Furthermore, the expression of MT2- MT3- and 
MT4-MMP antigens by endometrial endothelium correlated with angiogenic episodes of 
the menstrual cycle. Since MT2- and MT3-MMP are known to regulate capillary-like tube 
formation, these findings support earlier in vitro data on the role of MT3-MMP in the 
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regulation of endometrial angiogenesis. In addition to MT3-MMP, MT2-MMP may be 
associated with vascular remodelling processes in cycling endometrium as well.
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ABstrAct
objective: Successful implantation and placentation depend on the interaction be-
tween the endometrium and the embryo. Angiogenesis is crucial at this time. Here, 
the direct influence of the human embryo on in vitro endometrial angiogenesis was 
investigated.
Materials & Methods: Human endometrial microvascular endothelial cells (hEMVEC) 
were cultured in an in vitro angiogenesis model. Conditioned media (CM) of human 
embryos and recombinant angiogenic factors were used to stimulate in vitro angio-
genesis. VEGF-A was determined by enzyme-linked immunosorbent assay (ELISA).
results: Conditioned media of human embryos, containing significant amounts of 
vascular endothelial growth factor (VEGF)-A, caused an increase in hEMVEC tube 
formation. This effect was prevented by soluble VEGFR-1, which quenches VEGF-A 
activity. Recombinant EGF alone and leukaemia inhibitory factor in combination with 
VEGF-A stimulated hEMVEC tube formation. None of the other tested recombinant 
mediators, which have been described as produced by the early embryo/trophoblast 
(interleukin (IL) 10, transforming growth factor (TGF) β, placental growth factor 
(PLGF), hCG, colony-stimulating factor 1, interferon-γ, insulin-like growth factor I and 
II, IL-6, platelet-derived growth factor, and TGFα), had an effect on tube formation 
by hEMVEC.
conclusions: For the first time, it is shown that the human embryo is able to stimulate 
in vitro endometrial angiogenesis at the time of implantation, a process that is medi-
ated by VEGF-A.
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introduction
Successful implantation and subsequent placentation depend on the interaction between 
a receptive decidualised endometrium and an intrusive blastocyst. Angiogenesis plays 
a major role in the formation of a receptive endometrium and an adequate functioning 
of the placenta.
When the blastocyst enters the uterine cavity, its survival depends on endometrial se-
cretion. After attachment and invasion, it is fed and oxygenated by the decidualised 
endometrium. Maternal blood supply, via an extensive endometrial vascular network, 
to the embryo is indispensable for further growth. In the peri-implantation period, lo-
cal enhancement of angiogenesis is necessary to support further differentiation of the 
endometrium, ultimately leading to the formation of the maternal part of the placenta. 
The stimulus for this process might very well come from the implanting blastocyst it-
self, which in this way optimises its implantation site [Van der Weiden et al., 1996]. 
Inadequate angiogenesis in the peri-implantation phase may lead to a less receptive 
endometrium. This can result in implantation failure or aberrant placental formation, 
which in turn may affect the pregnancy outcome, as demonstrated in morphological 
studies demonstrating poor placental vascular development in foetal growth restriction 
[Ahmed, Perkins 2000].
Before the embryo and the endometrium can make physical contact, an interaction by 
signalling molecules must have been established [Norwitz et al., 2001]. The exact nature 
of this interaction is not fully resolved yet. It is unknown whether the blastocyst is able to 
induce the angiogenic process in the endometrium directly or indirectly via the epithelial 
or stromal cells [Armant et al., 2000; Kimber 2000; Krussel et al., 2000a; Salamonsen 
et al., 2000]. Following penetration of the epithelial lining, the embryo has to establish 
a closer contact with endothelial cells. A direct regulation of angiogenesis by the blasto-
cyst/early trophoblast might be possible during that phase of implantation.
The production of cytokines and hormones varies at specific stages of embryonic dif-
ferentiation. Human blastocysts produce activin, colony stimulating factor (CSF)-1, epi-
dermal growth factor (EGF), interferon (IFN) γ, insulin-like growth factor (IGF) I and II, 
interleukin (IL) 1α and -β, IL-6, IL-10, leukemia inhibitory factor (LIF), platelet-derived 
growth factor (PDGF), transforming growth factor (TGF) α and β, tumour necrosis fac-
tor (TNF) α, vascular endothelial growth factor (VEGF)-A, and hCG, whereas human 
first-trimester trophoblasts produce EGF, IGF-II, placental growth factor (PLGF), TGFα 
and β, TNFα, and hCG. These molecules may enable the implanting embryo to induce 
angiogenesis locally at the implantation site. Among these factors, VEGF-A is known to 
be a highly specific mitogen for endothelial cells [Ferrara 2001]. It induces angiogenesis 
and increases the permeability of blood vessels [Dvorak et al., 1995].
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Here, the influence of the embryo on endometrial angiogenesis was investigated by 
evaluating the effect of conditioned medium from human embryos (IVF culture medi-
um) on isolated human endometrial microvascular endothelial cells (hEMVEC) in an in 
vitro angiogenesis model, which we have previously characterised [Koolwijk et al., 2001]. 
Furthermore, individual recombinant cytokines, known to be expressed by the human 
embryo and first-trimester trophoblast, together with hCG were tested on hEMVEC to 
determine which factors are involved in inducing angiogenesis at the time of implanta-
tion.
MAteriALs And Methods
Materials
Penicillin/streptomycin, L-glutamine and medium 199 (M199) with and without phe-
nol red and supplemented with 20 mmol/L HEPES was obtained from BioWhittaker 
(Verviers, Belgium); Newborn calf serum (NBCS) was obtained from Life Technologies 
(Grand Island, NY, USA). Human serum (HS) was obtained from a local blood bank and 
was prepared from fresh blood from 10-20 healthy donors, pooled and stored at 4°C; it 
was heat-inactivated before use. Human serum albumin (HSA) was obtained from San-
quin (Amsterdam, The Netherlands). Tissue culture plastics and microtiter plates came 
from Costar/Corning (Cambridge, MA) and Falcon (Becton Dickinson, Bedford, MA). A 
crude preparation of endothelial cell growth factor (ECGF) was prepared from bovine 
hypothalamus as described by Maciag et al [Maciag et al., 1979]. Heparin and thrombin 
were obtained from Leo Pharmaceutics Products (Weesp, the Netherlands). Human 
fibrinogen was purchased from Chromogenics (Mölndal, Sweden). Dr. H. Metzner and 
Dr. G. Seeman (Aventis Behring, Marburg, Germany) generously provided factor XIII. 
Fibronectin was a gift from Dr. J. van Mourik (CLB, Amsterdam, The Netherlands). Hu-
man recombinant VEGF-A and PLGF were purchased from RELIATech (Braunschweig, 
Germany); soluble VEGF receptor 1 (sVEGFR-1) was a generous gift from Dr. H.A. Weich 
(GBF, Braunschweig, Germany). Tumour necrosis factor α was a gift from Dr. J. Traver-
nier (Gent, Belgium). Recombinant human basic fibroblast growth factor (bFGF) was 
purchased from PeproTech (Rocky Hill,NJ). Recombinant human activin was obtained 
from Dr. Pawson via the National Hormone and Pituitary Program, The National Institute 
of Diabetes and Digestive and Kidney disease, The National Institute of Child Health and 
Human Development, and the US Department of Agriculture (Bethessa,MD). Recom-
binant human EGF, human CSF, IFNγ, IGF-I and –II, IL-1α, -1β, -6 and -10 and TGFα 
and -β were commercially obtained from PrepoTech (Rocky Hill, NJ). Human chorionic 
gonadotrophin (Pregnyl) was obtained from Organon (Oss, the Netherlands). Recombi-
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nant human LIF was purchased from Chemicon International (Temecula, CA, USA) and 
PDGF B/B from Roche (Mannheim,Germany).
human embryo conditioned medium
The study was conducted according to the guidelines of the Institutional Review Board, 
and informed consent was obtained from each patient. The IVF culture media used in 
our experiments were obtained from the IVF Department of the Reinier de Graaf Group 
(Diaconessenhuis, Voorburg, The Netherlands) and the Infertility Centre from the Gent 
University Hospital (Gent, Belgium). The media were collected during a period of 2 
years. Early stage human embryos obtained after oocyte pick-up and IVF were cultured 
in media until embryo transfer. The culture media used were: GPO medium [for the exact 
compounds see Rijnders, Jansen 1998], Complete P-1 and Complete Blastocyst Irvine 
media (Irvine Scientific, Santa Ana, Ca) and Earle’s medium supplemented with 0.08% 
(w/v) HSA, penicillin G (8 mg/L), sodium pyruvate (0.10 g/L), and sodium bicarbonate 
(2.1 g/L).
Early stage human embryos produce and accumulate mediators in the medium in which 
they are cultured. Pool A, B and C consisted of medium in which 12, 40 and 79 embryos 
(2-8 cell stage) were cultured originating from 7, 10 and 17 patients respectively. Pool 
D consisted of medium from 90 blastocysts originating from an unknown number of 
patients.
Earle’s medium or GPO medium (pool A, B and C) were refreshed after one or three days 
respectively. The Irvine medium (pool D) was changed on day 3 from Complete-1 Irvine 
medium to Complete Blastocyst Irvine medium. No data are available on the success 
rate of implantation of these embryos. Other materials used have been specified in the 
methods described or in the related references mentioned.
cell culture
Human endometrial microvascular endothelial cells (hEMVEC) were isolated from en-
dometrial tissue (collected according to the guidelines of the Institutional Review Board 
and informed consent was obtained from each patient) as previously described [Koolwijk 
et al., 2001] and maintained in indicator-free M199 supplemented with 20 mM HEPES 
(pH 7.3), 20% human serum, 10% heat-inactivated NBCS, 150 µg/mL ECGF, 5 ng/mL 
VEGF-A, 5 U/mL heparin, 100 IU/mL penicillin, and 100 mg/mL streptomycin (= hEM-
VEC culture medium). HEMVEC were cultured on fibronectin-coated wells at 5% CO
2
 
/ 95% air until confluence was reached and were subsequently detached with 0.05% 
trypsin / 0.025% EDTA and transferred into coated dishes at a split ratio of 1:3. Fresh 
medium was given three times a week with twice a two day interval and once a three day 
interval.
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incorporation of 3h-thymidine
Incorporation of 3H-thymidine into DNA was determined as the measurement of en-
dothelial cell proliferation. Confluent cultures of endothelial cells (passages 5 to 9 of 
three different donors) were detached by trypsin/EDTA solution and allowed to adhere 
and spread at a density of 104 cells per cm2 on fibronectin-coated dishes in indicator-
free M199-HEPES supplemented with 10% heat-inactivated and charcoal-treated NBCS, 
penicillin/streptomycin and 0.75 ng/mL VEGF-A for 18 h. The 0.75 ng/mL VEGF-A was 
added as a maintenance factor to prevent hEMVEC death under these control culture 
conditions. Then the cells were stimulated with conditioned medium, increasing con-
centrations of cytokines or hCG in the presence or absence of extra 6.25 ng/mL VEGF-A, 
as indicated in the text. After a total incubation period of 42 h, 3H-thymidine was added 
and the cells were incubated for another 6 h period. Subsequently, the 3H-labeled DNA 
was precipitated and counted in a liquid scintillation counter and the stimulation index 
was calculated as previously described [Koolwijk et al., 2001].
in vitro angiogenesis model
Human fibrin matrices were prepared as described previously [Koolwijk et al., 2001]. 
Confluent hEMVEC (passages 6 to11 of two different donors) were detached and seeded 
in a split ratio of 2:1 on the surface of the fibrin matrices and cultured for 24 h in indicator-
free M199 medium supplemented with 20% human serum, 10% NBCS, and penicillin/
streptomycin. Then the endothelial cells were cultured with the mediators indicated for 
2 - 5 days. Invading cells and the formation of capillary-like structures of endothelial cells 
in the three-dimensional fibrin matrix were analysed by phase contrast microscopy. The 
total length of the tube-like structures was measured [Kroon et al., 1999].
enzyme-Linked immunosorbent Assays (eLisA)
The VEGF-A antigen determinations were performed by the commercially available Duo-
Set ELISA Development Kit for human VEGF-A (R&D system, Minneapolis, MN), which 
recognizes VEGF-A
165
 and VEGF-A
121
. Human recombinant VEGF-A
165 
(R&D systems) was 
used as a standard.
statistics
The data are expressed as the mean ± SD/SEM or range. Statistical evaluations of the 
data were performed using the paired t-test and Wilcoxon rank test after the control 
conditions were set at a 100%. P < 0.05 was considered statistically significant.
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resuLts
early stage embryo-conditioned medium enhances heMVec proliferation and tube 
formation
We have used conditioned IVF culture medium of pool A to evaluate the effect of cy-
tokines and other mediators produced by early stage human embryos on hEMVEC pro-
liferation and the media of pools B, C and the blastocysts derived pool D on in vitro 
angiogenesis.
An increase in hEMVEC proliferation was observed when hEMVEC were stimulated with 
pool A. When 5% of the conditioned media was added, a maximum stimulation was 
observed, although this increase was not significant as compared with the control condi-
tion (with 0.75 ng/mL VEGF-A as maintenance factor, data not shown). When 5% of non-
conditioned culture media was added, no effect on hEMVEC proliferation was seen.
Pools B, C and D independently induced an increase in tube formation by hEMVEC when 
these cells were stimulated with 2.5-10% of the conditioned media (Fig. 1). The results 
of the three pools were taken together for statistical analysis. Quantification of the tube 
formation revealed that the effect was significant when 2.5-10% of the conditioned me-
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figure 1. Conditioned medium of early stage embryos stimulate in vitro hEMVEC tube formation.
Phase-contrast pictures were taken of hEMVEC cultured on top of a three-dimensional fibrin matrix under 
control conditions (A), after stimulation with VEGF-A (10 ng/mL, B), 5% (v/v) control IVF medium (C), 
or 5% (v/v) pooled conditioned medium (D). The number of tubular structures (examples indicated by 
arrows) increased after stimulation with VEGF-A or 5% pooled conditioned medium. Bar = 500 µM.
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dium was used and showed an increase of 150%, 151% and 135% when 2.5%, 5%, and 
10%, respectively, of the conditioned medium was used (control set at 100%)(Fig. 2A). 
At higher concentrations (20%) the ingrowth of vascular structures declined. The non-
conditioned IVF culture medium (control) had no effect on tube formation (Fig. 2A).
To test whether the enhancement of tube formation was due to expression of VEGF-A 
by the early stage embryos, sVEGFR-1 was added to the pools. Soluble VEGFR-1 cap-
tures VEGF-A and prevents its binding to cellular receptors. The presence of sVEGFR-1 
completely prevented VEGF-A-induced tube formation under our standard conditions. 
Addition of sVEGFR-1 inhibited the tube formation that was enhanced by pool C (Fig. 
2B). Similar results were obtained with pool B and D (data not shown). This suggests 
that early stage embryos are able to express VEGF-A to such a level that it was involved 
in the stimulation of tube formation by hEMVEC
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figure 2. Conditioned medium of embryos stimulate in vitro hEMVEC tube formation, an effect which is 
VEGF-A-mediated.
A. hEMVEC, from passage 5-10 of one donor, were cultured on top of a 3D fibrin matrix and stimulated 
with 2.5, 5, 10, and 20% (v/v) of pooled medium (pool B,C, or D;  with solid line). As control, the cells 
were stimulated with 2.5, 5, and 10, and 20% (v/v) of the IVF culture medium in which no embryos were 
grown ( with dotted line) or 10 ng/ml VEGF (solid bars). After 3-5 days of culturing, mean tube length 
was measured. Data are expressed as a percentage of the control and represent mean ± SEM of four 
independent experiments performed in duplicate wells. * = p < 0.05 compared to control condition. The 
mean tube length of the controls was 63.4 mm/cm2. B. Addition of 0.5 µg/mL sVEGFR-1 to control (M199 
supplemented with 10% NBCS and 20% HS) and VEGF-A stimulated conditions, inhibited the amount 
of capillary-like structures formed. The enhanced formation of capillary-like structures by hEMVEC after 
stimulation with 10% (v/v) embryo culture medium was also reduced by sVEGFR-1. Mean tube length 
was measured and expressed as a percentage of the control ± range. Hatched bars: without sVEGFR-1, 
solid bars: with sVEGFR-1. The mean tube length of the controls was 77.4 mm/cm2. The experiments were 
performed in duplicate wells.
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To confirm the presence of VEGF-A in the conditioned medium of day 2-3 and blastocyst-
stage embryos, VEGF-A concentrations in the media of pool B, C and D were assayed 
by ELISA. In the pooled media B, C and D, 10,700 pg/mL, 5200 pg/mL and 14 pg/mL 
VEGF-A antigen was detected respectively. The control medium of the pooled media B 
and C, in which no embryos were grown, contained 70 pg/mL of VEGF-A, whereas no 
VEGF-A antigen was detectable in the control medium of pool D.
effect of cytokines and hcg produced by the early embryo and first-trimester 
trophoblast on heMVec proliferation
Because conditioned medium of early embryos was able to induce hEMVEC proliferation 
and tube formation, the question arose which factors produced by the human embryo 
could be held responsible for these effects. As such, recombinant cytokines and hCG, 
known to be expressed by the human embryo and first-trimester trophoblast, were tested 
on hEMVEC proliferation and tube formation, both in the absence or presence of 6.25 
ng/mL VEGF-A.
VEGF-A was a potent stimulator of hEMVEC proliferation, as measured by 3H-thymidine 
incorporation [Koolwijk et al., 2001] and confirmed by an increase in cell number (deter-
mined at 48h; data not shown).
Under control conditions (with 0.75 ng/mL VEGF-A as maintenance factor), IL-1α and 
activin (only the highest concentration) significantly inhibited hEMVEC proliferation, 
whereas all the other tested cytokines (EGF, LIF, CSF-1, IFNγ, IGF-I, IGF-II, IL-1β, IL-6, 
IL-10, PDGF, TGFα, TGFβ, PLGF and hCG) did not have a significant effect. Only in-
cubation with increasing concentrations of IL-1α had a significant inhibitory effect on 
hEMVEC proliferation induced by 6.25 ng/mL VEGF-A (data not shown). Cell death in 
hEMVEC cultures was caused by TNFα, at concentrations of 1 and 2.5 ng/mL, but addi-
tion of 6.25 ng/mL VEGF-A prevented the TNFα-induced cell death (data not shown).
effect of cytokines and hcg produced by the early embryo and first-trimester 
trophoblast on in vitro angiogenesis by heMVec
Subsequently, the effect of factors expressed by the human embryo and first-trimester 
trophoblast on in vitro angiogenesis by hEMVEC was studied in the absence or presence 
of VEGF-A.
In the absence of VEGF-A, EGF significantly stimulated tube formation concentration de-
pendently. However, in combination with VEGF-A no additive effect of EGF was observed 
(Fig. 3C). Similarly to their inhibitory effect on hEMVEC proliferation, high concentra-
tions of activin (Fig. 3B), IL-1α (Fig. 3A) and IL-1β (not shown) significantly inhibited 
the amount of tubes formed. Interestingly, LIF (1 and 10 ng/mL) significantly stimulated 
the VEGF-A-enhanced tube formation but did not alter basal tube formation (Fig. 3D). 
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Interleukin-10, TGFβ, PLGF, hCG, CSF-1, IFNγ, IGF-I/-II, IL-6, PDGF, and TGFα in the 
indicated concentrations had no effect on tube formation (data not shown).
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figure 3. The influence of recombinant cytokines and hCG on the formation of capillary-like structures by 
hEMVEC.
HEMVEC were cultured on top of a three-dimensional fibrin matrix in M199 supplemented with 20% 
human serum and 10% NBCS and stimulated with increasing amounts of different cytokines and hCG in 
the absence (solid line) or presence (dotted line) of VEGF-A (10 ng/mL). After 2-5 days of culturing, mean 
tube length was measured by image analysis as described and expressed as a percentage of the control 
± range of two independent experiments performed in duplicate wells. * = p < 0.05 compared to control 
condition, ** = p < 0.05 compared to VEGF-stimulated condition.
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discussion
The data presented here demonstrate that conditioned media of human embryos con-
tained VEGF-A and stimulated in vitro endometrial angiogenesis, an effect counteracted 
by sVEGFR-1. The VEGF-A was the most potent mediator in stimulating hEMVEC pro-
liferation and tube formation among the known mediators expressed by the human 
embryo and first-trimester trophoblast, of which LIF could increase the VEGF-mediated 
tube formation.
Adequate interaction between embryo and endometrium is essential for successful 
implantation and placentation. The embryo locally prepares the endometrium for its 
nidation by producing various mediators [Lindhard et al., 2002; Lopata 1996; Norwitz 
et al., 2001; Tabibzadeh, Babaknia 1995; Van der Weiden et al., 1991]. Previously, Sak-
kas et al. described that the human blastocyst directly induces changes in endometrial 
epithelial cells [Sakkes et al., 2003]. Therefore it was suggested that the human embryo 
might also directly affect the endometrial endothelium, thus regulating endometrial an-
giogenesis, an important factor in the preparation process [Geva et al., 2002]. Studies 
in rats support the hypothesis that angiogenesis at the implantation site is a localized 
process controlled by the embryo, whereas angiogenesis, which occurs in the entire 
endometrium is maternally controlled [Abberton, Rogers 1995; Goodger, Rogers 1993]. 
Our data indicate that the human embryo is able to produce detectable concentrations 
of active VEGF-A and thus to stimulate local angiogenesis in the endometrium during 
the peri-implantation phase.
Krüssel et al. previously demonstrated that human embryos from the 10-cell up to the 
blastocyst stage were able to express mRNA, encoding for four different isoforms of 
VEGF-A (121, 145, 165, and 189) [Krussel et al., 2000b/2001]. Relatively highly expressed 
were isoforms 121 and 165, which are both secreted VEGF-A isoforms. However, they were 
not able to detect VEGF-A protein in the embryo culture medium, presumably because it 
was below the detection limit of the ELISA, which only detected VEGF-A 165. The ELISA 
we used detected both the 121 and 165 isoform. Furthermore, Krüssel et al. used a larger 
volume of conditioned medium per embryo (50 µL vs. 10-30 µL in our experiments).
The human embryos in our study were the only source of VEGF-A production, because 
little or no VEGF-A protein could be detected in the control IVF medium in which no 
embryos were cultured. After 24 (pool A to C) or 72 (pool D) h of culture the medium was 
changed. This eliminates other potential sources of cytokine production (by granulosa 
cells, cumulus cells and sperm cells). Krüssel et al. almost ruled out the possibility of 
paternal contamination by using embryos, which resulted from intracytoplasmic sperm 
injection [Krussel et al., 1999/2001]. They found that unfertilised oocytes did not express 
VEGF-A mRNA, which proved that the VEGF-A mRNA was truly embryonic [Krussel et 
al., 2000b].
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The amount of VEGF-A detected by ELISA varied in the pools. This could not be explained 
only by the difference in numbers of embryos from which the pools were derived. Differ-
ences in the culture media used in pools A to C on the one hand and pool D on the other, 
differences in embryonic stage and viability, or reuptake of VEGF-A by the blastocyst 
itself may contribute to and explain the phenomenon [Hornung et al., 1998].
It should be noted that the proliferation and outgrowth of tubular structures was re-
duced at high concentrations of embryo-conditioned medium. It is plausible that in ad-
dition to the stimulatory VEGF-A, also angiogenesis-inhibiting compounds are present, 
which only become effective at relatively high concentrations and point to a delicate 
balance between angiogenesis-stimulating and -inhibiting factors which strictly control 
angiogenesis.
Heterozygous and homozygous deletion of the VEGF-A gene in mouse embryos resulted 
in embryonic mortality at midgestation and in impaired placental development due to 
abnormal formation of intra- and extra-embryonic vessels [Carmeliet et al., 1996/1997; 
Ferrara et al., 1996]. This further underlines the importance of VEGF-A. However, the 
embryo might also produce other mediators which are able to induce or enhance angio-
genesis at the site of implantation. Such cytokines derived from the human embryo may 
act directly on angiogenesis or may affect angiogenesis indirectly by inducing VEGF-A 
(e.g. IL1β, hCG), or its receptors in endometrial cells [Licht et al., 2001; Sunder, Lenton 
2000].
One other candidate mediator that, in the presence of VEGF, might be involved in an-
giogenesis at the site of implantation is LIF. In our studies LIF had an indirect effect on 
angiogenesis. It increased the VEGF-mediated tube formation, whereas LIF by itself did 
not have an effect. In vivo, it has been shown that LIF was able to induce angiogenesis 
in the rabbit cornea and that female mice lacking a functional LIF gene are fertile but 
their blastocysts fail to implant and their uteri were found to be poorly vascularised 
[Chen et al., 1999; Stewart et al., 1992; Vasse et al., 1999]. However, in vitro, inconsistent 
effects of LIF on endothelial cells are described. Leukemia inhibitor factor, either or not 
in the presence of an angiogenic factor, was found to inhibit or stimulate endothelial 
cell proliferation and tube formation [Ferrara et al., 1992; Gendron et al., 2000; Hatzi 
et al., 2002; Pepper et al., 1995; Vasse et al., 1999]. Also on the influence of LIF on the 
proteolytic potential of endothelial cells, an important phase in angiogenesis, opposite 
results were found [Pepper et al., 1995; Sunder, Lenton 2000; Vasse et al., 1999]. These 
discrepancies can be attributed to the biological versatility of LIF which depends on cell 
species and origin.
Although the embryo only produces small amounts of angiogenic factors, locally high 
concentrations are reached owing to close contact between the embryo and maternal 
blood vessels. Together with the increased sensitivity of the endometrial endothelium 
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to angiogenic factors at the time of implantation, the embryo might very well cause an 
increased angiogenic response at the implantation site.
In conclusion, VEGF-A has been recognised as an important mediator in the process 
of endometrial angiogenesis during the menstrual cycle [Koolwijk et al., 2001; Rogers, 
Gargett 1998; Smith 1998]. The results of this study support a crucial role for embry-
onic VEGF-A in the process of angiogenesis during the peri-implantation phase. By the 
expression of VEGF-A, the embryo enables itself to induce angiogenesis directly at its 
implantation site, and as such creates an environment necessary for its survival and 
growth.
In contrast to tumour angiogenesis, endometrial angiogenesis at the time of implanta-
tion and placentation seems to be strictly orchestrated. Further studies should focus on 
the exact nature of the interactions between the human embryo and the endometrium 
regarding angiogenesis in the peri-implantation phase and during the formation of pla-
centa, and on the role of defective angiogenesis in implantation failure, which affects the 
outcome of gestation.
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ABstrAct
objective: To evaluate vascular adaptation to implantation by studying vascularisa-
tion and angiogenic factors in decidua basalis (DB), decidua parietalis (DP) and de-
cidual secretory endometrium (DSE) of first-trimester pregnancies. Comparing these 
tissues provides information about the regulation of vascularisation by pregnancy-
induced hormones and/or the extra-villous trophoblast (EVT).
patients & Methods: Decidual samples from vacuum-aspiration were collected from 
women (n=32) undergoing voluntarily first-trimester termination of pregnancy. Vas-
cularisation, determined by CD34-immunohistochemistry, and VEGF-A, PlGF, Flt-1, 
KDR, angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and TIE-2 protein and mRNA 
expression, determined by RT-PCR and immunohistochemistry, were evaluated in se-
rial paraffin sections.
results: Pregnancy-induced hormones and EVT influence vascularisation by enhanc-
ing vascular and luminal surface and reducing vessel density at the implantation site. 
These changes correlate with differences in gene and protein expression. PlGF mRNA 
and PlGF and Flt-1 protein expressions were elevated in DB under influence of EVT. 
Also the angiopoietins were differentially expressed, in favor of Ang-2, in DB.
conclusions: The EVT and pregnancy-induced hormones regulate vascularisation and 
the expression of angiogenic factors in decidua. The induction of PlGF, Flt-1, and 
Ang-2/Ang-1 ratio in DB suggests that these factors play a role in regulating angio-
genesis at the implantation site.
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introduction
Vascularised, receptive endometrium is essential for implantation and for the success 
of the embryo-maternal interaction [Zygmunt et al., 2003]. Disturbances in vascular 
development may play an important role in frequently occurring pathologies during 
pregnancy, such as early pregnancy wastage, pre-eclampsia and foetal growth restriction 
[Vailhe et al., 1999; Vuorela et al., 2000; Zygmunt et al., 2003].
Endometrial adaptation to implantation starts during the menstrual cycle by means of 
stromal decidualisation and the induction of angiogenesis, the formation of new vessels 
from existing vasculature. These processes continue after conception under influence 
of oestradiol, progesterone, hCG, cytokines and growth factors derived from corpus lu-
teum, endometrium and implanting embryo.
Angiogenic changes of the decidua include proliferation, migration and increased 
vascular permeability [Goodger, Rogers 1993; O’Shea et al., 1983]. After the 6th week of 
gestation, the arterioles are remodelled from low-capacitance high-resistance to high-
capacitance low-resistance vessels, and by the 12th week maternal blood flow to the inter-
villous space is established [Burton et al., 1999; Pijnenborg et al., 1983].
In general, angiogenesis is a multi-step process [Carmeliet 2003; Ferrara 2000; Plaisier 
et al., 2004; Smith 2000]. Numerous factors are able to regulate angiogenesis, of which 
the vascular growth factors, Vascular Endothelial Growth Factor-A (VEGF-A) and Placen-
tal Growth Factor (PlGF), are probably the most well known. VEGF interacts with the 
VEGFR-1 (Flt-1) and VEGFR-2 (KDR) to promote endothelial cell proliferation, cell migra-
tion and vascular permeability. In rabbits, VEGF, together with its receptor Flt-1, plays an 
active role in the angiogenic process during implantation [Das et al., 1997a].
PlGF shares biochemical and functional features with VEGF and interacts with VEGFR-1 
(Flt-1). PlGF and VEGF have synergistic effects regarding angiogenesis, but vessels in-
duced by PlGF are more mature and stable than vessels induced by VEGF [Carmeliet 
2003; Luttun et al., 2002]. PlGF is abundantly expressed in human placenta and may be 
an important paracrine regulator of decidual angiogenesis and an autocrine mediator of 
trophoblast function [Sherer, Abulafia 2001].
A second family of growth factors, the angiopoietins, and their receptor TIE-2 are also 
known for their regulating capacities regarding angiogenesis. The two ligands bind with 
equal affinity to TIE-2 but have different functions. Angiopoietin-1 maintains vessel in-
tegrity and plays a role in the later stages of vascular remodelling [Geva, Jaffe 2000]. 
Transgenic overexpression of Ang-1 in mice results in the development of more complex 
vascular networks [Suri et al., 1998].
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Angiopoietin-2 is a functional antagonist of Ang-1 and leads to loosening of cell/cell 
interactions and allows access to angiogenic inducers like VEGF [Maisonpierre et al., 
1997]. Co-expression of VEGF and Ang-2 induces angiogenesis, but Ang-2 results in 
vascular regression in the absence of angiogenic signals [Asahara et al., 1998]. Ang-1 is 
widely expressed in the adult, whereas Ang-2 is selectively expressed at sites of active 
angiogenesis, such as ovary, uterus and placenta [Davis et al., 1996; Maisonpierre et al., 
1997].
Vascular adaptation to implantation and its regulation have been studied thoroughly 
with regard to arterial remodelling and placental vascularisation [Craven et al., 1998; 
Kam et al., 1999]. However, it is unknown how maternal decidual vascularisation is regu-
lated and whether regulatory signals are originating from the extra-villous trophoblast 
and/or from pregnancy-induced hormones. Therefore, the present study was performed 
in three first-trimester decidual tissues: decidual secretory endometrium (DSE), decidua 
basalis (DB) and parietalis (DP).
By comparing these decidual tissues within subjects, the changes that occur indepen-
dently of trophoblast invasion, i.e. pregnancy-induced hormones, can be separated 
from the influence of the invasive extra-villous trophoblast (EVT, Fig. 1). Vascularisation 
pattern and the expressions of VEGF-A, PlGF, Flt-1, KDR, Ang-1, Ang-2 and TIE-2 were 
determined in these three decidual tissues. In this way, decidual vascular adaptation to 
embryonic implantation can be studied in detail.
 
 
 
 
 
Chapter 5 figure 1 
figure 1. Schematic representation of the influences of extra-villous trophoblast and pregnancy-induced 
hormones on decidual tissues of first-trimester pregnancies.
Vascularisation and angiogenic growth factors in human first-trimester decidua 77
MAteriALs And Methods
Materials
Lysis buffer (Tris 20 mM pH 7.4, EDTA 1 mM pH 8.0, 2% SDS), 20 mg/ml proteinase K 
(Life-Technologies Gibco BRL, Gaithersburg MD) and solution D (4 M guanidium iso-
thiocyanate, 0.75 M Sodiumcitrate, 10% sarkosyl and 2-mercapto-ethanol) were used for 
RNA isolation. cDNA synthesis was performed using Ready-to-go You-Prime first strand 
beads (Amersham Biosiences, Buckinghamshire, UK). Primer and probe (FAM/TAMRA 
double-labelled) sets for VEGF-A, VEGF-R1 (Flt-1), VEGF-R2 (KDR), PlGF, Angiopoietin-1 
(Ang-1), Angiopoietin-2 (Ang-2), TIE-2 and GAPDH (VIC-labelled) were purchased from 
Applied Biosystems (Foster City, CA USA).
The following first antibodies were used: broad spectrum polyclonal rabbit anti-cytoker-
atin (1:2000, Z0622, DAKO, Glostrup Denmark), monoclonal mouse anti-CD34 (1:1000, 
QBend/10, Novocastra, Newcastle upon Tyne, UK), polyclonal rabbit anti-VEGF-A (1:100, 
sc-152, Santa Cruz, CA, USA), polyclonal rabbit anti-VEGFR-1 (Flt-1, 1:50, sc-316, Santa 
Cruz, CA, USA), monoclonal anti-VEGFR-2 (KDR, 1:50, sc-6251, Santa Cruz, CA, USA), 
polyclonal goat anti-PlGF (1:200, sc-1880, Santa Cruz, CA, USA), polyclonal goat anti-
Angiopoietin-1 (1:50, sc-6319, Santa Cruz, CA, USA), polyclonal goat anti-Angiopoietin-2 
(1:50/, sc-7016, Santa Cruz, CA, USA) and polyclonal rabbit anti-TIE-2 (1:100, sc-9026, 
Santa Cruz, CA, USA).
The following second antibodies were used: biotinylated horse anti-mouse antibody 
(1:300, BA-2000, Vector, Burlingame, USA), biotinylated donkey anti-rabbit antibody 
(1:300, RPN1004, Amersham Biosciences, Buckinghamshire, UK), biotinylated rabbit 
anti-goat (1:300, E-0466, DakoCytomation, Glostrup, Denmark). Immunohistochemi-
cal reactions were visualised using avidin-biotin complex (DakoCytomation, Glostrup, 
Denmark) and NovaRED (Vector, Burlingame, USA).
study group
Decidua samples were obtained from women (n=32) with a healthy, viable intrauterine 
gravidity, undergoing vacuum aspiration due to a legal voluntarily abortion. The study 
was approved by the ethics committee of the Leiden University Medical Centre and in-
formed consent was provided by all study subjects. Foetal cardiac activity and gestational 
age were confirmed by ultrasound. Women with symptoms of a missed abortion, such as 
vaginal bleeding, and women with underlying pathologies were excluded. Inconsistency 
between the ultrasound-determined gestational age and the known last day of menstrua-
tion also led to exclusion.
Two groups were formed based on gestational age (GA). We created two distinct groups 
with mean GA<8-9 weeks and GA>8-9 weeks. This cut-off of GA 8-9 weeks was chosen 
because evidence exists that this period is associated with changes in placental vascu-
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larisation [Burton et al., 1999]. After 8-9 weeks of GA, the intervillous space is gradually 
filled with maternal blood, causing oxygen level and oxidative stress to rise, thereby 
stimulating placental differentiation and vascularisation. This process is thought to be 
largely completed at 12 weeks gestation. This cut-off was the basis of the early first-
trimester group (n=25) with a mean GA of 45.3 days (± 7.8) and the late first-trimester 
group (n=8) with a mean GA of 90.1 days (± 12.6). Maternal age and number of previ-
ous pregnancies and miscarriages did not differ significantly between the two groups. 
Patient characteristics of the study groups are given in Table 1.
tissue samples
Decidua samples were obtained from the aspirated tissue, fixed in formaldehyde and 
embedded in paraffin. A Hematoxilin Phloxin Safrane (HPS) staining was used to dif-
ferentiate between decidua and decidual secretory endometrium (DSE), which micro-
scopically resembles secretory endometrium during the menstrual cycle. Decidua basa-
lis (DB) and decidua parietalis (DP) were differentiated by the presence or absence of 
extra-villous trophoblasts using an anti-cytokeratin staining (Fig. 2). Only subjects with a 
complete set of DSE, DB and DP were included. Serial sections of the paraffin embedded 
tissue samples were used for all experiments and all outcome measures were compared 
between tissues within subjects.
rnA isolation and cdnA synthesis
RNA was extracted from paraffin embedded tissue samples based on methods described 
previously [Specht et al., 2001]. In short, 5 µm sections were mounted on RNase-free 
glass slides. The first and last sections were used to verify the presence of the tissues 
of interest. The other sections were deparaffinised and the tissues of interest, DSE, DP 
and DB (without villous tissue), were macro-dissected and dissolved in 190 µl lysis buf-
fer and 10 µl proteinase K for 18 hours at 60°C. Subsequently, 400 µl Solution D was 
added and RNA was isolated according to the Chomczynski method [Chomczynski, Sac-
chi 1987]. RNA quantity and quality was determined by measuring its absorbance in a 
table 1. Characteristics of the study subjects.
group i (n=25)
Mean ± SD
group ii (n=8)
Mean ± SD
Maternal Age (years) 29.4 ± 6.9 29.6 ± 14.4
Gestational age (days) 45.3 ± 7.8 90.1 ± 12.6
Gestational age (weeks)  6.5 ± 1.1 12.6 ± 1.8
Number of pregnancies  1.3 ± 0.3  1.6 ± 0.5
Number of Miscarriages  0.2 ± 0.1  0.4 ± 0.3
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spectrophotometer (Nanodrop ND-1000) and reverse transcription was performed with 
1 µg total RNA, random primers and a cDNA synthesis kit.
real-time rt-pcr
The mRNA expression was quantified according to the Taqman real-time PCR method 
using validated primer and probe (FAM/TAMRA double-labelled) sets for VEGF-A, VEGF-
R1 (Flt-1), VEGF-R2 (KDR), PlGF, Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), TIE-2. 
glycerylaldehyde-3-phosphate dehydrogenase (GAPDH, primers/VIC-labelled probe) 
was used as an endogenous reference gene. Other genes, β-actin, β
2
-microglobulin and 
cyclophilin, were also used as reference genes and showed comparable results (data not 
shown). RT-PCR reactions for target gene/GAPDH pairs were performed in duplicate, 
expressed in cycle threshold (Ct) and quantified into ng/µl using a standard curve of 
total RNA. The amount of RNA expression of DSE was set at 100% to compare DSE with 
DP and DB and the gene expression of DP was set at 100% to compare DP with DB. 
Water and negative-RT samples, obtained by the omission of the reverse transcriptase 
enzyme in the cDNA reaction, were used as negative controls.
immunohistochemistry
Serial sections were deparaffinised, endogenous peroxidase was quenched with 3% 
H
2
O
2
/methanol and aspecific binding was reduced by incubation with 5% bovine se-
rum albumin. Antigen retrieval in trypsin was used for the detection of TIE-2, whereas 
detection of cytokeratin, Ang-2 and Ki67 required boiling in 0.1 M citrate buffer. Primary 
antibodies were applied overnight at 4°C followed by incubation with a biotinylated sec-
ondary antibody. Antibody binding was visualised using avidin-biotin and streptavidin-
horseradish peroxidase conjugates. Sections were counterstained with Mayer’s hema-
toxylin. Specificity of the immunohistochemical reaction was verified by the omission of 
the first antibody as well as using normal mouse, goat or rabbit serum as first antibody. 
To evaluate the expression in extra-villous trophoblast, cytokeratin and target protein 
staining were performed on serial sections of 3 µm.
evaluation of the vascularisation pattern
CD34-stained endometrial sections were used to scan sequential fields. Two to four 
samples of each type of tissue were analysed of each study subject and six fields per 
sample were scanned at 100x magnification. The number of vessels per mm2, vascular 
surface per mm2 (mm2/mm2) and luminal surface (µm2/vessel) were determined using 
image analysis software (Qwin, Leica Microsystems).
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evaluation of immunohistochemical staining
Immunostaining was evaluated by calculating a staining index (SI): proportion of stained 
cells x staining intensity. The proportion of stained cells was expressed as 0, 1, 2 or 3, 
which marks positive staining signal in 0%, <10%, 10-50% or >50% of the cells of a 
particular cell population. The intensity of staining was expressed as 1, 2 or 3 (weak, 
moderate or strong staining, respectively). The minimum score was 0 and the maximum 
score 9 [Nap et al., 2004]. The average score of two independent observers was used to 
calculate the mean and total staining index (Mean and Total SI). The Mean SI represents 
the protein expression per studied cell type. The Total SI represents the total protein 
expression per tissue and was calculated as the sum of the Mean SI of endothelial cells 
(EC), peri-vascular smooth muscle cells (PSMC), glandular epithelium (GE) and stromal 
cells (SC) in DSE and DP samples. The Mean SI of EVT was also included in the Total SI 
of DB samples.
Figure 2, Plaisier et al
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figure 2. Cytokeratin expression and vascularisation in the three decidual tissues.
Differentiation between three decidual tissues was obtained by HPS and anti-cytokeratin staining (top 
panel). DSE and DP expressed cytokeratin only in glandular epithelial cells (closed arrows), whereas 
cytokeratin is also expressed in extra-villous trophoblasts of DB (open arrows). The vascularisation pattern 
in human decidual tissues was determined by image analysis of anti-CD34-stained sections (middle and 
bottom panel). CD34 antigen expression in endothelial cells (arrows) of DSE, DP and DB was compared 
within subjects. Data were analysed using the repeated measures ANOVA. A. The number of vessels per 
mm2, B. the vascular surface per area (mm2/mm2) and c. the luminal surface (µm2/vessel) were calculated 
and expressed as mean ± SEM. ∗ p<0.0001; ♦ p< 0.04. Bar =100 µm.
(see colour figures supplement)
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statistical analysis
All parameters were compared between DSE and DP, between DSE and DB and be-
tween DP and DB within subjects. A general linear model for repeated measurements, 
repeated measures ANOVA, was performed to analyse the double paired data within 
subjects of early first-trimester decidua as well as to compare data between the early and 
late first-trimester group (SPSS 11.5). Where appropriate we used Friedman’s test for 
non-parametric investigations of correlated observations. The used statistical analyses 
are described in legends and table footnotes. P-values of < 0.05 were considered signifi-
cant.
resuLts
Vascularisation in early first-trimester decidua
Intense CD34 staining was observed in all vessels of the three decidual tissues, with no 
difference in staining intensity between the tissues.
The vessel density was significantly elevated in DSE (116.4 vessels/mm2) compared to 
DP (41.7 vessels/mm2, p<0.001) and DB (31.8 vessels/mm2, p<0.0001); vessel density 
in DP and DB also differed significantly (p<0.03, Fig 2A). Since the stromal cells con-
centration differed between the tissues (434 cells/ mm2 in DSE, 208 cells/mm2 in DB 
and DP, p<0.05), vessel density was corrected for the stromal cell count. The corrected 
vessel density showed a similar pattern; density was elevated in DSE (0.28 vessels/
stromal cells) compared to DP and DB and elevated in DP (0.20 vessels/stromal cells) 
compared to DB (0.15 vessels/stromal cells).
The vascular surface was significantly smaller in DSE (0.020 ± 0.0001 mm2/mm2) com-
pared to DP (0.041 ± 0.001 mm2/mm2) and DB (0.063 ± 0.004 mm2/mm2, all p<0.0001, 
Fig. 2B). The vascular surface in DP differed significantly from that in DB (p<0.04).
DSE showed a significant smaller luminal surface in comparison with DP (208 versus 
1474 µm2/vessel, p<0.0001) and DB (3465 µm2/vessel, p<0.001); this parameter was 
also significantly smaller in DP compared to DB (p<0.05, Fig 2C).
Thus, pregnancy-induced hormones and extra-villous trophoblasts influence vasculari-
sation, since larger but fewer vessels were present in DP compared to DSE and in DB 
compared to DP (Fig. 1 and 2).
mrnA levels of angiogenic factors
The expression of several angiogenic growth factors and their receptors were evaluated 
at the RNA level (Table 2). All tested genes were expressed by the three decidual tissues. 
First, the mRNA levels of the angiogenic factors in DSE were compared with those in DP. 
Only TIE-2 was differentially expressed, reflected by a 49% reduction in DP compared 
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to DSE (p<0.02). The other genes, VEGF-A, PlGF, Flt-1, KDR, Ang-1 and Ang-2, showed 
comparable mRNA levels in DP and DSE (Table 2).
Subsequently, the mRNA levels in DSE were compared to those in DB. This comparison 
showed a 1286 % induction of PlGF, 61% reduction of Ang-1, 66% reduction of Ang-2 
and a 79% reduction of TIE-2 in DB compared to DSE (Table 2, p<0.02). The expressions 
of VEGF, Flt-1 and KDR did not differ significantly. Finally, mRNA expressions in DB were 
compared to that in DP to evaluate the influence of the extra-villous trophoblast (EVT). 
This comparison demonstrated a similar pattern as the comparison DSE to DB, namely 
an increased expression of PlGF (3000%) and reduced expressions of Ang-1 (45%), 
Ang-2 (64%) and TIE-2 (57%) in DB compared to DP (Table 2, all p<0.01).
the expression of angiogenic factors at protein level of early first-trimester decidua
The distribution of angiogenic factors was determined at the protein level in serial sec-
tions of DSE, DP and DB. The studied proteins were detectable in all decidual tissues 
(Table 3).
The protein expressions in DSE were compared to those in DP, which only showed a 
higher total staining index for Flt-1 in DP (Table 3, p<0.05). In addition, when DSE and 
DB were compared, higher endothelial and total expressions of both PlGF and its recep-
tor Flt-1 were demonstrated in DB. The total Ang-1 expression was lower in DB (Table 
3, p<0.05). Thirdly, DB was compared to DP and this showed a similar pattern as the 
comparison DSE and DB, namely higher total and endothelial expressions of PlGF and 
Flt-1 in DB (Table 3, Fig. 3A, C and E, p<0.05). Also, the total Ang-1 expression was less 
abundant in DB (p<0.01), which resulted in a higher Ang-2/Ang-1 ratio in DB than in the 
other tissues (2.6 vs.1.4 and 1.2, p<0.01). The expressions of VEGF-A, KDR, Ang-2 and 
TIE-2 proteins were comparable in the three tissues.
table 2. Differential gene expression in early first-trimester decidua a.
dseb dp dseb dB dpc dB
plgf 100 %  82 ± 21% 100 %  1286 ± 302%* 100 %  3000 ± 237%$
Vegf-A 100 %  85 ± 12% 100 %  96 ± 14% 100 %  134 ± 36%
kdr 100 %  105 ± 16% 100 %  74 ± 15% 100 %  76 ± 14%
flt-1 100 %  105 ± 14% 100 %  130 ± 24% 100 %  131 ± 23%
Ang-1 100 %  92 ± 17% 100 %  39 ± 11%* 100 %  55 ± 15%$
Ang-2 100 %  115 ± 29% 100 %  34 ± 8%* 100 %  36 ± 6%$
tie-2 100 %  51 ± 11%# 100 %  21 ± 5%* 100 %  43 ± 7%$
a RNA levels were determined by RT-PCR in DSE, DP and DB of early first-trimester (n=25) and compared 
within subjects. The ‘repeated measures ANOVA’ was performed to analyse the data.
b The RNA levels of DSE was set at 100% to compare mRNA levels in DSE with those in DP and DB.
c The RNA levels of DP was set at 100% to compare DP with DB.
# p < 0.02 DP compared to DSE, * p < 0.02 DB compared to DSE, $ p < 0.01 DB compared to DP.
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Endothelium displayed the expression of all angiogenic factors, except Ang-1 (Fig. 3A and 
F). VEGF-A was hardly detectable in endothelium (Fig. 3A and B). Ang-2 and KDR were 
mainly expressed by glandular epithelium and PSMCs, but also by endothelial cells (Fig. 
table 3. Protein expression of angiogenic factors in early first-trimester decidua a.
ecb psMcb geb scb eVtb total sic
Vegf dse 0.1 3.5 5.3 1.7 NP 10.6
dp 0.3 3.3 6.2 3.0 NP 13.1
dB 0.0 2.5 4.9 2.6 3.3 13.3
plgf dse 0.1 3.4 5.4 2.5 NP 11.4
dp 0.1 2.4 4.8 3.0 NP 10.3
dB 0.9 * 2.7 6.2 3.3 2.8 15.9 *
kdr dse 1.0 5.4 6.0 0.7 NP 13.1
dp 0.6 3.5 4.7 2.2 NP 11.0
dB 0.9 3.2 4.4 2.0 0.8 11.3
flt-1 dse 0.5 2.7 5.8 1.6 NP 10.6 &
dp 0.4 3.3 5.6 3.3 NP 12.6
dB 1.2 * 3.4 5.4 2.5 2.2 14.7 *
Ang-1 dse 0.0 1.1 4.7 0.3 NP 6.1
dp 0.0 1.3 4.4 0.9 NP 6.6
dB 0.1 0.0 3.1 0.2 0.0 3.4 *
Ang-2 dse 0.2 1.7 5.6 0.0 NP 7.5
dp 0.6 1.1 6.2 1.7 NP 9.6
dB 0.7 1.5 4.9 0.9 0.9 8.9
tie-2 dse 1.8 3.2 6.0 2.2 NP 13.2
dp 2.3 3.5 5.1 4.1 NP 15.0
dB 1.8 2.1 4.1 3.1 2.8 13.9
a The protein expression of angiogenic factors in DSE, DP and DB were compared within subjects. Friedman 
test, a non-parametrical test for paired samples, and the Wilcoxon test were used for statistical analysis.
bc The staining was expressed as mean staining indices per cell type and as the total staining indices (total 
SI), which is the sum of the mean staining indices of endothelial cells (EC), peri-vascular smooth muscle 
cells (PSMC), glandular epithelium (GE), stromal cells (SC) and extra-villous trophoblasts (EVT) per 
decidual tissue.
NP = not present. * p<0.05 in DB versus DP and DSE, & P<0.05 in DSE versus DP.
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3A, D and G). Moreover, TIE-2 showed the highest expression in endothelium (Table 3, 
Fig. 3A and H).
All angiogenic factors, except Ang-1, were also detected in extra-villous trophoblasts; 
PlGF, VEGF, Flt-1 and TIE-2 were moderately expressed, whereas KDR and Angiopoi-
etin-2 expressions were weak (Table 3, Fig. 4).
Vascularisation and expression of angiogenic factors in late first-trimester decidua
The vascularisation parameters in late first-trimester decidua showed similarities with 
vascularisation in the early first-trimester; the vascular and luminal surface were larger 
and vessel density was smaller in DP and DB compared to DSE and in DB compared 
to DP (all p<0.05, Fig. 5A, B and C). Comparison of the vascularisation patterns at both 
time points showed that the vessel density was lower in DB and DP of late first-trimester  
 
 
 
Chapter 5 figure 3 figure 3. Protein expression of angiogenic factors in endothelium of early first-trimester decidua.
The protein expression of angiogenic factors was determined in DSE, DP and DB. Friedman test, a non-
parametrical test for paired samples, and the Wilcoxon test were used for statistical analysis. A. Protein 
expression of each angiogenic factor in endothelium was expressed as the mean staining index ± SEM and 
B-h show examples of these expressions. B. Endothelial VEGF expression was not detectable in DB. c. PlGF 
was expressed in epithelium (open arrow) and endothelium (closed arrow) of DB. d. Endothelial KDR 
expression (closed arrow) and stromal KDR expression (open arrow) in DB. e. Endothelial Flt-1 expression 
in DB (arrow) f. Angiopoitein-1 in DB was detected in epithelium (open arrow), but not in stromal and 
endothelial cells (closed arrow). g. Endothelial angiopoietin-2 expression in DB (arrow). h. Endothelial 
TIE-2 expression in DB (arrow).  DSE,   DP,   DB. Bar = 100 µm (except F = 50 µm).
(see colour figures supplement)
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(17.8 vs. 31.8 vessels/mm2 in DB and 29.2 vs. 41.7 vessels/mm2 in DP, p<0.05). The 
luminal surface was larger, although not significantly, in DB and DP of late first-trimester, 
namely 5447 vs. 3465 µm2/vessel in DB and 1829 vs. 1474 µm2/vessel in DP (Fig.5B). The 
vascular surface was similar in decidua at the two time points (Fig. 5C).
Then, mRNA levels in early and late first-trimester were compared. VEGF-A and Ang-2 
mRNA were both induced in late first-trimester DB and DP as compared to early first-
trimester; the induction was 347% (p=0.08) in DB and 288% (p<0.01) in DP for VEGF-A 
and 257% (p<0.01) in DB and 171% (p<0.01) in DP for Ang-2. Genes in DSE showed no 
differential expression in time. At the protein level, total VEGF, Ang-1 and Ang-2 protein 
expressions were elevated in DB of late first-trimester compared to early first-trimester 
(165%, 288% and 174% respectively, p<0.002). Interestingly, VEGF and PlGF proteins 
 
 
Chapter 5 figure 4 
figure 4. Protein expression of angiogenic factors in extra-villous trophoblasts (EVT) of early first-trimester 
decidua.
The prot in expression of angiogenic factors in EVT in decidua basalis (DB) was studied in serial sections 
stained against cytokeratin and the target protein. A. Protein expression in EVT was expressed as the mean 
staining index ± SEM. B. Cytokeratin (arrows) and c. serial PlGF expression (arrows) in EVT. Bar = 50 um.
(see colour figures supplement)
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were detected in higher amounts on the endothelium of late first-trimester decidua than 
in early first-trimester (Fig. 5D and E, p<0.05). Endothelial Flt-1, KDR, Ang-2 and TIE-2 
expressions were comparable in early and late first-trimester.
discussion
The present study showed differences in vascularisation pattern between decidual se-
cretory endometrium (DSE), decidua basalis (DB) and decidua parietalis (DP). These 
vascular changes correlated with differences in gene expression. Furthermore, analysis 
of vascularisation in early and late first-trimester decidua suggests that decidual vascu-
larisation is remodelled as gestation progresses to meet up with the increasing needs of 
the implanting embryo.
Maternal vascular adaptation to implantation and its regulation has been subject to 
discussion, but has only been studied thoroughly with regard to arterial remodelling and 
villous vascularisation [Craven et al., 1998; Kam et al., 1999]. The present study focused 
on decidual vascular adaptation to implantation and its regulation. The comparison 
of three decidual tissues, DSE, DB and DP, within subjects provides the opportunity 
 
Chapter 5 figure 5 
 
 
figure 5. Vascularisation pattern and endothelial protein expression in early versus late first-trimester 
decidua.
The vascularisation pattern in human early (black bars) and late (white bars) first-trimester decidual tissues 
was determined by image analysis of anti-CD34-stained sections. Data were analysed using the repeated 
measures ANOVA. A. The number of vessels per mm2, B. the vascular surface per area (mm2/mm2) and c. 
the luminal surface (µm2/vessel) were expressed as mean ± SEM. VEGF expression was not detectable in 
early first-trimester endothelium of DB (arrow, d), whereas the expression was present in late first- trim. 
endothelium of DB (arrow, e). Early first-trimester and late first-trimester. Bar = 50 um, ∗ p<0.04.
(see colour figures supplement)
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to separate the influence of the extra-villous trophoblast (EVT) from the changes that 
occur independently of trophoblast invasion (Fig. 1). Furthermore, all methods were 
performed on serial paraffin sections, which allowed studying vascularisation, RNA and 
protein expression in the same tissue.
Changes in vascularisation pattern, the increase of vascular and luminal surfaces and 
decrease of vessel density, were detected between the three decidual tissues DSE, DP 
and DB. The enlargement of the vascular surface per area in DB and DP has been re-
ported previously and likely is functionally related to the increased blood flow during 
pregnancy [Kam et al., 1999; Gibbons, Dzau 1994]. The increase in luminal diameter may 
represent an additional modulatory effect, although the possibility that this was due to 
vasodilatation cannot be excluded. Increased luminal diameter in DP and DB could also 
be induced by a relatively low oxygen levels, but whether oxygen levels in DP, DB and 
DSE differ is not known [Charnock-Jones 2002].
The vessel density in decidual secretory endometrium (116 vessels/mm2) is lower than 
the vessel density reported in cycling secretory endometrium, 186 vessels/mm2 reported 
by Rogers et al and 195 vessels/mm2 by Plaisier et al [Plaisier et al., 2006; Rogers et al., 
1993]. Possibly, vascularisation in DSE is already affected by hormones, although the 
decidual morphology is not yet present. The decreased vessel density in DP and DB 
compared to DSE and DB compared to DP suggests fusion or degeneration of vascular 
structures. Vailhe et al reported a non-significant decreased vessel density in DB com-
pared to DP, but did not study DSE [Vailhe et al., 1999]. The vessel density reported in 
their study, ranging between 20 and 30 vessels/mm2, is comparable with our findings. 
Overall, the vascular differences between the decidual tissues indicate a regulatory role 
in decidual vascularisation for both pregnancy-induced hormones and the EVT.
Both steroidal hormones and EVT are able to modulate vascularisation directly or indi-
rectly via angiogenic factors like VEGF-A, PlGF, angiopoietins and hCG [Greb et al., 1997; 
Hyder, Stancel 1999/2000; Krikun et al., 2004b; Licht et al., 2003; Simoncini et al., 2003; 
Toth et al., 1994/2001; Wulff et al., 2000; Zygmunt et al., 2002]. Therefore, we studied 
whether the changes in vascularisation in the decidual tissues correlated with a differ-
ential expression of angiogenic factors. First, gene and protein expressions in DSE and 
DP were compared. Although TIE-2 mRNA was the only differentially expressed mRNA, 
its protein expression was not significantly differing between DSE and DP. This suggests 
that TIE-2 protein expression is not influenced by pregnancy-induced hormones, which 
is in agreement with the finding that TIE-2 protein expression is not regulated during the 
menstrual cycle [Krikun et al., 2000]. The presence of endothelial TIE-2 in all decidual 
tissues suggests that TIE-2 plays a rather general role in decidual vascularisation.
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The differential expression of the studied angiogenic factors did not provide a satisfac-
tory explanation for the vascular differences between DSE and DP. Possibly, steroidal 
hormones act through other angiogenic factors or exert direct effects on decidual en-
dothelium.
Subsequently, the expressions of angiogenic factors in DB were compared to those in 
DSE and DP. Ang-1, Ang-2 and TIE-2 mRNA expressions were significantly lower in DB 
compared to both DSE and DP and therefore appear to be regulated by the EVT. The 
decreased TIE-2 expression might result from the decreased Ang-1 and/or Ang-2 levels, 
since mice lacking Ang-1 have reduced TIE-2 mRNA levels [Suri et al., 1996]. At protein 
level, the Ang-2/Ang-1 ratio was significantly elevated in DB compared to DP and DSE, 
suggesting that vessel destabilization is favoured over vessel maturation in DB. The 
high amount of Ang-2, together with the abundant VEGF expression, may lead to more 
angiogenesis in DB which is in concordance with the increased vascular surface in DB 
[Asahara et al., 1998].
Interestingly, all three decidual tissues showed Ang-2/Ang-1 ratios in favour of Ang-2. 
Embryonic implantation normally occurs under hypoxic conditions and oxygen levels 
in decidua are relatively low in the first-trimester, ranging between 50 and 75 mmHg 
[Jauniaux et al., 2000]. Hypoxia enhances Ang-2 transcription and destabilizes Ang-1, 
which may result in the increased Ang-2/Ang-1 ratio [Zhang et al., 2001]. Although 
implantation appears to favour Ang-2, a small amount of Ang-1 must be essential for 
implantation since disruption of the Ang-1 gene in mice results in embryonic lethality 
[Suri et al., 1996].
Another striking observation was the abundant induction of PlGF mRNA and proteins in 
DB compared to DSE and DP. The increased PlGF protein expression was not only due 
to PlGF production by EVT, since all studied cell types, except PSMCs, showed increased 
PlGF protein expression in DB. Furthermore, uterine NK cells are known for their PlGF 
production as well and probably contribute to the production of angiogenic factors in 
decidua as well.
Interestingly, PlGF and its receptor, Flt-1, were mainly expressed on endothelium of DB. 
PlGF, together with Flt-1, is able to potently induce angiogenesis resulting in mature and 
stable vessels [Arroyo et al., 2004; Carmeliet et al., 2001; Khaliq et al., 1996; Luttun et al., 
2002; Torry et al., 1999]. The induction of PlGF and Flt-1 mRNAs and proteins in decidua 
basalis suggests that both factors play a specific role in regulating angiogenesis at the 
site of implantation and may, at least partially, account for the vascular changes noticed 
in decidua basalis.
VEGF mRNAs and proteins were abundantly, but not differentially, expressed in all de-
cidual tissues and KDR, Flt-1 and VEGF proteins were expressed on endothelium in 
Vascularisation and angiogenic growth factors in human first-trimester decidua 89
DB and DP. These findings suggest a general role for VEGF in angiogenesis in human 
decidual tissues.
As gestation progresses, vascular adaptation continues which manifested itself in the 
present study by decreased vessel density in DB and DP. VEGF and Ang-2 mRNA and 
VEGF, Ang-1 and -2 protein expressions were increased in late first-trimester DB. These 
increased levels of the angiogenic factors suggest increased angiogenic activity at the 
implantation site as gestation progresses. This was further supported by the increased 
endothelial expression of PlGF and VEGF proteins in late first-trimester decidua.
The vascular adaptation to implantation is clearly important in the development of a 
healthy pregnancy. We have shown that vascular adaptation occurs under influence of 
both pregnancy-induced hormones and the extra-villous trophoblast, by enhancing the 
vascular surface, reducing vessel density and regulating the expression of angiogenic 
factors. VEGF-A, via KDR, probably plays a general role in supporting decidual vascu-
larisation, whereas the angiopoietins, via TIE-2, and PlGF, via Flt-1, appear to be key 
regulators of the vascular adaptive process and may, partially, account for the vascu-
lar changes at the site of embryonic implantation in decidua basalis. Finally, studying 
vascularisation during mammalian implantation hopefully leads to new understandings 
of currently inexplicable events associated with pregnancy, such as pre-eclampsia and 
missed abortions.
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ABstrAct
objective: Proteolysis is essential for decidual development during embryonic im-
plantation, but little is known regarding the expression and functions of membrane-
type matrix metalloproteinases (MT-MMPs) and urokinase and its receptor uPAR in 
decidua. Therefore, their protein and mRNA expressions were analysed in three first-
trimester decidual tissues, decidual secretory endometrium (DSE), decidua parietalis 
(DP) and basalis (DB).
Methods: Decidua was obtained during first-trimester pregnancy termination. uPA, 
uPAR, and MT1/2/3/5-MMP expression were studied by RT-PCR and immunohis-
tochemistry, and CD56-positive uNK cells and CD68-positive macrophages were 
quantified in serial sections.
results/conclusion: The mRNAs and antigens of all proteases and uPAR were de-
tectable in the decidual tissues and extravillous trophoblasts (EVT). mRNA levels of 
all proteases and uPAR, except MT5-MMP, were elevated in both DB and DP com-
pared to DSE, being significant for MT1-MMP and uPAR in DP. MT2- and MT3-MMP 
mRNAs in DB were 24- and 10-fold higher than in DSE, and 19- and 7-fold increased 
compared to DP. At the protein level uPA and uPAR were particularly elevated in 
DB, while pro-angiogenic MT1- and MT3-MMPs were elevated in both DB and DP 
compared to DSE. MT2-MMP was prominent present in all conditions. The number 
of uNK cells was increased in DB and DP versus DSE, while a comparable increase 
in macrophages did not reach statistical significance. These data are consistent with 
a differential regulation of peri-cellular proteases in decidua by pregnancy-induced 
hormones, immune cells and EVT.
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introduction
Proteolysis is essential for decidual remodelling and vascularisation during implanta-
tion. Disturbances in decidual development may play a role in the pathogenesis of mis-
carriages and pre-eclampsia [Solberg et al., 2003; Vailhe et al., 1999; Vuorela et al., 2000; 
Zygmunt et al., 2003]. Endometrial adaptation to implantation starts during the receptive 
secretory phase of the menstrual cycle and continues throughout the first-trimester. This 
adaptation includes decidualisation, tissue remodelling, angiogenesis, and immune cell 
invasion. The invasion of immune cells is enormous: from 8% of total stromal cells dur-
ing the menstrual cycle up to 30% during the first-trimester. Approximately 70% of these 
leucocytes are uNK cells and 10% are macrophages [Bulmer et al., 1991].
Decidual remodelling, cell invasion as well as angiogenesis are facilitated by proteolysis. 
Trophoblasts, uNK cells and endothelial cells require proteolytic activity to degrade their 
extra cellular matrix (ECM) proteins and to migrate [Al Atrash et al., 2001; Heymans 
et al., 1999; Pepper 2001; Stetler-Stevenson 1999; Salamonsen 1999]. These cells are 
able to generate proteolytic activity by either producing proteases or using proteases 
on neighbouring cells and/or ECM [Albertsson et al., 2000; Kim et al., 2000; Koolwijk et 
al., 2001; Salamonsen 1999; Van den Heuvel et al., 2005b]. Key regulators of proteolysis 
belong to the family of matrix metalloproteinases (MMPs), in particular to the subgroup 
of membrane-type matrix metalloproteinases (MT-MMPs), and to the plasmin/plasmi-
nogen system [Alfano et al., 2005; Kindzelskii et al., 2004; Reuning et al., 2003].
The membrane-associated localisation of MT-MMPs makes them suited for pericellular 
proteolysis [Egeblad, Werb 2002; Hotary et al., 2000; Seiki, Yana 2003; Van Hinsbergh et 
al., 2006]. We studied the transmembrane-spanning MT-MMPs, MT1- (MMP-14), MT2- 
(MMP-15), MT3- (MMP-16) and MT5-MMP (MMP-24). Only these MT-MMPs have the 
proteolytic potential to induce capillary tube formation, while the GPI-anchored MT4- 
and MT6-MMP were unable to do so [Hotary et al., 2000]. MT-MMPs are inhibited by 
tissue inhibitors of matrix metalloproteinases (TIMPs); TIMP-1 inhibits all MT-MMPs, 
except MT1-MMP, while TIMP-2 and -3 inhibit all MT-MMPs [Hernandez-Barrantes et al., 
2002; Visse, Nagase 2003]. MT1-MMP is also inhibited by TIMP-4 [Bigg et al., 2001].
MT1-MMP is the best known MT-MMP, which degrades ECM components and pro-
motes cell migration, angiogenesis and tumour metastasis [Collen et al., 2003; Galvez et 
al., 2001; Hiroaka et al., 1998; Lafleur et al., 2002; Seiki, Yana 2003; Sounni et al., 2002; 
Visse, Nagase 2003;]. MT2- and MT3-MMP are less well studied and are known to be 
involved in cell migration and invasion. MT1-, MT2- and MT3-MMP induce angiogenesis 
in vitro and MT2- and MT3-MMP may even be potential regulators of endometrial angio-
genesis in vivo [Collen et al., 2003; Galvez et al., 2001; Hiroaka et al., 1998; Hotary et al., 
2000; Hotary et al., 2002; Lafleur et al., 2002; Plaisier et al., 2004; Plaisier et al., 2006]. 
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MT5-MMP is known for a gelatinolytic effect in the brain, which induces embryonic brain 
development and axonal growth [Llano et al., 1999; Pei 1999].
With regard to MT-MMPs in decidua, only MT1- and MT2-MMP have been studied. MT1- 
and MT2-MMP RNA and protein expression are described in decidual extracts, stromal 
cells, and the extra-villous trophoblast [Bai et al., 2005; Bjorn et al., 2000; Curry, Osteen 
2003; Hurskainen et al., 1998; Nakano et al., 2001; Nawrocki et al., 1996]. MT-MMPs 
are assumed to regulate trophoblast invasion during implantation [Salamonsen 1999]. 
Whether migration of other cell types, e.g. immune and endothelial cells, is also regu-
lated by MT-MMPs remains to be seen.
The plasminogen activator (PA) system is based on the protease plasmin, which cleaves 
most ECM components. The circulating protein plasminogen is converted into the active 
protease plasmin by either tissue-type plasminogen activator (tPA) or urokinase-type 
plasminogen activator (uPA). tPA is mainly involved in clot dissolution, whereas uPA 
mediates pericellular proteolysis during cell migration, tissue remodelling and angio-
genesis [Van Hinsbergh et al., 2006]. uPA binds a specific cell-surface receptor, uPAR, 
which restricts the uPA-activity to the cell environment and enables activation of plasmin 
directly on the cell surface. The activity of uPA is regulated by at least two specific serine 
proteinase inhibitors, plasminogen activator inhibitor type-1 and -2 (PAI-1/2) [Spengers, 
Kluft 1987].
The role of uPA mediated plasminogen activation in cell migration has been studied 
for a variety of cells and for endothelial cells, leucocytes, and trophoblasts in particular 
[Heymans et al., 1999; Reuning et al., 2003; Pepper 2001; Blasi et al., 1987; Hu et al., 
1999; Salamonsen et al., 2003]. Both uPA and uPAR expression has been detected in the 
invasive trophoblast cells, which indicates a role for uPA and uPAR play in trophoblast 
invasion [Hofmann et al.,1994; Hu et al., 1999; Multhaupt et al.,1994; Pierleoni et al., 
1998; Salamonsen et al., 1999].
Little information is available regarding the expression of MT-MMPs and uPA/uPAR in 
the various decidual tissues and cell types. Moreover, their regulation and involvement 
in decidual remodelling, vascularisation, and immune cell and trophoblast invasion is 
not well established.
Endometrial adaptation to pregnancy is induced by pregnancy-induced hormones, i.e. 
hCG, oestradiol and progesterone, immune cells, and the extra-villous trophoblasts 
(EVT). The differential presence of these factors results in the generation of various first-
trimester decidual tissues. Decidual secretory endometrium (DSE) is only pre-decidual-
ised and will develop into decidua parietalis (DP) under influence of pregnancy-induced 
hormones. Decidua basalis (DB) will arise in the additional presence of the EVT. The 
present study analyses the expression of MT-MMPs and uPA/uPAR at mRNA and pro-
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tein level in decidual secretory endometrium (DSE), decidua parietalis (DP) and decidua 
basalis (DB). These parameters will be compared between tissues within subjects. In 
this way, MT-MMP and uPA/uPAR expression in various decidual cell types and decidual 
tissues can be determined. As the influx and activity of immune cells, in particular uNK 
cells and macrophages, may influence that production of proteases, we also compared 
the accumulation of these cells in the same decidual tissues. These data may shed light 
on the functions of the studied proteases in human decidua and might generate new 
hypotheses regarding the inception of pregnancy.
MAteriALs And Methods
study group
Decidua samples were obtained from women (n=32) with a viable intrauterine gravidity, 
undergoing a legal voluntarily abortion. The study was approved by the Institutional Re-
view Board, the ethics committee, of the Leiden University Medical Centre and informed 
consent was provided by all study subjects. Foetal cardiac activity and gestational age 
were confirmed by ultrasound. Women with symptoms of a missed abortion, such as 
vaginal bleeding, and women with underlying pathologies were excluded. Inconsistency 
between the ultrasound-determined gestational age and the known last day of menstrua-
tion also led to exclusion.
Two groups were formed based on a gestational age (GA) of <8-9 and of > 8-9 weeks. 
This cut off was chosen since after 8-9 weeks GA the intervillous space is gradually filled 
with maternal blood, causing the oxygen level and the oxidative stress to rise and thereby 
stimulating placental differentiation and vascularisation [Burton et al., 1999]. This pro-
cess is thought to be largely completed at 12 weeks gestation. The early group (n=25) 
has a mean GA of 45.3 days (6+3 weeks) and the late group (n=8) has a mean GA of 90.1 
days (12+6 weeks). Maternal age and number of previous pregnancies and miscarriages 
did not differ significantly between the two groups. Patient characteristics of the study 
groups are given in Table 1.
tissue samples
Decidua samples were obtained from the aspirated tissue (vacuum aspiration), fixed in 
formaldehyde overnight and embedded in paraffin. Hematoxylin Phloxin Safrane (HPS) 
and anti-cytokeratin staining were performed. Hematoxylin (50 g potassium aluminium-
sulfate, 1 g haematox, 500 mg citric acid, 25 g chloralhydrate, 200 mg NaJO
3
 in 1000 ml 
aqua dest,) stains nuclei and calcium blue. Phloxin (0.25 g phloxin in 100 ml aquadest) 
stains erytrocytes, cytoplasm, fibrin and muscle red. Safrane (3 g safrane in 1000 ml 
100% alcohol) stains calcium free bone, cartilage and collagen yellow. The HPS staining 
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was used to differentiate between decidua and decidual secretory endometrium (DSE), 
which microscopically resembles secretory endometrium. Decidua basalis (DB) and 
decidua parietalis (DP) were differentiated by the presence or absence of extra-villous 
trophoblasts using an anti-cytokeratin staining (see section immunohistochemistry, 
Figure 5).
DSE, DP and DB were obtained from the same curettement and therefore originate from 
the same depth and area of the uterine wall. Only subjects with at least two complete 
set of DSE, DB and DP were included. Serial sections of the paraffin embedded tissue 
samples were used for all experiments and all parameters were compared between tis-
sues within subjects.
rnA isolation and cdnA synthesis
RNA was extracted from paraffin embedded tissue samples [Plaisier et al., 2007; Specht 
et al., 2001]. Several samples per patient were used and these samples contained a 
proportionate amount of cells and cell types. In short, 5 µm sections were mounted on 
RNase-free glass slides. The first and last sections were used to verify the presence of 
the tissues of interest. The other sections were deparaffinised and the tissues of interest, 
DSE, DP or DB (without villous tissue), were macro-dissected and dissolved in 190 µl 
lysis buffer (Tris 20 mM pH 7.4, EDTA 1 mM pH 8.0, 2% SDS) and 10 µl proteinase K (20 
mg/ml proteinase K, Life-Technologies Gibco BRL, Gaithersburg) for 18 hours at 60°C. 
Subsequently, 400 µl Solution D (4 M guanidium isothiocyanate, 0.75 M sodium citrate, 
10% sarkosyl and 2-mercapto-ethanol) was added and RNA was isolated [Chomczynski, 
Sacchi 1987].
RNA quantity and quality were analysed in a spectrophotometer (Nanodrop ND-1000). 
Reverse transcription was performed with 1 µg total RNA, random primers and cDNA 
synthesis kit according to the manufacturer’s protocol and the obtained 32 µl cDNA was 
diluted 1:3 (Ready-to-go You-Prime first strand beads, Amersham Biosciences, Bucking-
hamshire, UK).
table 1. Characteristics of the study subjects.
early first- trimester group
 (n=25)
Mean ± SD
Late first- trimester group
(n=8)
Mean ± SD
Maternal Age (years)a 29.4 ± 6.9 29.6 ± 14.4
Gestational age (days) a 45.3 ± 7.8 90.1 ± 12.6
Number of previous pregnancies a  1.3 ± 0.3  1.6 ± 0.5
Number of previous miscarriages a  0.2 ± 0.1  0.4 ± 0.3
a p>0.05.
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real-time rt-pcr
The mRNA levels were semi-quantified according to the Taqman real-time PCR method 
using validated primer and probe (FAM/TAMRA double-labelled) sets for MT1-, MT2-, 
MT3-, and MT5-MMP, uPA and uPAR. glycerlylaldehyde’-3-phosphate dehydrogenase 
(GAPDH, primers/VIC-labelled probe) was used as an endogenous reference gene (all 
primer/probe sets purchased from Applied Biosystems, Foster City, CA USA). Other 
genes, β-actin, β
2
-microglobulin and cyclophilin, were also used as reference genes and 
showed comparable results (data not shown).
RT-PCR reactions for target gene/GAPDH pairs were performed in 12.5 µl reactions, 
containing 2.5 µl cDNA solution, using mastermix (RT-QP2X-03, Eurogentec, Maas-
tricht, The Netherlands), DNAse free water and the above described primer/probe sets. 
Reactions were performed in duplicate, expressed in cycle threshold (Ct). A standard 
curve for each primer/probe pair was created by determining Ct values of various con-
centrations of total RNA (range 125-0.016 ng/µl). Then Ct values of the samples were 
quantified into ng/µl. RNA levels in DSE was set at 100% to compare DSE with DP and 
DB and the gene expression of DP was set at 100% to compare DP with DB. Water and 
negative-RT samples, obtained by the omission of the reverse transcriptase enzyme in 
the cDNA reaction, were used as negative controls.
immunohistochemistry
Serial sections were deparaffinised, endogenous peroxidase was quenched with 3% 
H
2
O
2
/methanol and aspecific binding was reduced by incubation with 5% bovine se-
rum albumin. Antigen retrieval in a trypsin solution was used for detection of MT2- and 
MT5-MMP [Plaisier et al., 2006]. Heat retrieval in citrate buffer (pH 6.0) was used for 
detection of CD56 and CD68.
The following first antibodies were used: broad spectrum polyclonal rabbit anti-cytok-
eratin (1:2000, Z0622,DAKO,Glostrup Denmark), monoclonal mouse anti-CD56 (IgG
1
, 
1:50, MONX 10844, clone 1B6, Monosan, Uden, the Netherlands), monoclonal mouse 
anti-CD68 (IgG
1
,1:200,M0814, DAKO,GlostrupDenmark), monoclonal mouse anti-MT2-
MMP (IgG
1
, 1:250, 162-22G5, Oncogene Research Products, San Diego, USA), mono-
clonal mouse anti-MT3-MMP (IgG
1
, 1:300, 117-10C6, Oncogene Research Products, San 
Diego, USA), polyclonal rabbit anti-MT5-MMP (1:200, M6684, Sigma-Aldrich, USA), 
monoclonal mouse anti-uPA (IgG
1
, 1:50, 3689, American Diagnostica Inc, Greenwich, 
USA). Polyclonal rabbit anti-MT1-MMP (1:1000) and anti-uPAR (1:400) antibodies were 
produced and characterised as previously described [Collen et al., 2003; Plaisier et al., 
2004; van Boheemen et al., 1995; Koolwijk et al., 1996]. The following secondary antibod-
ies were used: biotinylated horse anti-mouse antibody (1:300, BA-2000, Vector, Burl-
ingame, USA), biotinylated donkey anti-rabbit antibody (1:300, RPN1004, Amersham 
Biosciences, Buckinghamshire, UK).
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Primary antibodies were applied overnight at 4°C followed by one hour incubation with 
biotinylated secondary antibody. Antibody binding was visualised using StreptABCom-
plex/HRP, a streptavidin complexed with biotinylated peroxidase (K0377, DakoCytoma-
tion, Glostrup, Denmark) and NovaRED™ substrate (SK-4800, Vector, Burlingame, 
USA) according to the manufacturer’s protocol. Only CD56 immunohistochemistry was 
stained with DAB (diaminobenzidin). All incubations were performed in 1% bovine se-
rum albumin in PBS.
Sections were counterstained with Mayer’s haematoxylin. Specificity of the immunohis-
tochemical reaction was verified by the omission of the first antibody as well as using 
non-immune mouse IgG
1
, concentration adjusted to primary IgG
1
 concentration, and 
rabbit serum instead of first antibody. To evaluate the expression in extra-villous tro-
phoblast, cytokeratin and target protein staining were performed on serial sections of 3 
µm.
evaluation of immunohistochemical staining
Immunostaining of CD56+ and CD68+ cells was evaluated by counting the number of 
positive cells and the number of stromal cells in a 16 µm2 grid (10 fields per tissue per 
patient). In this way, the mean percentage of positive cells per stromal cells and per µm2 
could be determined.
To limit the possible bias of subjectivity during the evaluation of the immunostaining, we 
have chosen to evaluate the immunostaining of the proteases and uPAR by calculating 
a staining index (SI): proportion of stained cells x staining intensity [Plaisier et al., 2006; 
Plaisier et al., 2007; Nap et al., 2004]. The proportion of stained cells was expressed as 
0, 1, 2 or 3, which marks positive staining signal in 0%, <10%, 10-50% or >50% of the 
cells of a particular cell type. The intensity of staining was expressed as 1, 2 or 3 (weak, 
moderate or strong, respectively). The minimum score was 0 and the maximum score 
9. The average score of two independent observers was used to calculate the mean and 
total staining index (Mean and Total SI).
The Mean SI represents the protein expression per studied cell type. The Total SI rep-
resents the total protein expression per tissue and was calculated as the sum of the 
Mean SI of endothelial cells (EC), perivascular smooth muscle cells (PSMC), glandular 
epithelium (GE) and stromal cells (SC) in DSE and DP samples. The Mean SI of EVT was 
also included in the Total SI of DB samples.
statistical analysis
All parameters were compared between DSE and DP, between DSE and DB and between 
DP and DB within subjects. A general linear model for repeated measurements, repeated 
measures ANOVA, was performed to analyse the double paired data within subjects of 
early first-trimester decidua as well as to compare data between the early and late first-
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trimester group (SPSS 11.5). Sphericity was corrected using the Greenhouse-Geisser cor-
rection. Where appropriate we used Friedman’s test for non-parametric investigations of 
correlated observations. The used statistical analyses are described in legends and table 
footnotes. P-values of < 0.05 were considered significant.
resuLts
mrnA levels of proteases in early first-trimester decidua
The expression of uPA, uPAR and the transmembrane spanning MT-MMPs were evalu-
ated at the mRNA level. All these genes were expressed by the three decidual tissues 
(Table 2).
First, the amounts of specific mRNAs in decidual parietalis (DP) were compared to 
those in decidua secretory endometrium (DSE, 100%). mRNA levels of uPAR and all 
proteases, except MT5-MMP, were elevated in DP, but only MT1-MMP (171%, p<0.05) 
and uPAR (185%, p<0.01) were significantly induced. The mRNA levels of MT5-MMP, 
were comparable in DP and DSE (Table 2).
Subsequently, the mRNA levels in decidua basalis (DB) were compared to those DSE 
(100%). This comparison showed a reduction of MT5-MMP (84%, p<0.01) and an induc-
tion of uPAR (208%, p<0.01), MT1-MMP (198 %, p<0.05), MT2-MMP (2329%, p<0.01) 
table 2. Differential mRNA levels in early first-trimester pregnancies (percentage ± SD) a.
dse b dp dB dp c dB
Mt1-MMp 100 ± 14 %  171 ± 29 %#  198 ± 52 %# 100 %  155 ± 44 %
Mt2-MMp 100 ± 33 %  308 ± 119 %  2329 ± 428 %* 100 %  1929 ± 316 %*
Mt3-MMp 100 ± 30 %  150 ± 32 %  1023 ± 288 %* 100 %  768 ± 119 %*
Mt5-MMp 100 ± 12 %  70 ± 8 %  16 ± 2 %* 100 %  25 ± 3 %#
upA 100 ± 20 %  232 ± 74 %  125 ± 31 % 100 %  62 ± 16 %#
upAr 100 ± 13 %  185 ± 22 %*  208 ± 27 %* 100 %  128 ± 19 %
a mRNA levels were determined by RT-PCR in DSE, DP and DB of early 1st trimester (n=25) and compared 
within subjects. Mean cycle threshold (Ct) per gene: GAPDH 25-26, MT1-MMP 27, MT2-MMP 30, MT3-
MMP 30, MT5-MMP 29, uPA 31, uPAR 30. Cycle threshold were converted into ng/µl using a standard curve 
of total RNA and values were corrected for RNA input by calculating the ratio (ng/µl (target gene))/ (ng/µl 
(GAPDH)) The ‘repeated measures ANOVA’ was performed to analyse the data.
b The mRNA expression of DSE was set at 100% to compare mRNA levels in DSE with those in DP and DB. 
Fold induction was calculated as the ratio (DP)/(DSE) and (DB)/(DSE).
c The mRNA expression of DP was set at 100% to compare DP with DB. Fold induction was calculated as 
the ratio (DB)/(DP).
# p < 0.05, * p < 0.01.
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and MT3-MMP (1023%, p<0.01) in DB compared to DSE. The expression of uPA did not 
differ significantly (Table 2).
Finally, mRNA content in DB was compared to that in DP (100%). This comparison 
showed a reduced amount of MT5-MMP (75%, p<0.05) and uPA (38%, p<0.05) and 
markedly increased expression of MT2-MMP (1929%, p<0.01) and MT3-MMP (768%, 
p<0.01) in DB compared to DP. The concentrations of MT1-MMP and uPAR mRNA did 
not differ in DB compared to DP (Table 2).
immunohistochemistry of proteases in early first-trimester decidua
The presence and cellular localisation of the six proteins involved in pericellular prote-
olysis were determined at the protein level in serial sections of DSE, DP and DB. The 
studied proteins were detectable in all decidual tissues, and their presence was graded 
as mean staining indices (mean SI) per cell type and total staining indices (total SI) 
based on the sum of the cell types-dependent indices (Table 3, Figure 1, 2 and 3).
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figure 1. Protein levels of proteases in early first-trimester decidua.
The level of proteases was determined in DSE, DP and DB. A. MT1-MMP antigen was detectable in epithelial 
(open arrow), endothelium (closed arrow) and stromal cells (closed arrowhead) of DSE. B. MT2-MMP 
antigen in epithelium (open arrow), stromal cells (closed arrowhead) and pericytes (open arrowhead) of 
DB. c. Epithelial (open arrow) and stromal (closed arrowhead) MT3-MMP antigen in DB. Pericytes not 
present in this field. d. MT5-MMP antigen in epithelium (open arrow), and only dimly in stromal cells 
(closed arrowheads) of DP. e. uPA antigen in epithelium (open arrow), stromal cells (closed arrowhead) 
and endothelium (closed arrows) in DB. Pericytes not present in this field. f. Epithelial (open arrow), 
endothelial (closed arrows) and stromal cells (closed arrowheads) uPAR protein in DB. A-d,f Bar = 100 
µm, e. Bar = 50 µm.
(see colour figures supplement)
Protease expression in human first-trimester decidua 101
The total staining indices in DSE were comparable to those in DP with only a higher total 
SI for MT1-MMP in DP (Table 3, p<0.05). Secondly, when DSE and DB were compared, 
only an elevated total SI for uPA was found in DB compared to DSE (Table 3, p<0.05). 
Thirdly, DB was compared to DP and this showed a similar pattern; only an elevated total 
SI for uPA in DB compared to DSE (Table 3, p<0.05).
Analysis of the protein expression in the various cell types showed that the mean stain-
ing indices were most abundant in glandular epithelial cells, followed by perivascular 
smooth muscle and stromal cells (Table 3, Figure 1). Endothelium displayed weak ex-
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figure 2. Protein levels of proteases in endothelium of early first-trimester decidua.
A. Presence of protease antigens in endothelium (EC) was expressed as the mean staining index ± SEM and 
B-f show examples of endothelial protease expression. B. Endothelial (arrows) and stromal (arrowheads) 
MT1-MMP was detectable in DB. c. MT2-MMP was detected in endothelium (arrows) of DB. d. Endothelial 
MT3-MMP antigen (arrows) in DSE. e. uPA antigen in endothelium (closed arrows), epithelium (open 
arrow) and stromal cells (arrowhead) in DB f. uPAR in DB was detected in endothelial cells (arrows) and 
stromal cells (arrowheads). B-f. Bar = 50 µm.
(see colour figures supplement)
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pression of all proteins, except MT5-MMP. MT5-MMP was not detectable (Figure 2). 
Significant differences were not found between the three decidual tissues with regard to 
table 3. First-trimester protein expression in early versus late first-trimester pregnancies a.
ecb psMcb geb scb eVtb total sic
early 
first-
late 
first-
early 
first-
late 
first-
early 
first-
late 
first-
early 
first-
late 
first-
early 
first-
late 
first-
early 
first-
late
first-
Mt1 dse 0.6 0.0* 1.8 0.3 4.0 2.0 0.6 0.2 NP NP 7.0#  2.5*
dp 0.7 0.0* 2.2 0.3 4.8 2.5 1.5 0.2 NP NP 9.2  3.0*
dB 0.6 0.0* 1.7 1.0 3.7 3.0 1.7 1.2 1.1 0.5 8.8 5.7
Mt2 dse 1.3 0.5 3.4 0.7 4.2 3.5 1.1 0.0 NP NP 10.0  4.7*
dp 1.0  0.3* 3.7 1.5 4.3 2.7 1.8 0.5 NP NP 10.8  5.0*
dB 0.7 0.4 2.3 1.0 3.7 3.8 1.7 2.2 1.0 1.3 9.4 8.7
Mt3 dse 0.5 0.0 2.2 0.7 4.8 1.0 0.3 0.0 NP NP 7.8  1.7*
dp 0.1 0.0 2.4 0.7 4.9 1.0 1.5 0.0 NP NP 8.9  1.7*
dB 0.0 0.0 1.6 1.0 5.2 1.0 1.7 0.0 1.2 0.0 8.8  2.0*
Mt5 dse 0.0 0.0 0.3 0.0 1.7 2.0 0.2 0.2 NP NP 2.2 2.2
dp 0.0 0.0 0.3 0.0 1.6 2.2 0.2 0.5 NP NP 2.1 2.7
dB 0.0 0.0 0.2 0.0 1.5 1.8 0.3 0.3 0.1 0.3 2.1 2.4
upA dse 0.2 0.1 1.8 2.0 4.4 3.9 1.8 1.5 NP NP 8.2 7.5
dp 0.3 0.3 1.8 1.7 4.4 4.1 2.4 2.6 NP NP 8.9 8.7
dB 0.4 0.5 2.1 2.0 5.4 5.3 4.7 5.5 1.3 1.1 13.9$ 14.4
upAr dse 0.3 0.5 0.9 1.8 5.6 3.8 1.8 1.5 NP NP 8.6 7.6
dp 0.2 0.0 0.7 1.7 5.5 4.3 1.6 1.7 NP NP 8.0 7.7
dB 0.4 0.8 0.7 2.2 5.4 5.0 2.7 2.5 0.9 1.2  10.1  11.7
a Specific antigens of pericellular acting proteases in DSE, DP and DB were determined by 
immunohistochemistry, scored per cell type and compared within subjects. Friedman test, a non-
parametrical test for paired samples, and the Wilcoxon test were used for statistical analysis within groups 
and the general linear model was used to analyse differences between the two groups.
bc The staining was expressed as mean staining indices per cell type and as the total staining indices (total 
SI), which is the sum of the mean staining indices of endothelial cells (EC), perivascular smooth muscle 
cells (PSMC), glandular epithelium (GE), stromal cells (SC) and extra-villous trophoblasts (EVT) per 
decidual tissue.
NP = not present. # p<0.05 in DSE versus DP and $ p<0.05 in DB versus DP and DSE in the early first-
trimester group. * p<0.05 in late vs early first-trimester decidua.
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endothelial protein expression. However, it should be noted that MT3-MMP was present 
in the endothelium of DSE, but largely reduced in DP and undetectable in those cells of 
DB. The same pattern was also displayed by endothelial MT2-MMP and by the staining 
of MT2- and MT3-MMP in smooth muscle cells (Table 3, Figure 1 and 2).
All proteases studied were present in extra-villous trophoblasts, although MT5-MMP 
stained only dimly. Furthermore, all proteases were detectable in villous trophoblasts; 
uPAR, MT1-, MT2-, MT3- and MT5-MMP were moderately expressed in both syncytiotro-
phoblasts as cytotrophoblasts. The expression of uPA was weak in cytotrophoblasts, 
while it was abundantly present in syncytiotrophoblasts (Table 3, Figure 3).
proteases in early versus late first-trimester decidua
The mRNA levels of proteases in late first-trimester decidua were compared to those in 
early first-trimester decidua (100%, Table 4). The levels of MT1-MMP (206%, p<0.02) and 
MT2-MMP (1047%, p<0.02) mRNAs were elevated, whereas MT3-MMP mRNA content 
was reduced (62%, p<0.05) in DSE of late compared to early first-trimester pregnancies. 
Comparison of DP between both groups showed elevated mRNA levels of MT1-MMP 
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figure 3. Protein levels of proteases in villous and extra-villous trophoblasts (EVT) of early first-trimester 
decidua.
The presence of protease antigens in villous and extravillous trophoblasts in decidua basalis (DB) was 
studied in serial sections stained against cytokeratin and the target protein. A. Immunostaining in syncytio- 
and cytotrophoblasts (synCTB and CTB) was expressed as the mean staining index ± SEM. B. and c. uPAR 
and cytokeratin antigens in serial expression in EVT (closed arrows) and epithelium (open arrows). d. uPA 
antigens in syncytiotrophoblast (open arrow) and not in cytotrophoblast (closed arrow). B-d. Bar = 50 
µm.
(see colour figures supplement)
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(215%, p<0.02) and uPAR (207%, p<0.02) and reduced mRNA expression of MT3-MMP 
(77%, p<0.05) in late first-trimester tissues. The mRNA levels of these proteases in DB 
showed no differences between the two groups (Table 4).
At the protein level, total and mean staining indices of MT1- and MT2- MMP were re-
duced in DSE and DP of late first-trimester compared to early first-trimester (p<0.05). 
The total and mean SI of MT3-MMP were reduced in all cell types of all tissues in late 
first-trimester decidua (Table 3, p<0.05).
The mean SI’s of MT1-, MT2- and MT3-MMP in endothelium were reduced in late versus 
early first-trimester DSE, DP and DB. Strikingly, endothelial MT1 and MT3-MMP expres-
sion was not even detectable in late first-trimester decidua. uPA and uPAR displayed 
comparable staining indices in endothelial cells at the two time points, while MT5-MMP 
was absent in these cells in both conditions (Table 3).
Analysis of unk cells (cd56 +) and macrophages (cd68 +)
The presence of CD56 and CD68 antigens was determined in DSE, DP and DB of both 
the early and late first-trimester group and expressed as the percentage positive cells per 
total number of stromal cells.
The CD56 staining showed inhomogeneous staining, mainly localised around vessels 
and glands, which was corrected for by analysing various samples per patient. The 
number of CD56+ (uNK) cells in DP and DB was comparable, 18 ± 6% and 21 ± 4% 
respectively, of the total number of stromal cells. Both DP and DB showed a significantly 
larger number of CD56+ cells then DSE (9 ± 2%, p<0.05). No significant differences were 
detected between early and late first-trimester decidua (Figure 4 A and C).
table 4. mRNA expression in late first-trimester pregnancies compared to early first-trimester pregnancies (100%). a
Late 1st
dse b
Late 1st
dp b
Late 1st
dB b
Mt1-MMp  206 %* 215 %*  150 %
Mt2-MMp 1047 %*  80 %  110 %
Mt3-MMp  38 %#  23 %#  92 %
Mt5-MMp 111 %  98 %  107 %
upA 131 % 205 %  168 %
upAr 160 %  207 %*  137 %
a mRNA levels was determined by RT-PCR in DSE, DP and DB of early and late first-trimester (n=25 and n=8 
respectively) and compared within subjects. The ‘repeated measures ANOVA’ was performed to analyse 
the data.
b The mRNA levels in DSE, DP and DB of early first- trimester decidua were set at 100% to compare with 
mRNA levels in DSE, DP and DB of late first-trimester decidua.
*p<0.02, # p<0.05
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The CD68 staining showed scattered positive cells throughout the tissues (range 
1.0-2.2%). Although the number of macrophages appeared to increase from DSE to DP 
to DB, these differences were not significant. The two time points also showed no sig-
nificant differences (Figure 4 B and D).
discussion
The present study demonstrates that the mRNA and protein content of the pericellu-
lar-acting MT-MMPs and uPA/uPAR varied between decidual secretory endometrium 
(DSE), decidua basalis (DB) and decidua parietalis (DP). Furthermore, the percentage 
of CD56-positive cells was two-fold lower in DSE than in DB and DP. A comparable 
increase in macrophages did not reach statistical significance. It is likely that the dif-
ferential expression of the proteases is mainly due to the different effects of pregnancy-
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figure 4. CD56- and CD68- positive cells in early and late first-trimester decidua.
A. CD56-positive cells in decidua, expressed as the mean number of positive cells per total number of 
stromal cells (mean ± SD) B. CD68-positive cells in decidua, expressed as the mean number of positive 
cells per total number of stromal cells (mean ± SD). c. CD56 expression in decidua basalis, bar = 100 µm. 
Blow up shows CD56+ cells (arrows) surrounding a vessel and gland, bar = 50 µm d. CD68-positive cell 
(arrow) in decidua parietalis, bar = 50 µm. e. Negative control, bar = 100 µm. * p<0.05 versus DSE
(see colour figures supplement)
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induced hormones (hCG, oestradiol and progesterone), the extra-villous trophoblast 
and/or immune cells on the three decidual tissues. Our study suggests that uPAR and 
MT1-MMP are enhanced by pregnancy-induced hormones, and possibly uNK cells, and 
uPA, MT2-, MT3-MMPs by EVT. In addition, MT5-MMP appears reduced by the EVT. 
Finally, we show differences in protease expression and presence of immune cells as 
gestation progresses.
decidual tissues and their contributors
Endometrial adaptation to pregnancy is induced by pregnancy-induced hormones, i.e. 
hCG, oestradiol and progesterone, immune cells, and the extra-villous trophoblasts 
(EVT). Pregnancy-induced hormones are involved in the development of decidua pari-
etalis (DP) from the decidual secretory endometrium (DSE), while the additional pres-
ence of the EVT induces the generation of the decidua basalis (DB). This may imply that 
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figure 5. Human first-trimester decidual tissues.
Representation of the influences of immune cells, extra-villous trophoblast and pregnancy-induced 
hormones (*hCG, oestradiol and progesterone) on first-trimester decidual tissues. Differentiation between 
decidual secretory endometrium (DSE), decidua parietalis (DP) and basalis (DB), was obtained by HPS 
and cytokeratin staining. DSE and DP express cytokeratin in glandular epithelium (open arrows), whereas 
cytokeratin is also expressed in EVT (closed arrows) of DB. Bar =100 µm.
(see colour figures supplement)
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differences in protease expression between DB and DP are due to interactions of the 
decidual tissue with the trophoblast. However, NK cells have also been suggested to vary 
between term DB and DP [Sindram-Truijllo et al., 2003]. As these uNK cells are known to 
produce many chemokines and angiogenic growth factors [Hanna et al., 2006;Li et al., 
2001a; Lash et al., 2006], the uNK cells may also be able to influence the production of 
proteases in DB and DP. Other investigators were unable to detect differences in uNK 
numbers in DP and DB [Khong 1987; Haller et al., 1995; Bulmer, Lash 2005]. Indeed, 
in our study we also found similar amounts of uNK cells in DB and DP being 18% and 
21%, respectively. This excludes an involvement of the number of uNK on the difference 
between DB and DP, but possible differences in the functional properties of the uNK 
cells in DB and DP cannot yet be excluded.
The percentual contribution of uNK cells and macrophages to the immune cell and 
overall stromal cell populations were comparable with those reported by other investiga-
tors [Tuckerman et al., 2007; Quenby et al., 1999; Bulmer et al., 1991]. Interestingly, the 
amounts of uNK cells were twofold higher in DB and DP than in DSE (9%). A compa-
rable increase in macrophages did not reach statistical significance (range 1.0-2.2% of 
total stromal cells). To our knowledge the difference between DSE and DB/DP has not 
been systematically investigated before.
The foregoing information is summarised in Figure 5, which presents a model that 
describes the influences of uNK cells, extra-villous trophoblast and pregnancy-induced 
hormones on DSE, DP and DB. This model enables us to discuss changes that occur 
independently of trophoblast invasion, and those that are mainly induced by pregnancy-
induced hormones and/or uNK cells, from changes influenced by the invasive extra-vil-
lous trophoblast [Plaisier et al., 2007]. The effects of uNK cells require further functional 
studies.
pericellular proteases in early first-trimester decidua
MT1-MMP mRNA and protein expression were significantly induced in decidua basalis 
and parietalis (DB and DP) as compared to decidual secretory endometrium (DSE), but 
no differences were found between DB and DP. This suggests that decidual MT1-MMP 
expression is induced rather by pregnancy-induced hormones and/or uNK cells then by 
invasive trophoblasts (EVT). This confirms an earlier study which showed that invasive 
trophoblasts are not required for the induction of MT1-MMP [Nakano et al., 2001]. Fur-
thermore, the apparent induction of MT1-MMP in DP and DB might be explained by the 
influx of NK cells in those tissues, as NK cells are known to contain MT1-MMP [Alberts-
son et al., 2000]. MT1-MMP may also play a role in uNK cell migration.
Although the regulation of MT1-MMP expression seems unaffected by the EVT, MT1-
MMP is expressed by the EVT. This suggests a role in trophoblast invasion, which indeed 
has been reported previously [Hurskainen et al., 1998; Nawrocki et al., 1996; Tanaka et 
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al., 1998]. Finally, the fact that MT1-MMP is induced in various cell types of decidua pari-
etalis and basalis also points to a role in decidual remodelling and/or vascularisation.
MT2-MMP and MT3-MMP mRNA levels were increased and MT5-MMP mRNA expres-
sion was reduced in DB compared to both DSE and DP. This suggests that these mRNA 
levels are mainly influenced by the presence of the EVT. Together with their antigens 
being present in invasive trophoblasts, this suggests a role in trophoblast invasion. 
However, no significant differences were detected in the overall presence of MT2-, MT3- 
and MT5-MMP proteins between the three types of decidua. MT2-MMP and MT3-MMP 
protein levels were reduced in endothelium and perivascular smooth muscle cells of 
DP and DB as compared to DSE. Endothelial protein expression of the other proteases 
showed no differences between the tissues. Interestingly, we recently determined the 
vascularisation pattern in serial sections of the same specimens, which showed highly 
enhanced vascularisation at the implantation site. Comparison of these data with the 
endothelial expression of MT2- and MT3-MMPs shows that the amounts of these en-
dothelial MT-MMPs correlated well with the number of vascular structures/mm2 and 
correlate inversely with the luminal surface of these vascular structures [Plaisier et al., 
2007]. Furthermore, experiments with endometrial endothelial cells in vitro indicated 
that MT2- and MT3-MMP are potential candidates for regulation of endometrial angio-
genesis [Plaisier et al., 2006; Plaisier et al., 2007]. These data leads us to hypothesise 
that MT2-MMP and MT3-MMP play a role in vascular adaptation to pregnancy at the 
implantation site.
UPA and uPAR were detected in the various decidual cell types. In contrast to cycling 
secretory endometrium, in which endothelial and stromal cells contained uPA antigen 
and glandular epithelium did not [Koolwijk et al., 2001], glandular epithelial cells are 
positive for uPA antigen in first-trimester tissues together with the endothelium and part 
of the stromal cells. The expression of uPAR largely follows the pattern of uPA and is 
clearly present in endothelial cells. The presence of uPAR in EVT is confirmed by previ-
ous studies and suggests a role in trophoblast invasion [Floridon et al., 1999; Pierleoni 
et al., 1998,].
Interestingly, the expression of uPA mRNA and antigen showed different patterns. The 
mRNA levels suggest a stimulatory influence of pregnancy-induced hormones and/or 
uNK cells, as well as an inhibiting influence of the EVT. This latter observation may 
be explained by the downregulation of uPA mRNA by hCG, an important product of 
trophoblasts [Salamonsen 1999; Yagel et al., 1993]. However, uPA was increased at the 
protein level in all cell types in DB compared to DP and DSE. The presence of uPA is 
not only determined by the ability of the cells to produce uPA, but also by their content 
of uPAR, which binds and internalises uPA in complex with its inhibitor PAI-1 [Blasi, 
Carmeliet 2002; Kroon et al., 1999]. Furthermore, uPA and uPAR are present in a part of 
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the stromal cells that probably include the uNK and other leukocytes. This is in concert 
with the notion that the uPA/uPAR system is used, probably together with MT-MMPs, by 
leukocytes for their invasion into tissues [Albertsson et al., 2000; Al Atrash et al., 2001]. 
Moreover, the increase in uNK cells may thus contribute to the increased uPA antigens 
observed in DB as compared to DSE.
early versus late first-trimester pregnancies
The expression of uPA and uPAR mRNA and proteins showed no differences between 
early and late first-trimester decidua, indicating that the uPA/uPAR system remains under 
a constant regulation as gestation progresses. No data are available in literature regard-
ing uPA/uPAR during these time points. In contrast, the differential mRNA expression 
of the matrix metalloproteinases suggests that these proteases are regulated over time. 
The overall amounts of MT1-, MT2- and MT3-MMP were reduced in all decidual tissues 
in late compared to early first-trimester pregnancy.
Furthermore, the MT1- MT2- and MT3-MMP antigen expression in endothelium and 
perivascular smooth muscle cells was also reduced in all types of decidua of late first-
trimester pregnancy. We recently determined the vascularisation pattern in serial sec-
tions of the same early and late first-trimester decidua samples and this showed that 
vascularisation is regulated as gestation progresses. The endothelial expression of MT1-, 
MT2- and MT3-MMPs correlated well with the differences in vascularisation between 
early and late first-trimester decidua [Plaisier et al., 2007]. These data again point to a 
role for these MT-MMPs in determining the degree and pattern of neovascularisation as 
gestation progresses.
conclusion
Decidual adaptation is important in the development of a healthy pregnancy. We showed 
that the expression of various pericellular-acting proteases varied between decidual 
secretory endometrium (DSE), decidua basalis (DB) and decidua parietalis (DP). Fur-
thermore, uNK cells (CD56+) and macrophages (CD68+) were present in all decidual 
tissues and only the percentage of uNK cells differed between the tissues. The differen-
tial presence of several proteases enabled hypothesising about their regulation, i.e. by 
pregnancy-induced hormones, the EVT and/or immune cells, as well as their functions, 
e.g. in immune cell infiltration, trophoblast invasion and/or vascularisation (Figure 5).
UPAR and MT1-MMP expression appeared regulated by pregnancy-induced hormones 
and/or uNK cells, whereas the presence of uPA, MT2-, MT3-, and MT5-MMP appeared 
regulated by the extra-villous trophoblast. All proteases were expressed by the EVT and 
might be involved in trophoblast invasion. MT2- and MT3-MMP are known candidates 
in regulating angiogenesis and together with their differential expression this suggests 
that they may not only support decidual remodelling and trophoblast invasion during 
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implantation but also, partially, account for the vascular changes at the implantation 
site. Finally, we show differences in protease expression as gestation progresses. A bet-
ter understanding of decidualisation may contribute to new insights in currently non-
explicable pathological events associated with pregnancy, such as miscarriages and 
pre-eclampsia.
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ABstrAct
objective: Decidual vascular development is important for implantation. This study 
analysed decidual vascular adaptation to implantation in correlation with miscarriage 
in decidual secretory endometrium (DSE), decidua parietalis (DP) and basalis (DB) 
of miscarriage patients and matched controls.
Methods: Decidua was obtained during first-trimester termination of pregnancy (con-
trols) and vacuum-aspiration in case of missed abortion (cases). Vascularisation and 
the expression of VEGF-A, PlGF, flt-1, KDR, Angiopoietin-1, Angiopoietin-2, TIE-2, and 
membrane-type matrix metalloproteinases MT1-, MT2-, MT3- and MT5-MMP were 
determined at mRNA and protein level. uNK cells (CD56), macrophages (CD68), pro-
liferation (Ki67) and apoptosis (activated-caspase-3) were evaluated in consecutive 
sections.
results: Decidual vascularisation showed differences between cases and controls, i.e. 
fewer vessels with larger circumference in cases. This correlated with the differential 
expressions of various factors at mRNA/antigen level and with increased endothe-
lial flt1, KDR, MT2- and MT5-MMP expression miscarriage patients. The differences 
between cases and controls were probably not based on altered proliferation and/or 
apoptosis, since Ki67 and active caspase-3 showed comparable expression levels in 
both groups. Although DB of cases and controls showed similar amounts of CD56- 
and CD68-positive cells, the missed abortion group did show elevated levels of CD56 
in DSE and of CD68 in DSE and DP compared to the control group.
conclusion: The differences in vascularisation and in the expression of angiogenic 
factors and proteases between both groups suggest a correlation between decidual 
vascularisation and the occurrence of miscarriages.
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introduction
Decidual vascular adaptation to implantation is important for the success of pregnancy 
and already starts during the receptive secretory phase of the menstrual cycle. Decidu-
alisation, vascular remodelling and invasion of immune cells are prominent processes 
in the first weeks after fertilisation [Bulmer et al. 1991; Salamonsen et al. 2003; Smith 
2000]. Immune cells increase from 8% of total stromal cells during the menstrual cycle 
up to 30% during the first-trimester. Approximately 70% of these leucocytes are uterine-
NK (uNK) cells and 10% are macrophages [Bulmer et al. 1991].
Vascular adaptation includes (pseudo-)vasculogenesis, arterial remodelling, and angio-
genesis, the formation of new vessels out of existing ones [Burton et al. 1999; Pijnenborg 
et al. 1983]. Angiogenesis is characterised by increased vascular permeability, endothelial 
cell proliferation and migration, and is regulated by various growth factors, e.g. vascular 
endothelial growth factor (VEGF), placental growth factor (PlGF) and angiopoietins, and 
proteases like the membrane-type matrix metalloproteinases [Carmeliet 2003; Pepper 
2001]. Disturbances in vascular development may play a role in the pathogenesis of 
miscarriages [Vailhe et al. 1999; Vuorela et al. 2000; Zygmunt et al. 2003].
The angiogenic growth factors VEGF-A and PlGF are extensively studied in the vascular 
development of the placenta [Plaisier et al. 2007; Smith 2000; Vuorela et al. 1997]. VEGF 
is one of the earliest genes activated during pre-implantation embryo development and 
is produced by maternal decidual cells and by the invading blastocyst and trophoblast 
[Kapiteijn et al. 2006; Jackson et al. 1994; Plaisier et al. 2007]. VEGF is a potent inducer 
of angiogenesis and interacts with the Flt-1 (VEGFR-1) and KDR (VEGFR-2) to promote 
endothelial cell proliferation, migration and vascular permeability. KDR is generally rec-
ognized as the central VEGF receptor in angiogenesis, while Flt-1 plays a supporting role. 
During pregnancy, also a soluble variant of Flt-1 (sFlt-1) is formed, which quenches VEGF 
and thereby limits its activity [Maynard et al. 2003].
PlGF shares biochemical and functional features with VEGF, but only interacts with Flt-1. 
PlGF and VEGF have synergistic effects regarding angiogenesis, however PlGF induced 
vessels are suggested to be more mature and stable than vessels induced by VEGF alone 
[Carmeliet et al. 2001]. PlGF is abundantly expressed in human placenta and may be an 
important paracrine regulator of decidual angiogenesis and an autocrine mediator of 
trophoblast function [Sherer, Abulafia 2001; Plaisier et al. 2007].
The angiopoietins and their receptor TIE-2 are also known for their regulating capacities 
regarding angiogenesis. The two ligands bind with equal affinity to TIE-2 but have differ-
ent functions. Angiopoietin-1 (Ang-1) maintains vessel integrity and probably plays a role 
in the later stages of vascular remodelling [Geva et al. 2000]. Angiopoietin-2 (Ang-2) is a 
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functional antagonist of Ang-1 and leads to loosening of cell-cell interactions and allows 
access to angiogenic inducers like VEGF [Geva et al. 2000].
Ang-1, Ang-2 and TIE-2 are detected in various maternal cells, endovascular tropho-
blasts, and (syn-) cytotrophoblasts during human first-trimester pregnancy. These find-
ings suggest an additional role for angiopoietins in regulating trophoblast behaviour 
in the development of uteroplacental circulation [Plaisier et al. 2007; Dunk et al. 2000; 
Zhang et al. 2001]. An association of the angiopoietins with miscarriage has not been 
described, but reduced endothelial TIE-2 expression has been linked to the occurrence 
of miscarriage [Vuorela et al. 2000].
The membrane-associated localisation of MT-MMPs makes them suited for pericellular 
proteolysis [Hotary et al. 2000; van Hinsbergh et al. 2006]. We studied the transmem-
brane-spanning MT-MMPs, MT1- (MMP-14), MT2- (MMP-15), MT3- (MMP-16) and 
MT5-MMP (MMP-24), since these MT-MMPs have the proteolytic potential to induce 
capillary tube formation. The GPI-anchored MT4- and MT6-MMP were unable to do so 
[Hotary et al. 2000].
MT1-MMP is the best known MT-MMP and promotes cell migration, angiogenesis and 
tumour metastasis [Visse, Nagase 2003]. MT2- and MT3-MMP are less well studied 
but are also involved in cell migration and invasion. MT1-, MT2- and MT3-MMP induce 
angiogenesis in vitro and MT2- and MT3-MMP may even be potential regulators of endo-
metrial angiogenesis in vivo [Hotary et al., 2000; Plaisier et al. 2004/2006]]. MT5-MMP 
is known for the induction of embryonic brain development and axonal growth [Llano et 
al., 1999].
MT1- and MT2-MMP RNA and protein expression are described in decidual extracts, 
stromal cells, and the extra-villous trophoblast [Bjorn et al. 2000; Nawrocki et al. 1996; 
Curry,Osteen 2003]. These MT-MMPs are assumed to regulate trophoblast invasion dur-
ing implantation [Salamonsen et al. 2003]. To which extent migration of other cell types, 
e.g. immune and endothelial cells, is also regulated by MT-MMPs remains to be seen.
Vascular adaptation to implantation has mainly been studied with regard to physiology 
[Craven et al, 1999; Kam et al. 1999]. Recently, the potential regulation of decidual vascu-
larisation by both the extra-villous trophoblast (EVT) and pregnancy-induced hormones 
has been described. Moreover, the differential expression of VEGF-A, the angiopoietins, 
PlGF, Flt-1, MT2- and MT3-MMP suggested their role in regulating the vascular adaptive 
process in uncomplicated first-trimester pregnancies [Plaisier et al. 2007/2008]. Few 
studies have addressed the question whether vascularisation and its regulatory factors 
are involved in the pathogenesis of first-trimester complications, like miscarriage. A 
higher decidual vessel density was correlated with missed abortions [Vailhe et al. 1999]. 
Also, differential antigen expression of VEGF and its receptors has been correlated to re-
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current miscarriage [Vuorela et al. 2000]. Moreover, elevated uterine MMP and reduced 
TIMP expression has been linked to failed implantation [Jokimaa et al. 2002].
The present study determined decidual vascular adaptation to implantation in correla-
tion with failure of implantation, i.e. missed abortion. Vascularisation pattern and the 
expressions of the above described angiogenic factors and proteases were determined 
in three first-trimester decidual tissues, decidual secretory endometrium (DSE), decidua 
parietalis (DP) and basalis (DB) of miscarriage patients and matched controls. The com-
parison of these parameters between the two groups enabled hypothesising about their 
correlation with the occurrence of miscarriages.
MAteriALs And Methods
study group
The study was approved by the ethics committee of the Leiden University Medical Centre 
and informed consent was provided by all study subjects.
Decidua samples in the case group were obtained during vacuum-aspiration from 
missed abortion patients. Missed abortion was diagnosed based on ultrasound exami-
nation and absence of clinical miscarriage symptoms. Aspirated tissue was analysed by 
an independent pathologist and samples with pathologic abnormalities were excluded. 
Patients with pathological conditions known to interfere with implantation, like haemo-
static abnormalities, auto-antibodies, etc, were also excluded. Gestational age at foetal 
death was determined by ultrasound.
Decidua samples in the control group were obtained from women with a healthy, viable 
intrauterine gravidity, undergoing vacuum aspiration in case of a legal voluntarily abor-
tion. Foetal cardiac activity and gestational age were confirmed by ultrasound. Women 
with symptoms of miscarriage, with underlying illnesses, and cases with discrepancy 
between the ultrasound-determined gestational age and last day of menstruation were 
excluded in both control and case group.
Cases and controls were matched based on maternal and gestational age. These param-
eters and number of previous pregnancies and miscarriages did not differ significantly 
between the cases and the controls. Patient characteristics of the study groups are given 
in Table 1.
tissue samples
Decidua samples were obtained from the aspirated tissue (vacuum aspiration), fixed in 
formaldehyde overnight and embedded in paraffin. Hematoxylin Phloxin Safrane (HPS) 
and anti-cytokeratin staining were performed. Hematoxylin (50 g potassium aluminium 
sulfate, 1 g hematox, 500 mg citric acid, 25 g chloralhydrate, 200 mg NaJO
3
 in 1000 ml 
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aqua dest) stains nuclei and calcium blue. Phloxin (0.25 g phloxin in 100 ml aquadest) 
stains erythrocytes, cytoplasm, fibrin and muscle red. Safrane (3 g safrane in 1000 ml 
100% alcohol) stains calcium free bone, cartilage and collagen yellow.
The HPS staining was used to differentiate between decidua and decidual secretory en-
dometrium (DSE), which microscopically resembles secretory endometrium. Decidua 
basalis (DB) and decidua parietalis (DP) were differentiated by the presence or absence 
of extra-villous trophoblasts using an anti-cytokeratin staining (see section immunohis-
tochemistry). DSE, DP and DB were obtained from the same curettement and therefore 
originate from the same depth and area of the uterine wall. Only subjects with at least 
two complete sets of DSE, DB and DP were included (n=11 in missed abortion group 
and n=16 in control group). Serial sections of the paraffin embedded tissue samples 
were used for all experiments and all parameters were compared between tissues within 
subjects.
rnA isolation and cdnA synthesis
RNA was extracted from paraffin embedded tissue samples [Plaisier et al. 2007]. Several 
samples per tissue per patient were used and these samples contained a proportionate 
amount of cells and cell types. In short, 5 µm sections were mounted on RNase-free 
glass slides. The first and last sections were used to verify the presence of the tissues of 
interest. The other sections were deparaffinised and the tissues of interest, DSE, DP or 
DB (without villous tissue), were dissected and dissolved in 190 µl lysis buffer (Tris 20 
mM pH 7.4, EDTA 1 mM pH 8.0, 2% SDS) and 10 µl proteinase K (20 mg/ml proteinase 
K, Life-Technologies Gibco BRL, Gaithersburg) for 18 hours at 60°C. Subsequently, 400 
µl Solution D (4 M guanidium isothiocyanate, 0.75 M sodium citrate, 10% sarkosyl and 
2-mercapto-ethanol) was added and RNA was isolated [Plaisier et al. 2007].
RNA quantity and quality were analysed in a spectrophotometer (Nanodrop ND-1000). 
The OD260/280 of the RNA samples ranged between 1.85 and 2.00. Reverse transcrip-
tion was performed with 1 µg total RNA, random primers and cDNA synthesis kit accord-
ing to the manufacturer’s protocol and the obtained 32 µl cDNA was diluted 1:3 (Ready-
to-go You-Prime first strand beads, Amersham Biosciences, Buckinghamshire, UK).
table 1. Characteristics of the study subjects.
controls
(n=16)
Missed Abortions
(n=11)
Maternal Age (years) a 31.0 ± 1.3  33.3 ± 1.6
Gestational age (days) a 50.4 ± 2.7  53.8 ± 3.3
Gestational age (weeks) a  7.2 ± 0.4  7.7 ± 0.5
Number of previous pregnancies a  1.5 ± 0.4  2.6 ± 0.5
Number of previous miscarriages a  0.3 ± 0.1  0.8 ± 0.4
a All p>0.05.
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real-time rt-pcr
The mRNA levels were quantified according to the Taqman real-time PCR method using 
validated primer and probe (FAM/TAMRA double-labelled) sets for VEGF-A, VEGF-R1 
(Flt-1), VEGF-R2 (KDR), PlGF, Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), TIE-2, 
MT1-MMP, MT2-MMP, MT3-MMP, and MT5-MMP. glycerlylaldehyde’-3-phosphate de-
hydrogenase (GAPDH, primers/VIC-labelled probe) was used as an endogenous refer-
ence gene. Other genes, β-actin, β
2
-microglobulin and cyclophilin, were also used as 
reference genes and showed comparable results (data not shown, all primer/probe sets 
purchased from Applied Biosystems, Foster City, CA USA).
RT-PCR reactions for target gene/GAPDH pairs were performed in 12.5 µl reactions, con-
taining 2.5 µl cDNA solution, using mastermix (RT-QP2X-03, Eurogentec, Maastricht, 
The Netherlands), DNAse free water and the above described primer/probe sets. Reac-
tions were performed in duplicate, expressed in cycle times (Ct) and quantified into ng/
µl using a standard curve of total RNA. The amount of RNA expression of DSE was set at 
100% to compare DSE with DP and DB and the gene expression of DP was set at 100% 
to compare DP with DB. Water and negative-RT samples, obtained by the omission of the 
reverse transcriptase enzyme in the cDNA reaction, were used as negative controls.
immunohistochemistry
Serial sections were deparaffinised, endogenous peroxidase was quenched with 3% 
H
2
O
2
/methanol and aspecific binding was reduced by incubation with 5% bovine serum 
albumin. Antigen retrieval in trypsin was used for the detection of CD34, TIE-2, MT2- and 
MT5-MMP. Heat retrieval in 0.1 M citrate buffer was used for the detection of cytokera-
tin, Ang-2, Ki67, CD56 and CD68.
The first antibodies are described in Table 2. Polyclonal rabbit anti-MT1-MMP was pro-
duced and characterised as previously described [Plaisier et al. 2004]. The following 
second antibodies were used: biotinylated horse anti-mouse antibody (1:300, BA-2000, 
Vector), biotinylated donkey anti-rabbit antibody (1:300, RPN1004, Amersham Biosci-
ences), biotinylated rabbit anti-goat (1:300, E-0466, DakoCytomation).
Primary antibodies were applied overnight at 4°C followed by one hour incubation with 
biotinylated secondary antibody. Antibody binding was visualised using StreptABCom-
plex/HRP, a streptavidin complexed with biotinylated peroxidase (K0377, DakoCytoma-
tion, Glostrup, Denmark) and NovaRED™ substrate (SK-4800, Vector, Burlingame, 
USA) according to the manufacturer’s protocol. Only CD56 immunohistochemistry was 
stained with DAB (diaminobenzidine). All incubations were performed in 1% bovine 
serum albumin in PBS.
Sections were counterstained with Mayer’s hematoxylin. Specificity of the immunohis-
tochemical reaction was verified by the omission of the first antibody as well as using 
non-immune mouse IgG
1
, concentration adjusted to primary IgG
1
 concentration, and 
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goat and rabbit serum instead of first antibody. To evaluate the expression in extra-villous 
trophoblast, cytokeratin and target protein staining were performed on serial sections 
of 3 µm.
evaluation of the vascularisation pattern
CD34-stained decidual sections were used to scan sequential fields [Vailhe et al. 1999]. 
Two to four samples of each type of tissue of each study subject were analysed and six 
fields per sample were scanned at 100x magnification. The area within the stained ves-
sels and the number of vessels per field were analysed using an image analysis software 
(Qwin, Leica Microsystems) and these data were used to calculate the number of vessels 
per mm2, total vascular surface per mm2 (mm2/mm2) and the luminal surface (µm2/
vessel).
evaluation of immunohistochemical staining
In order to avoid intensity differences in the staining we analysed control samples (16 
donors) simultaneously with the samples of 11 cases. Immunostaining of Ki67, active 
Caspase-3 (aCasp-3), CD56 and CD68 was evaluated by counting the number of positive 
cells and total stromal cells in ten 16 µm2 fields per tissue per patient. In this way, the 
mean percentages of positive cells per stromal cells and per µm2 were determined. In 
table 2. Specifications of the primary anibiodies.
Antigen source clone-number species pre-treatment dilution
Cytokeratin DakoCytomatation Z0622 Rabbit Citrate HR 1:2000
CD34 Novocastra QBEnd/10 Mouse (IgG1) 0.1% Trypsin 1:1000
CD56 Monosan MONX 10844 Mouse (IgG1) Citrate HR 1:50
CD68 DakoCytomatation M0814 Mouse (IgG1) Citrate HR 1:200
Ki67 Novocastra Ncl-L-Ki67-MM1 Mouse (IgG1) Citrate HR 1:50
Act Casp 3 Cell Signaling 9661 Rabbit None 1:300
VEGF-A Santa Cruz Tech Sc-152 (A-20) Rabbit None 1:100
PlGF Santa Cruz Tech Sc-1880 (C-20) Goat None 1:50
Flt-1 Santa Cruz Tech Sc-316 (C-17) Rabbit None 1:50
KDR Santa Cruz Tech Sc-6251 (A-3) Mouse (IgG1) None 1:50
Ang-1 Santa Cruz Tech Sc-6319 (N-18) Goat None 1:100
Ang-2 Santa Cruz Tech Sc-7016 (N-18) Goat Citrate HR 1:150
TIE-2 Santa Cruz Tech Sc-9026 (H-176) Rabbit 0.1% Trypsin 1:100
MT1-MMP TNO QoL Rabbit None 1:1000
MT2-MMP Oncogene IM48L Mouse (IgG1) 0.1% Trypsin 1:250
MT3-MMP Oncogene IM50L Mouse (IgG1) None 1:100
MT5-MMP Sigma M6684 Rabbit 0.1% Trypsin 1:200
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case of Ki67 and aCasp-3, the expression in endothelial and epithelial cells was also 
determined similarly.
Immunostaining of the other antigens was evaluated by calculating a staining index 
(SI): proportion of stained cells x staining intensity. The proportion of stained cells was 
expressed as 0, 1, 2 or 3, which marks positive staining signal in 0%, <10%, 10-50% or 
>50% of the cells of a particular cell population. The intensity of staining was expressed 
as 1, 2 or 3 (weak, moderate or strong staining, respectively). The minimum score was 
0 and the maximum score 9 [Plaisier et al. 2007]. The average score of two independent 
observers was used to calculate the mean and total staining index (Mean and Total SI). 
The inter-observer variability was 6% for VEGF-A, 7% for PlGF, 11% for Flt-1, 10% for 
KDR, 5% for Ang-1, 6% for Ang-2, 9% for TIE-2, 4% for MT1-MMP, 14 % for MT2-MMP, 
8 % for MT3-MMP, 7 % for MT5-MMP (mean variability 8%).
The Mean SI represents the protein expression per studied cell type. The Total SI rep-
resents the total protein expression per tissue and was calculated as the sum of the 
Mean SI of endothelial cells (EC), peri-vascular smooth muscle cells (PSMC), glandular 
epithelium (GE) and stromal cells (SC) in DSE and DP samples. The Mean SI of EVT was 
also included in the Total SI of DB samples.
statistical analysis
Data are expressed as mean ± SEM. All parameters were compared between DSE and 
DP, between DSE and DB and between DP and DB within subjects. A general linear 
model for repeated measurements, repeated measures ANOVA, was performed to ana-
lyze the double paired data within the case and control group as well as to compare data 
between the case and control group. Where appropriate, the Friedman’s test for non-
parametric investigations of correlated observations and the wilcoxon test for paired 
samples were used to study differences within the two groups (SPSS 11.5). The used 
statistical analyses are described in legends and table footnotes. P-values of < 0.05 were 
considered significant.
resuLts
the vascularisation pattern in cases and controls
Intense CD34 staining of vascular structures was observed in all decidual tissues of con-
trols and missed abortion cases. Their vessel density as well as their total and luminal 
surfaces were quantified in all controls (n=16) and cases (n=11).
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Controls
Vessel density was significantly elevated in DSE (116.1 ± 8.5 vessels/mm2) compared to 
DP (39.1 ± 3.3) and DB (30.9 ± 3.8); vessel density in DP and DB also differed signifi-
cantly (all p<0.01, Figure 1A). The total vascular surface was significantly smaller in DSE 
(0.021 ± 0.002 mm2/mm2) compared to DP (0.040 ± 0.004) and DB (0.055 ± 0.007). 
The total surface in DP differed significantly from that in DB (all p<0.01, Figure 1B). The 
luminal surface was significantly smaller in DSE compared to DP (203.8 versus 1576.0 
µm2/vessel) and DB (2928.1 µm2/vessel); this parameter was also significantly smaller 
in DP compared to DB (all p<0.01, Figure 1C). Thus, larger but fewer vessels were pres-
ent from DSE to DP to DB.
Cases versus Controls
The vessel density was significantly lower in DP and DB of cases compared to the con-
trols; 29.6 vessels/mm2 versus 39.1 in DP and 19.8 versus 30.9 in DB respectively (both 
p<0.05, Figure 1A). The luminal surface of the cases was significantly higher in DP and 
DB of cases; 3604 µm2/vessel versus 1576 in DP and 5661 versus 2928 in DB respectively 
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figure 1. Vascularisation pattern in cases and controls.
The vascularisation pattern in decidual tissues of controls (n=16, black bars) and cases (n=11, white bars) 
was determined by image analysis of anti-CD34-stained sections. A. Vessel density (number of vessels per 
mm2), B. the total vascular surface (mm2/mm2) and c. the luminal surface (µm2/vessel) were calculated 
and expressed as mean±SEM. # p<0.05 within controls, ∗ p<0.05 in cases versus controls. The bottom 
panels show examples of vascularisation in decidua parietalis and basalis of cases and controls (control; 
left panels) and cases (missed abortions; MA: right panels).
(see colour figures supplement)
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(both p<0.04, Figure 1C). The total vascular surface and all the parameters in DSE did 
not differ between cases and controls.
Angiogenic factors and proteases in cases and controls: mrnA levels
The expression of various angiogenic growth factors and MT-MMPs were evaluated at 
the mRNA level in the three decidual tissues in cases and controls. The data of cases 
and controls are separately described in Table 3a and 3b. Their relative content in cases 
versus controls is described in Table 4. 
The data of the 16 controls on mRNA levels of angiogenic factors and proteases are 
given in Table 3a. They were highly comparable to previous data on control samples of 
25 different women [Plaisier et al., 2007; Plaisier et al., 2008].
table 3a differential mrnA content of angiogenic factors and proteases in first-trimester decidua of controls.
mrnA content (ng/µl) a mrnA (fold induction)
dse dp dB dse b dp dB dp c dB
plgf 1.09 ± 0.22 0.69 ± 0.23 10.1 ± 2.1 1.0 0.7 ± 0.3 12.7 ± 2.7* 1.0 35.8 ± 2.8#
Vegf-A 0.18 ± 0.04 0.20 ± 0.04 0.21 ± 0.05 1.0 1.1 ± 0.2 1.2 ± 0.2 1.0 1.5 ± 0.3
kdr 0.85 ± 0.17 1.68 ± 0.56 1.23 ± 0.50 1.0 1.1 ± 0.1 1.2 ± 0.1 1.0 0.9 ± 0.2
flt-1 0.81 ± 0.12 0.76 ± 0.09 0.94 ± 0.15 1.0 1.1 ± 0.1 1.2 ± 0.1 1.0 1.3 ± 0.2
Ang-1 0.10 ± 0.02 0.09 ± 0.02 0.03 ± 0.01 1.0 0.9 ± 0.1  0.5 ± 0.1* 1.0  0.6 ± 0.1#
Ang-2 0.51 ± 0.13 0.33 ± 0.04 0.16 ± 0.05 1.0 1.1 ± 0.2  0.4 ± 0.1* 1.0  0.6 ± 0.2#
tie-2 3.58 ± 0.52 1.87 ± 0.39 0.76 ± 0.20 1.0  0.5 ± 0.1$  0.3 ± 0.1* 1.0  0.6 ± 0.1#
Mt1-MMp 3.35 ± 0.43 6.05 ± 0.91 5.69 ± 1.11 1.0  2.1 ± 0.4$ 1.7 ± 0.5* 1.0 1.4 ± 0.4
Mt2-MMp 0.09 ± 0.03 0.06 ± 0.02 1.45 ± 0.39 1.0 3.1 ± 1.1 23.3 ± 4.2* 1.0 19.3 ± 3.2#
Mt3-MMp 7.39 ± 1.89 6.20 ± 1.77 16.3 ± 2.5 1.0 1.4 ± 0.3 7.7 ± 1.0* 1.0 11.4 ± 2.4#
Mt5-MMp 39.88 ± 4.89 28.75 ± 7.35 5.94 ± 0.80 1.0 0.7 ± 0.2 0.1 ± 0.0* 1.0  0.3 ± 0.1#
mRNA content was determined by RT-PCR in DSE, DP and DB of early first-trimester pregnancies and 
compared within subjects of the control group. The ‘repeated measures ANOVA’ was performed to analyse 
the data.
a Mean cycle threshold (Ct) per gene: GAPDH 25, VEGF-A 26.0, PlGF 29.2, KDR 28.5, Flt-1 28.4, Ang-1 33, 
Ang-2 27.4, TIE-2 32.1, MT1-MMP 27, MT2-MMP 30, MT3-MMP 30, MT5-MMP 29. Cycle threshold were 
converted into ng/µl using a standard curve of total RNA. Then values were corrected for RNA input by 
calculating the ratio (ng/µl (target gene))/ (ng/µl (GAPDH)) and mean ± SD ratios are showed in the 
columns DSE, DP and DB.
b Fold induction was calculated as the ratio (DP)/ (DSE) and (DB)/ (DSE) to compare mRNA levels in DB 
and DP with those in DSE (1.0) within subjects. Discrepancies between absolute and percental data might 
originate from inter-individual differences.
c Fold induction was calculated as the ratio DB)/ (DP) to compare DB with DP (1.0) within subjects.
$ P<0.05 DP vs DSE, * p<0.05 DB vs DSE, # p<0.05 DB vs DP
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Cases versus Controls
The mRNA levels in cases are given in Table 3b and the comparison of these levels to 
the mRNA contents of controls is described in Table 4. The mRNA expression in DSE 
showed an upregulation of KDR (3.5), Flt-1 (3.5), TIE-2 (2.7), and MT1-MMP (2.4) and a 
reduced MT3-MMP expression (0.7) in DSE of cases compared to controls (1.0) (p<0.01, 
Table 4). Regarding the mRNA levels in DP, VEGF-A (2.1), KDR (4.4), Flt-1 (3.8), Ang-2 
(2.1), and TIE-2 (3.6) expression was significantly elevated and MT3-MMP expression 
was reduced in the case group (Table 4).
Finally, the mRNA levels in DB showed upregulation of all angiogenic factors, except 
PlGF, in decidua of the cases. On the other hand, none of the protease were differentially 
expressed (Table 4).
Angiogenic factors and proteases in cases and controls: immunohistochemistry
The presence and cellular localisation of the various antigens were determined in serial 
sections of DSE, DP and DB. The studied proteins were detectable in all decidual tissues 
Table 3b Differential mRNA content of angiogenic factors and proteases in first-trimester missed abortion decidua.
mrnA content (ng/μl) a mrnA (fold induction) 
dse dp dB dse b dp dB dp c dB
plgf 1.81 ± 0.67 0.44 ± 0.06 10.67 ± 3.11 1.0 0.6 ± 0.1 13.4 ± 3.9* 1.0 21.2 ± 4.2#
Vegf-A 0.29 ± 0.04 0.40 ± 0.05 0.84 ± 0.17 1.0 1.7 ± 0.3  3.7 ± 0.9* 1.0   2.3 ± 0.4#
kdr 2.97 ± 0.57 5.74 ± 1.79 3.90 ± 0.99 1.0 2.6 ± 0.7 2.1 ± 0.8 1.0 1.4 ± 0.6
flt-1 2.68 ± 0.14 2.88 ± 0.52 2.44 ± 0.47 1.0 1.0 ± 0.2 0.9 ± 0.2 1.0 0.9 ± 0.1
Ang-1 0.12 ± 0.02 0.10 ± 0.01 0.09 ± 0.02 1.0 1.3 ± 0.4 1.0 ± 0.3 1.0 1.0 ± 0.1
Ang-2 0.80 ± 0.14 0.68 ± 0.10 1.46 ± 0.41 1.0 1.3 ± 0.3 3.1 ± 1.0 1.0 2.6 ± 0.6
tie-2 7.97 ± 0.72 6.04 ± 0.94 4.58 ± 1.08 1.0 0.8 ± 0.1 0.6 ± 0.2 1.0 0.9 ± 0.3
Mt1-MMp 8.09 ± 1.49 6.73 ± 0.65 8.40 ± 1.48 1.0 1.1 ± 0.2 1.3 ± 0.3 1.0 1.2 ± 0.1
Mt2-MMp 0.12 ± 0.03 0.05 ± 0.03 1.21 ± 0.22 1.0 0.6 ± 0.3 18.0 ± 4.4* 1.0  73.5 ± 12.4#
Mt3-MMp 1.93 ± 0.35 0.93 ± 0.23 13.3 ± 2.30 1.0 0.8 ± 0.3 10.2 ± 2.1* 1.0  24.3 ± 5.4#
Mt5-MMp 26.97 ± 4.32 28.44 ± 5.82 9.54 ± 1.85 1.0 1.2 ± 0.3 0.4 ± 0.1* 1.0   0.6 ± 0.2 #
mRNA content was determined by RT-PCR in DSE, DP and DB of early first-trimester pregnancies and 
compared within subjects of the Missed Abortion group. The ‘repeated measures ANOVA’ was performed 
to analyse the data.
a Mean cycle threshold (Ct) per gene: GAPDH 25, VEGF-A 26.0, PlGF 29.2, KDR 28.5,  Flt-1 28.4, Ang-1 33, 
Ang-2 27.4, TIE-2 32.1, MT1-MMP 27, MT2-MMP 30, MT3-MMP 30, MT5-MMP 29. Cycle threshold were 
converted into ng/μl using a standard curve of total RNA. Then values were corrected for RNA input by 
calculating the ratio (ng/μl (target gene))/ (ng/μl (GAPDH)) and mean ± SD ratios are showed in the 
columns DSE, DP and DB.
b Fold induction was calculated as the ratio (DP)/ (DSE) and  (DB)/ (DSE) to compare mRNA levels in DB 
and DP with those in DSE (1.0) within subjects. Discrepancies between absolute and fold induction data 
might originate from inter-individual differences.
c Fold induction was calculated as the ratio DB)/ (DP) to compare DB with DP (1.0) within subjects. 
$ P<0.05 DP vs DSE, * p<0.05 DB vs DSE, # p<0.05 DB vs DP
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and their presence was graded as median staining indices (median SI) per cell type and 
total staining indices (total SI) based on the sum of the cell types-dependent indices 
(Table 5a and 5b).
Controls
First, the total expression of the studied antigens in DP and DSE were compared. This 
showed a more abundant total expression of Flt-1, TIE-2 and MT1-MMP in DP (Table 5a 
and 5b, p<0.05). Then, the staining patterns in DB and DSE were compared; the total 
SI’s of PlGF, Flt-1, TIE-2, and MT1-MMP were increased whereas the total SI of Ang-1 was 
decreased in DB. Finally, the comparison between DP and DB showed an increased PlGF 
total SI and a decreased Ang-1 total SI in DB.
The antigen expression was most abundant in glandular epithelial cells, followed by 
perivascular smooth muscle and stromal cells. Endothelium displayed the expression of 
all angiogenic factors, except Ang-1 and MT5-MMP. TIE-2 showed the highest expression 
in endothelium. The endothelial protein expression of PlGF and Flt-1 showed significant 
differences between the three decidual tissues and MT2-MMP appeared less abundantly 
expressed in DB compared to DP and DSE (Table 5a and 5b, Figure 3). All angiogenic 
factors, except Ang-1 and MT5-MMP very dimly, were also detected in extra-villous tro-
table 4. Fold induction mRNA expression in first-trimester decidua of cases versus controls (set at 1.0).
dse dp dB
plgf 1.7 1.5 1.1
Vegf-A 1.6  2.1* 4.9*
kdr  3.5*  4.4# 5.3*
flt-1  3.5*  3.8* 2.7*
Ang-1 1.2 1.3 2.8#
Ang-2 1.6  2.1* 8.3*
tie-2  2.7*  3.6* 5.3*
Mt1-MMp  2.4* 1.7 1.8
Mt2-MMp 1.3 1.7 0.8
Mt3-MMp  2.6#  0.3# 0.8
Mt5-MMp 0.6 0.8 1.8
mRNA levels of angiogenic factors and proteases in DSE, DP and DB were compared between cases and 
matched controls (1.0). The ‘repeated measures ANOVA’ was performed to analyse the data. Mean cycle 
threshold (Ct) per gene: GAPDH 25-26, MT1-MMP 27, MT2-MMP 30, MT3-MMP 30, MT5-MMP 29. Cycle 
threshold were converted into ng/µl using a standard curve of total RNA and values were corrected for RNA 
input by calculating the ratio (ng/µl (target gene))/ (ng/µl (GAPDH)). Fold induction was calculated as the 
ratio ng/µl (case)/ ng/µl (controls).
* p<0.01, # p<0.05
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Figure 2
Plaisier et al
Negative
Ang-1
Flt-1
MT5-MMP
Controls Cases
figure 2. Antigen presence of angiogenic factors and proteases in cases and controls.
Examples of the antigen expression of Ang-1, Flt-1 and MT5-MMP in controls (left site of panel) and cases 
(right site of panel). Ang-1 antigen presence in epithelial cells (open arrow) in DB of controls, compared to 
their presence in stromal (closed arrow), epithelial cells (open arrow) and PSMC (open arrowhead) in DB 
of cases. flt-1 antigen presence in epithelial cells (open arrow) and stromal cells (closed arrow) in DB of 
controls, compared to their elevated presence in DB of cases. (compare figure 3 for endothelial expression). 
M5-MMp antigens in epithelial cells (open arrow) in DB of controls, compared to their presence in PSMC 
(open arrowhead), endothelial (closed arrowhead), stromal (closed arrow) in DB of cases. negative controls 
using non-immune mouse IgG
1
 (left) and omission of the first antibody (right). All panels bar = 100 µm.
(see colour figures supplement)
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phoblasts; PlGF, VEGF, Flt-1 and TIE-2 were moderately expressed, whereas KDR and 
Angiopoietin-2 expressions were weak (Table 5a and 5b).
Cases versus Controls
The comparison of the antigen expression between cases and controls is described in 
Table 5a and 5b and Figure 2 and 3. Firstly, comparing protein expressions in DSE of 
cases and controls showed a reduced total staining index for KDR and increased total SI 
for MT5-MMP in DSE of cases (Table 5a and 5b, p<0.05).
MT2-MMP
Figure 3
Plaisier et al
Flt-1
KDR
Controls Cases
figure 3. Antigen presence of angiogenic factors and proteases in endothelium in cases and controls.
Examples of the differential endothelial expression (arrowheads) of flt-1, KDR and MT2-MMP between DB 
specimens of cases (right site of panel) and controls (left site of panel) are given. All panels: bar = 50 µm.
(see colour figures supplement)
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With regard to DP, the total expression of flt-1 was elevated in the case group (Table 5a 
and 5b, p<0.05). The proteases showed differential expression as well, reflected by a 
reduced total MT3-MMP and MT5-MMP expression in missed abortion decidua.
The angiogenic factors in DB were differentially expressed; the total SI of flt-1 and Ang-1 
expression were elevated in missed abortion DB (p<0.05), in particular in perivascular 
smooth muscle cells and stromal cells. In addition, reduced total MT3-MMP and el-
evated total MT2- and MT5-MMP were detected in DB of cases (p<0.05, Figure 2).
The endothelial protein expression of KDR, Flt-1, MT2- and MT5-MMP showed differen-
tial expression between cases and controls (Table 5a and 5b, Figure 3). Finally, the Ang-1 
expression was significantly elevated and the Ang-2 expression appeared decreased in 
DP and DB of cases compared to controls (Figure 2). This trend was also detected in 
DSE tissues. Subsequently, the Ang-2/Ang-1 ratio was decreased in all tissues of cases 
compared to controls (p<0.02 for DB and DP, p<0.05 for DSE).
the expression of proliferation (ki67) and apoptosis (active caspase 3) markers
To evaluate whether cell proliferation and apoptosis contributed to the observed chang-
es, we evaluated the presence of active caspase-3 and the proliferation marker Ki67. The 
expression of active Caspase-3 (aCasp-3) in epithelial (range 17-25%), endothelial (range  
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figure 4. Proliferation, apoptosis, and immune cells in cases and controls.
The number of positive cells per total stromal cells for A. active Caspase-3 (apoptosis marker), B. Ki67 
(proliferation marker), c. CD56 (uNK cell marker), and d. CD68 (macrophage marker) were determined 
via immunohistochemistry and expressed in graphs as mean ± SEM. #P<0.05 in DB versus DSE and DP of 
controls. * P<0.05 in cases versus controls.
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0.0-0.1%) and stromal (range 1.6-7.2%) cells was comparable in both groups. The dif-
ferences between the decidual tissues within each group were similar, except for the 
expression in stromal cells. The controls showed a significantly decreased percentage of 
stromal aCasp-3 expression in DSE and DP compared to DB and the cases displayed the 
same trend (Figure 4A).
The expression of proliferation marker Ki67 in epithelial (range 0.3-1.9%), endothelial 
(range 0.3-2.3%) and stromal (range 2.6-8.1%) cells was comparable in cases and con-
trols. Strikingly, the endothelial and stromal expression appeared to be decreased in DSE 
and DP compared to DB in both cases and controls (Figure 4B).
the expression of unk cell (cd56) and macrophage (cd68), markers
Because decidualisation is accompanied by a large influx of immune cells, which can 
influence angiogenesis, we determined the number of uNK cells and macrophages in 
the tissues of controls and cases. The CD56 staining showed inhomogeneous staining, 
mainly situated surrounding vessels and glands, which was corrected for by analysing 
various samples per patient. DSE showed a significantly increased number of uNK cells 
in the case group of 15±2% positive cells per total number of stromal cells versus 9±2% 
in the control group. No significant differences were detected in between the two groups 
DP (18±6% vs 26±4%) and DB (21±4% vs 20±4%, Figure 4C).
The CD68 staining showed scattered positive cells throughout the tissues (range 
0.4-3.2%). No significant differences were detected in DSE and DB between the two 
groups. The number of macrophages was significantly increased in DP of cases com-
pared to controls (Figure 4D).
discussion
The present study showed that the vascularisation pattern varied in decidual secretory 
endometrium (DSE), decidua parietalis (DP) and decidua basalis (DB) of missed abor-
tion cases and matched controls, i.e. fewer vessels with larger circumference, were pres-
ent in DP and DB of cases. Strikingly, these differences correlated with the differential 
expression of several angiogenic molecules at mRNA and antigen level, including the 
endothelial protein expression of Flt1, KDR and MT2-, MT3- and MT5-MMP. These find-
ings might indicate a correlation between decidual vascularisation and the occurrence 
of miscarriages.
Maternal vascular adaptation to implantation and its regulation has been subject to 
discussion, but has mainly been studied with regard to arterial remodelling and villous 
vascularisation [Craven et al., 1999; Kam et al., 1999]. Recently the potential regulation 
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of decidual vascularisation by the extra-villous trophoblast (EVT), immune cells and 
pregnancy-induced hormones has been described [Plaisier et al. 2007/2008]. The pres-
ent study compared the vascularisation pattern and the expression of angiogenic factors 
and proteases in miscarriage cases and matched controls, which enabled hypothesising 
about their correlation with the occurrence of miscarriages. All methods were performed 
on serial paraffin sections, which allowed studying all parameters in the same tissue. 
Karyotyping was not allowed. However, no differences in the number of leucocytes in 
general, in uNK cells and macrophages, and in decidual architecture were previously 
detected between chromosomally normal and abnormal pregnancies [Quack et al. 2001; 
Greenwold et al. 2003; Shimada et al. 2006]. Thus, the lack of karyotyping will probably 
not significantly bias our observations.
The vascularisation pattern showed increasing vascular and luminal surfaces and de-
creasing vessel density from DSE to DP to DB in both uncomplicated and complicated 
first-trimester pregnancies. Vailhe et al reported a decreased vessel density in DB com-
pared to DP, but did not study DSE [Vailhe et al. 1999]. The authors described a vessel 
density ranging between 20 and 30 vessels/mm2, which is comparable to our findings. 
The changes in vascular pattern from DSE to DP to DB may be related to mechanical 
factors and/or proteins regulating angiogenesis. For instance, the lower vessel density 
and the enlargement of the vascular surface in DB may be associated with the increased 
blood flow in the proximity of the implantation site [Gibbons et al. 1994; Kam et al. 1999; 
Plaisier et al. 2007]. Increased luminal size might also be induced by a relatively low 
oxygen level [Charnock-Jones et al. 2002].
The decreased vessel density and increased vascular surface in DB and DP might also 
be due to an altered balance between angiogenesis regulating factors. Changes in the 
relative content of VEGF, angiopoietins and their receptors have been associated with 
the formation of dilated or enlarged microvessels [Adams, Alitalo, 2007; Nagy et al, 
2003[. Whether the altered contents of angiopoietin-1 (higher) and MT-MMPs (lower) 
in smooth muscle cells of cases reflect an altered interaction between pericytes and 
endothelial cells contributing to changes in vasculature is yet unknown and requires 
further studies.
Comparison of cases and controls showed that the total vascular surface did not differ 
between the two groups. However, the arrangement of the vessels did differ in DB and 
DP, i.e. a significant decreased vessel density and increased luminal surface in DB and 
DP of cases. This is not in concordance with the previously described increased vessel 
density in DP of missed abortions tissue specimens (Vailhe et al. 1999).
The differences in vascularisation patterns between controls and cases resemble the dif-
ferences between early and late first-trimester vascularisation, respectively, suggesting 
that a too fast maturation of the vasculature is associated with the pathogenesis of mis-
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carriages [Plaisier et al 2007]. The pre-maturely ripening may allow access of maternal 
blood in the intervillous space too early in the development of pregnancy, which was also 
demonstrated in vivo by Doppler ultrasound imaging [Greenwold et al. 2003; Jauniaux, 
Burton 2005]. This might result in increased oxygen levels with subsequent excessive 
oxidative stress, which is able to modulate the architecture of vasculature and the ex-
pression of peri-cellular proteases and angiogenic factors [Burton et al.1999, Sharkey et 
al.2000, Kingdom, Kaufman 1997, Zhang et al. 2001].
The role of smooth muscle cells has been described regarding vascular adaptation to 
pregnancy. The quantification of smooth muscle cells in the studied samples may pro-
vide interesting information in the future.
Steroidal hormones, the EVT, and immune cells are able to modulate vascularisation 
directly or indirectly via angiogenic factors [Hanna et al. 2006; Hyder, Stancel 1999; 
Simoncini et al. 2003; Zygmunt et al. 2002]. We confirm the previously described po-
tential role for VEGF-A (via KDR), the angiopoietins (via TIE-2) and PlGF (via Flt-1) in 
the regulation of decidual vascularisation [Plaisier et al. 2007]. Additionally, their pos-
sible association with the differential vascularisation pattern in the miscarriage group 
is evaluated. The closer the tissue is situated near the implanting embryo, the more 
angiogenic factors show increased expressions in cases compared to controls. PlGF, the 
most abundantly regulated factor in uncomplicated first-trimester decidua [Plaisier et al. 
2007], is not differentially expressed and appears not to be involved in the pathogenesis 
of missed abortions. In which way the increased expression of angiogenic factors are 
related to the fewer but larger vessels remains to be elucidated in future research.
In contrast with the mRNA results, the antigen expression of the angiogenic factors 
showed remarkable little differences between cases and controls. Apparently, the regula-
tion at transcriptional level could not be detected at the translational level. Reasons for 
this might be an increased cytoplasma storage of the antigens, reduced bio-availability 
or the higher sensitivity of RT-PCR. Only the endothelial and total expression of Flt-1 and 
KDR antigens and the total expression of Flt-1 and Ang-1 were differentially expressed. 
Thus, the receptors of VEGF and PlGF, and not the growth factors themselves, seem to 
be regulated at the protein level. It should be noted that our assays did not differentiate 
between the expression of Flt-1 and the soluble form of Flt-1, which is known to have a 
counter regulatory role in VEGF signal transduction during in early pregnancy [Maynard 
et al. 2003].
Decidual tissues of controls showed an Ang-2/Ang-1 ratio in favour of Ang-2, whereas 
decidual tissues of cases showed a ratio in favour of Ang-1. This altered ratio might be 
based on different oxygen levels in both groups, since hypoxia enhances Ang-2 transcrip-
tion and destabilises Ang-1 [Zhang et al 2001]. The favour of Ang-1 in cases might in part 
explain the observed decreased vessel density with increased circumference, since Ang-1 
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promotes the generation of a more complex vascular network and vessels of increased 
luminal size [Geva et al. 2000; Asahara et al. 1998]. In addition, less complex and fewer 
large arteries are reported in Ang-1 -/- mice [Suri et al. 1996].
The expression of pericellular acting proteases was assessed in decidua of both groups. 
MT1-MMP did not show differential expression between cases and controls. The dif-
ferential expression at protein but not at RNA level suggests that MT2- and MT5-MMP 
are regulated at translation and not at transcription level. The differential endothelial 
antigen levels of MT2, MT3- and MT5-MMP may be partially responsible for the differ-
ences in vascular pattern in DB and DP. Especially, since we know that MT2- and MT3-
MMP are likely to be regulators of decidual angiogenesis [Hotary et al. 2000; Plaisier 
et al. 2004/2006]. In which way MT5-MMP is involved in decidual vascularisation and 
possibly other decidual remodelling processes remains a question.
Causal conclusions from histo-pathological studies of abortion tissue are often ques-
tioned since foetal death may occur days before evacuation, allowing post-mortem 
inflammatory or apoptotic reactions during this “retention time”. No effect has been 
described of retention time on the outcome of vascular parameters [Meegdes et al. 1988; 
Nelen et al. 2000; Lisman et al. 2004]. This most likely excludes a contribution of “re-
tention time” to the observed vascularisation differences between cases and controls. 
Nevertheless, inflammatory, proliferation, and apoptotic processes were analysed.
The expression of proliferation and apoptosis markers suggests an increased cellular 
turnover from DSE to DP to DB in both cases and controls. The level of proliferation and 
apoptosis was comparable in cases and controls, suggesting that our data were not seri-
ously biased by differences in proliferation and apoptosis in response to foetal loss. The 
amount and distribution of apoptosis is comparable with earlier reports and the elevated 
apoptosis level in DB compared to DP has been described in uncomplicated pregnan-
cies [Joswig et al. 2003; Marx et al. 1999; Von Rango et al. 2003]. No references data were 
available regarding proliferation in the various decidual tissues, although moderate Ki67 
expression has been described in DB [Korgun et al. 2006].
Similar numbers of uNK cells were demonstrated in DP and DB of cases and controls, 
but their number was significantly increased in DSE of cases. Reports on uNK cells and 
miscarriages describe increased uNK cells in receptive endometrium of patients with 
recurrent miscarriages (RM) [Quenby et al. 1999; Tuckerman et al. 2007]. The abundant 
presence of uNK cells in DSE samples may reflect these observations. The difference 
between cases and controls were levelled in DP and DB, possibly by hormone regulated 
uNK cell migration to normal values [Van den Heuvel et al., 2005b].
The number of macrophages has been reported not to be related to miscarriages [Hill 
et al. 1995; Quack et al. 2001]. We detected increased amounts of macrophages in DP of 
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cases and not in DSE and DB. Strikingly, the number of uNK cells and macrophages at 
the actual implantation site did not differ between the two groups
conclusion
Vascular adaptation to implantation is important in the development of a healthy preg-
nancy. Here, the involvement of decidual vascularisation was studied in relation to mis-
carriages. Differences were observed in vascularisation pattern between decidual tissues 
of cases and controls. Strikingly, the vascular differences correlated with the differential 
expressions of several angiogenic molecules at mRNA and antigen level. Furthermore, 
the endothelial antigen levels of MT3-MMP were decreased and of Flt1, KDR and MT2- 
and MT5-MMP were enhanced in DP and DB of cases. These findings might indicate a 
correlation between decidual vascularisation and the occurrence of miscarriages.
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ABstrAct
objective: Disturbances in decidual and placental vascular development may play a 
role in the pathogenesis of pregnancy complications. This study focused on the role 
of angiogenic factors in the first-trimester in the pathogenesis of pre-eclampsia (PE) 
and/or foetal growth restriction (FGR).
Materials and Methods: First-trimester decidua was obtained during chorionic villous 
sampling. The expression of VEGF-A, PlGF, Flt-1, KDR, Angiopoietin-1, Angiopoietin-2 
and TIE-2 mRNA was determined by RT-PCR and related to the pregnancy outcome.
results: First-trimester decidua expressed all angiogenic factors. VEGF-A, PlGF, KDR, 
Ang-1, Ang-2 and TIE-2 appeared increased in FGR compared to matched controls, 
whereas PlGF, Ang-1 and TIE-2 appeared increased in PE compared to controls. Flt-1 
mRNA levels were comparable in both PE and FGR compared to the controls. The 
differential expression of angiogenic factors appeared to be more prominent in FGR 
than in PE.
conclusions: These first-trimester samples provided a unique opportunity to obtain 
information regarding the onset of PE and FGR. First-trimester changes in angiogenic 
factor expression may well occur as a compensatory mechanism. In turn, this may un-
intentionally set the stage for increased angiogenesis and altered decidual/placental 
vascular adaptation, which may be part of the pathogenesis of PE and/or FGR.
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introduction
Disturbances in decidual and placental vascular development may play a role in com-
plications of pregnancy, like pre-eclampsia (PE) and foetal growth restriction (FGR) 
[Ahmed, Perkins 2000; Ong et al., 2000; Torry et al., 2004]. PE affects 5-10% of pregnan-
cies and is responsible for substantial maternal and neonatal morbidity and mortal-
ity. Predominant features are maternal systemic vascular endothelial dysfunction and 
microangiopathy. Target organs are the brain (seizures or eclampsia), liver (Hemolysis, 
Elevated Liver enzymes, Low Platelets (HELLP) Syndrome), kidney (proteinuria) and the 
utero-placental unit (fetal distress and growth restriction). Failure of placental vascular 
development has been linked to the pathogenesis of PE and FGR [Luttun, Carmeliet 
2003; Maynard et al., 2003].
Decidual vascular adaptation to pregnancy is characterised by high levels of both angio-
genesis, the formation of new vessels from existing vasculature, and vasculogenesis, 
blood vessel generation from angioblast precursor cells [Burton et al., 1999; Pijnenborg 
et al., 1983]. Additionally, vascular mimicry or pseudo-vasculogenesis is also taking place 
where cytotrophoblasts convert to an endothelial phenotype. Failure of angiogenesis and 
pseudo-vasculogenesis has been proposed as processes in the inception of PE and FGR 
[Zhou et al., 2002].
Numerous factors are thought to play a role in normal vascular adaptation to implanta-
tion [Geva et al., 2002]. Vascular Endothelial Growth Factor-A (VEGF-A) and Placental 
Growth Factor (PlGF), are probably the best studied factors [Das et al., 1997a; Plaisier et 
al., 2007; Chung et al., 2004]. VEGF interacts with VEGFR-1 (Flt-1) and VEGFR-2 (KDR) 
to promote endothelial cell proliferation, cell migration and vascular permeability. In 
rabbits, VEGF, together with its receptor Flt-1, plays an active role in the angiogenic 
process during implantation [Das et al., 1997a]. PlGF shares biochemical and functional 
features with VEGF and interacts with VEGFR-1 (Flt-1). PlGF and VEGF-A have synergis-
tic effects regarding angiogenesis, but vessels induced by PlGF are more mature and 
stable than vessels induced by VEGF-A [Carmeliet et al., 2001; Luttun et al., 2002]. PlGF 
is abundantly expressed in human placenta. Both VEGF-A and PlGF may be important 
paracrine regulators of decidual angiogenesis and autocrine mediators of trophoblast 
function [Plaisier et al., 2007; Sherer, Abulafia 2001]. The soluble variant of Flt-1 has been 
associated with the pathogenesis of PE [Luttun, Carmeliet 2003; Maynard et al., 2003].
A second family of growth factors, the angiopoietins, is also known for their regulating 
capacities regarding angiogenesis [Geva, Jaffe 2000]. Angiopoietin-1 (Ang-1) and An-
giopoietin-2 (Ang-2) bind with equal affinity to their receptor TIE-2, but have different 
functions. Ang-1 maintains vessel integrity and plays a role in the later stages of vascular 
remodelling [Geva, Jaffe 2000]. Ang-2 is a functional antagonist of Ang-1 and leads to 
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loosening of cell-cell interactions and allows access to angiogenic inducers like VEGF 
[Maisonpierre et al., 1997]. Co-expression of VEGF and Ang-2 induces angiogenesis, but 
Ang-2 results in vascular regression in the absence of angiogenic signals [Asahara et 
al., 1998]. Ang-1 and Ang-2 have both been detected in decidual and placental tissues 
[Maisonpierre et al., 1997; Plaisier et al., 2007].
Various decidual celltypes are capable of producing angiogenic factors. We recently 
showed the production of PlGF, KDR, Flt-1, Ang-2 and TIE-2 by endothelial cells and 
extra-villous trophoblasts. Decidual stromal cells, glandular epithelium and perivascular 
smooth muscle cells were found to produce all studied angiogenic factors [Plaisier et al,. 
2007]. Uterine NK cells are also abundantly present in first-trimester decidua and are 
known to produce PlGF, VEGF, Ang-1 and Ang-2 [Li et al., 2001a].
The possible correlation of PE and FGR with impaired vascular development has been 
studied in placental tissues mainly after the onset of disease [Geva et al., 2002; Rob-
erts, Cooper 2001; Taylor et al., 2003]. However, whether decidual vascularisation is also 
related to the pathogenesis of both diseases is not known. Information regarding the 
expression of angiogenic factors in first-trimester tissues would be helpful in under-
standing PE and FGR. The present study focused on the role of first-trimester angiogenic 
growth factors in the pathogenesis of PE and/or FGR. The expression of VEGF-A, PlGF, 
Flt-1, KDR, Ang-1, Ang-2 and TIE-2 was determined in first-trimester decidua obtained 
during routine chorion villous sampling. The included patients were followed through-
out their pregnancy to be able to relate the angiogenic factor expression to the pregnancy 
outcome, i.e. uncomplicated, PE or FGR.
MAteriALs & Methods
study group and tissue collection
Decidual samples were obtained from viable first-trimester pregnancies during routine 
chorionic villous sampling (CVS). CVS was performed vaginally between 10 and 12 weeks 
of gestation. Main indications were maternal age and serum screening related risk for 
aneuploidy. Gestational age was calculated according to the last menstrual period and 
confirmed by ultrasound (crown lump length). After CVS, surplus decidual tissue was 
microscopically separated from the chorion villi and immediately stored at -20 ˚C until 
RNA isolation. One sample per person was collected with an average size of 5-15 mg.
Follow-up of the pregnancies was available through a postpartum questionnaire. Patients 
experiencing FGR (FGR, n=10) and PE/HELLP (n=9) were selected. PE was defined as 
diastolic blood pressure (BP) of minimal 90 mmHg, or a raise of 15 mmHg compared 
to first-trimester BP, combined with proteinuria of at least 300 mg/day. For FGR, criteria 
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according to Kloosterman were used [Kloosterman 1969]. Birth weight was corrected for 
gestational age and FGR was defined as a corrected birth weight below the 5th percentile. 
All cases were matched to controls based on gestational age, maternal age and parity 
at time of CVS (n=19). Patients with concurrent morbidity (e.g. diabetes) or medication 
were excluded. Foetal karyotyping showed no chromosomal abnormalities. The weight 
and the number of smokers were comparable between cases and controls. Patients were 
informed that surplus material was used for research, according to the “Guideline for 
Good Use” by the Federation of Medical Scientific Associations and informed consent 
was provided by all study subjects. Patient characteristics are described in Table 1.
rnA isolation and cdnA synthesis
Tissue samples were incubated in 1.5 ml RNA Later Ice (Ambion, Austin, TX, USA) for 
48 hours at -20°C. After centrifugation, the tissue samples were lysed in lysisbuffer (RLT 
buffer (Qiagen) and β-mercapto-ethanol) using plastic mortars and RNA isolation was 
performed using RNAeasy columns (Qiagen Benelux BV, Venlo, Netherlands) following 
recommended protocol. mRNA was dissolved in RNAse free water. mRNA quantity and 
quality was determined by measuring its absorbance in a spectrophotometer (Nano-
drop ND-1000) and reverse transcription was performed with 1 µg total RNA, random 
primers and a cDNA synthesis kit (Ready-to-go You-Prime first strand beads, Amersham 
Biosiences, Buckinghamshire, UK). The obtained 32 µl cDNA was diluted 1:3.
real-time rt-pcr
mRNA expression was quantified according to the Taqman real-time PCR method us-
ing validated primer and probe (FAM/TAMRA double-labelled) sets for VEGF-A, Flt-1, 
KDR, PlGF, Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), TIE-2. Glycerylaldehyde-3-
phosphate dehydrogenase (GAPDH, primers/VIC-labelled probe) was used as an en-
dogenous reference gene (all purchased from Applied Biosystems, Foster City, CA, USA). 
table 1. Characteristics of the FGR and PE study groups and matched control groups.
fgr
(n=10)
mean ± sd
control 
(n=10)
mean ± sd
pe/heLLp 
(n=9)
mean ± sd
control
(n=9)
mean ± sd
At cVs Age (years) 39.5 ± 2.1 39.6 ± 2.1 39.2 ± 1.9 39.2 ± 1.9
gA (days) 75.6 ± 3.2 76.5 ± 2.5 78.6 ± 3.9 77.3 ± 4.4
parity  1.5 ± 1.4  1.1 ± 0.6  0.7 ± 0.9  0.7 ± 0.9
At delivery gA (days) 278 ± 11 282 ± 12 261 ± 22 271 ± 10
Birth weight (g) 2477 ± 286* 3648 ± 475 2648 ± 798 3420 ± 382
* p<0.05 versus control group
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β-actin, β
2
-microglobulin, and cyclophilin were also used as reference genes and showed 
similar results (data not shown).
RT-PCR for target gene/GAPDH pairs was performed in 12.5 µl reactions, containing 2.5 
µl cDNA solution, using mastermix (RT-QP2X-03, Eurogentec, Maastricht, the Nether-
lands), DNAse free water and the above described primer/probe sets. Reactions were 
performed in duplicate and mRNA levels were expressed in cycle threshold (Ct). To cor-
rect for the RNA input, the difference in Ct values of target and reference genes (dCt = 
Ct(target gene) – Ct(GAPDH)) was calculated. The difference between cases and con-
trols (ddCt) was calculated as ddCt= dCt(case) – dCt(control) and the fold induction was 
calculated as 2 – ddCt. In addition, Ct values were quantified into ng/µl using a standard 
curve of total RNA. Cases and controls were compared by the ratio ng/µl(case)/ ng/
µl(control). Water and negative-RT samples, obtained by the omission of the reverse 
transcriptase enzyme in the cDNA reaction, were used as negative controls.
statistics
The mRNA expression levels were compared between cases and matched controls. A 
general linear model for repeated measurements, ANOVA, was performed to analyse the 
paired data between matched cases and controls (SPSS 11.5). P-values of < 0.05 were 
considered significant.
resuLts
The expression of the angiopoietins and their receptor TIE-2 and of VEGF, PlGF and their 
receptors KDR and Flt-1 were evaluated. The mRNA levels in all cases were calculated 
and expressed as ddCt, ng/µl and as fold induction compared to the control group (Table 
2 and 3). All factors were present at mRNA level in decidua of cases as well as controls.
control group
The control patients were matched to the cases; ten controls to FGR patients and nine 
controls to PE patients. First, mRNA expression was analysed in all the control patients. 
In these controls, PlGF showed the most abundant expression with a mean of 4.6 ng/µl 
(± 1.8). KDR, Flt-1 and Ang-2 showed a moderate expression with means of 0.4 ng/µl (± 
0.1), 0.5 ng/µl (± 0.1) and 0.8 ng/µl (± 0.3) respectively. VEGF-A, Ang-1 and TIE-2 were 
only dimly expressed with means of 0.04 ng/µl (± 0.01), 0.01 ng/µl (± 0.00) and 0.15 
ng/µl (± 0.06) (data not shown).
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fetal growth restriction group
The FGR group showed no significant differential expression compared to the con-
trol group (100%). Strikingly, the expression of VEGF-A (53-fold), PlGF (33-fold), KDR 
(26-fold), Ang-1 (59-fold), Ang-2 (8-fold) and TIE-2 (37-fold) appeared unregulated in 
cases compared to controls. However, significance was not reached due to the large 
inter-individual variation. Flt-1 showed comparable expression levels in cases and con-
trols. The same pattern was found with regard to the data described as dCt (Table 2 and 
3).
pre-eclampsia group
The PE group showed no significant differential expression compared to the control 
group (100%). PlGF (35-fold), Ang-1 (29-fold) and TIE-2 (68-fold) appeared unregulated 
in cases compared to controls. However, these differences were not significant due to 
the large inter-individual variation. VEGF-A, KDR, Flt-1 and Ang-2 showed comparable 
expression levels in cases and controls. With regard to the data described as dCt, the 
same pattern was found (Table 2 and 3).
table 2. First-trimester decidual mRNA expression of angiogenic factors (in cycle threshold (Ct)).
mrnA content (dct)
mean ± seM a
fold induction
mean ± seMb
Angiogenic factor fgr
(n=10)
pe
(n=9)
fgr
(n=10)
pe
(n=9)
Vegf-A -1.5 ± 1.2 -0.5 ± 0.8 83 ± 70  3 ± 1
plgf 0.5 ± 1.6 -2.0 ± 1.4 31 ± 21 51 ± 34
kdr -0.5 ± 1.8 -1.8 ± 1.1 32 ± 25 17 ± 9
flt-1 0.4 ± 0.6 -1.1 ± 0.7 2 ± 0.9  8 ± 6
Ang-1 -1.5 ± 1.9 -1.7 ± 1.6 84 ± 50 68 ± 40
Ang-2 -0.4 ± 1.3  0.1 ± 1.3 11 ± 5  6 ± 5
tie-2 -1.2 ± 1.5 -3.1 ± 1.3 34 ± 25  110 ± 83
First-trimester decidual mRNA expression was determined by RT-PCR and compared between pregnancies 
resulting in FGR or PE and their matched controls. The ‘repeated measures ANOVA’ was performed to 
analyse the data.
a mRNA content was expressed in cycle threshold (Ct). Mean Ct per gene: GAPDH 25, VEGF-A 26.0, 
PlGF 29.2, KDR 28.5, Flt-1 28.4, Ang-1 33, Ang-2 27.4, and TIE-2 32.1. The Ct values were corrected for the 
mRNA input, by calculating the difference in Ct of target and reference genes: dCt = Ct(target gene) – 
Ct(GAPDH).
b The difference between cases and controls (ddCt) was calculated as ddCt= dCt(case) – dCt(control). Fold 
induction in cases compared to controls was calculated as 2 – ddCt.
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discussion
The results showed that first-trimester decidual tissues obtained from chorionic villous 
sampling expressed all examined angiogenic factors. mRNA levels of VEGF-A, PlGF, 
KDR, Ang-1, Ang-2 and TIE-2 appeared unregulated in FGR cases compared to matched 
controls. In addition, PlGF, Ang-1 and TIE-2 mRNA appeared unregulated in PE cases 
compared to matched controls. However, the large inter-individual variation disallowed 
an unequivocal conclusion. The differential expression of angiogenic factors appeared 
more prominent in FGR than in PE.
The origin of both PE and FGR probably starts in the first-trimester, before the onset of 
overt disease during the last trimester. Our first-trimester decidual samples provide a 
unique opportunity to obtain information regarding the onset of PE and FGR. The fact 
that the decidual samples were obtained together with villous tissue offers valid infor-
mation on the original localization in utero, namely underneath the implantation site. 
Shortcomings are also present. No histological investigation could be performed on the 
number of trophoblasts and other cell types, because of the small amounts of material 
in each sample. Also, the study groups are small because of the rarity of the samples. 
This results in rather high standard deviations, which makes interpretation of the data 
table 3. First-trimester decidual mRNA expression of angiogenic factors (in ng/ µl).
mrnA content
mean ± seM a
fold induction
mean ± seM b
Angiogenic factor fgr
(n=10)
pe
(n=9)
fgr
(n=10)
pe
(n=9)
Vegf-A 0.1 ± 0.0 0.1 ± 0.0 53 ± 46  2 ± 1
plgf 4.1 ± 1.8 8.2 ± 3.1 33 ± 21  35 ± 24
kdr 0.7 ± 0.3 1.7 ± 0.8 26 ± 17 13 ± 8
flt-1 0.6 ± 0.2 2.0 ± 1.3 2 ± 1  3 ± 2
Ang-1  0.02 ± 0.0 0.4 ± 0.4 59 ± 34 29 ± 21
Ang-2 0.4 ± 0.2 3.6 ± 2.0 8 ± 4  5 ± 3
tie-2 0.9 ± 0.8  19.6 ± 19.5 37 ± 30 68 ± 47
First-trimester decidual mRNA expression was determined by RT-PCR and compared between pregnancies 
resulting in FGR or PE and their matched controls. The ‘repeated measures ANOVA’ was performed to 
analyse the data.
a mRNA content was expressed in cycle threshold (Ct). Mean Ct per gene: GAPDH 25, VEGF-A 26.0, PlGF 
29.2, KDR 28.5, Flt-1 28.4, Ang-1 33, Ang-2 27.4, and TIE-2 32.1. Cycle threshold were converted into ng/µl 
using a standard curve of total RNA. Values were corrected for mRNA input by calculating the ratio (ng/µl 
(target gene))/ (ng/µl (GAPDH)) and these values are expressed as “mRNA content” in the table.
b Fold induction in cases compared to controls was calculated as the ratio ng/µl (case)/ ng/µl (controls).
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difficult. However, the 10- to 100-fold induction of genes in these small groups promises 
significant differences when groups could be expanded.
Current knowledge regarding PE suggests that defective vascular remodelling of mater-
nal spiral arteries leads to impaired invasion of trophoblasts, placental insufficiency and 
ischemia [Luttun, Carmeliet 2003]. The affected placenta releases soluble anti-angiogenic 
factors, like soluble Flt-1 (sFlt-1) and endoglin (sEng) [Maynard et al., 2003; Clark et al., 
1998b; Tjoa et al., 2007]. These factors alter the angiogenic balance, mainly by neutralis-
ing VEGF and PlGF. Furthermore, these factors are able to induce systemic endothelial 
dysfunction and finally to induce clinical PE [Maynard et al., 2003; Ahmad, Ahmed 2004; 
Hayman et al., 1999; Sugimoto et al., 2003]. The serum and placental levels of these fac-
tors have been studied extensively in term pregnancies, without reaching complete con-
sensus with regard to VEGF. Several reports described increased, comparable and even 
decreased VEGF levels in placenta of term PE pregnancies [Geva et al., 2002; Chung et 
al., 2004; Ranheim et al., 2001; Sgambati et al 2004]. PlGF was decreased in serum of 
PE in the third-trimester [Lam et al., 2005; Roberts, Cooper 2001]. Term placental tissue 
showed reduced Ang-2 mRNA and equal Ang-1 mRNA in PE [Zhang et al., 2001]. No 
reports on these angiogenic factors are available regarding first-trimester tissues.
In the present study, mRNA levels of PlGF, Ang-1 and TIE-2 appeared unregulated in 
future PE patients compared to controls. VEGF-A, KDR, Flt-1 and Ang-2 showed com-
parable expression levels. No previous reports were found to reference these data in 
first-trimester tissues. Only first-trimester serum data are available, showing reduced 
PlGF and increased VEGF and sflt-1 in first-trimester serum of PE patients [Levine et al., 
2004; Bosio et al., 2001].
The studied Flt-1 represents both the soluble and membrane-bound Flt-1 and unfortu-
nately no differentiation can be made between both types. The comparable overall Flt-1 
expression in PE cases probably corresponds to the described decline of membrane 
bound Flt-1 and the known increase of soluble Flt-1 [Tsatsaris et al., 2003].
FGR has been proposed to be induced by relatively high oxygen levels, which cause a 
disturbed expression of angiogenic factors and altered angiogenesis in placental villi 
[Burton 1997; Kingdom, Kaufmann 1997; Regnault et al., 2003]. These relative hyper-
oxic conditions may cause the decreased VEGF and increased PlGF expression in FGR 
placentas, since these factors are inversely regulated by oxygen [Lyall 1997; Khaliq et al., 
1999]. An ovine model for FGR demonstrated increased Ang-1, Ang-2 and TIE-2 levels 
in early gestation before FGR was clinically detected. Later in gestation decreased TIE2 
expression was associated with FGR [Erickson Hagen et al., 2005]. Whether decidual an-
giogenesis is also affected by the altered oxygen levels in FGR is still not demonstrated 
but plausible.
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Present study showed that the mRNA levels of angiogenic factors in first-trimester de-
cidua were altered in the FGR group compared to the control group, although differenc-
es were not significant. The expression of VEGF-A, PlGF, KDR, Ang-1, Ang-2 and TIE-2 
appeared unregulated in FGR cases and Flt-1 showed comparable expression levels in 
cases and controls.
The relative hyperoxia in FGR and the oxygen effect on angiogenic factors are mainly de-
scribed in feto-placental tissues and trophoblasts. If the theory is valid for first-trimester 
decidua, one would expect decreased VEGF and Ang-2 and increased Ang-1 and PlGF 
mRNA levels in FGR patients [Zhang et al., 2001; Regnault et al., 2003; Khaliq et al., 
1999; Sharkey et al., 2000]. However, mRNA levels of all four genes appeared increased 
in FGR compared to matched controls. This might be explained by a different expres-
sion and regulation of angiogenic factors in first-trimester compared to third-trimester 
tissues. For example, VEGF-A and Ang-1 were shown to increase and Ang-2 to decrease 
as gestation progresses [Geva et al., 2002]. In contrast, others demonstrated a decline 
in VEGF-A mRNA as gestation progresses [Cooper et al., 1996]. In addition, oxygen influ-
ences in decidua may differ from its influences in villous tissue and/or trophoblasts. 
No references were found regarding oxygen regulation in decidua. Finally, histological 
differences or differences in the number of trophoblasts between the studied specimens 
cannot be ruled out.
The differential expression of angiogenic factors appeared more prominent in FGR than 
in PE and therefore a more pronounced disbalance between angiogenic factors might 
be involved in the pathogenesis of FGR. Overall, enhanced angiogenic factors in both 
patient groups might represent an (ineffective) vascular rescue mechanism in response 
to unidentified situation(s) and/or event(s). This compensatory mechanism may in turn 
unintentionally induce increased non-branching angiogenesis, altered decidual and pla-
cental vascular adaptation and functional placental insufficiency that may all result in PE 
and/or FGR during late gestation.
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Pregnancy demands significant physiologic adaptations, including vascular remodelling, 
of the uterine environment to facilitate adequate implantation. The timing of angiogenic 
processes is of paramount importance for the development of a receptive endometrium 
suitable for implantation. Disturbances in uterine blood supply are associated with first-
trimester miscarriages and third trimester perinatal morbidity and mortality caused by 
pre-eclampsia (PE) and foetal growth restriction (FGR). This thesis assessed the role of 
angiogenesis in cycling endometrium and during human implantation. Furthermore, we 
attempted to evaluate the involvement of angiogenesis in the pathogenesis of missed 
abortions, PE and FGR.
Angiogenesis And periceLLuLAr proteAses in cycLing endoMetriuM
Angiogenesis occurs on a regular basis as part of the growth and regression of the human 
endometrium during the menstrual cycle. There is evidence for multiple mechanisms 
of endometrial angiogenesis; angiogenesis during post-menstruation repair, elongative 
angiogenesis during the early and late proliferative phase and intussusception during 
the secretory phase. However, neither the timing of vascular growth during the men-
strual cycle nor the mechanisms by which endometrial vessels are formed are currently 
completely understood, thus placing major limitations on our understanding of how 
angiogenesis promoters and inhibitors may act in the endometrium [Rogers,Gargett 
1998]. With the development of in vitro systems mechanistic questions regarding the 
regulation of endometrial angiogenesis may become answered.
Previously, an in vitro model for endometrial angiogenesis was developed using human 
endometrial microvascular endothelial cells (hEMVEC) on fibrin and/or collagen 3D ma-
trix. These cells have unique characteristics. They express high amounts of urokinase-type 
plasminogen activator (uPA), express various matrix metalloproteinases (MMPs) and 
membrane-type-MMPs (MT-MMPs), and display high angiogenic activity in response 
to vascular endothelial growth factor (VEGF). These characteristics are demonstrated 
in their in vivo counterparts as well [Chung et al., 2002; Freitas et al., 1999; Goffin et al., 
2003; Koolwijk et al., 2001; Maatta et al., 2000; Skinner et al., 1999; Zhang et al., 2000]. 
The combination of enhanced uPA expression and the high angiogenic activity directed 
us to determine the contribution of pericellular proteolysis to endometrial angiogenesis 
in vitro.
We demonstrated that both uPA/plasmin and MMPs contribute to the invasion and 
tubular structure formation of hEMVEC. Besides uPA, these cells express various MMPs, 
amongst which MT3-MMP (MMP-16) and MT4-MMP (MMP-17) and smaller amounts 
of MT1-MMP (MMP-14), MT2-MMP (MMP-15), MT5-MMP (MMP-24) and MT6-MMP 
(MMP-25). These data are in agreement with observations reported from immunohis-
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tochemical studies in endometrial tissue [Chung et al., 2002; Freitas et al., 1999; Goffin 
et al., 2003; Maatta et al., 2000; Skinner et al., 1999; Zhang et al., 2000].
MT1-, MT2-MMP and MT3-MMP are known inducers of capillary-tube formation and 
their mRNA levels increase during tube formation in vitro [Hotary et al., 2000; Lafleur et 
al., 2002; Shofuda et al., 2001]. Experiments with overexpression of MMP inhibitors (tis-
sue inhibitor of matrix metalloproteinases (TIMP) -1 and -3), which are also expressed 
by endometrial endothelial cells in vivo [Freitas et al., 1999; Maatta et al., 2000; Rodgers 
et al., 1994], indicated that hEMVEC utilise a unique pattern of MT-MMPs during angio-
genesis compared to endothelial cells originating from other tissues [Collen et al., 2003; 
Galvez et al., 2001; Hotary et al., 2002; Lafleur et al., 2002]. Moreover, the relative high 
expressions of MT3-MMP mRNAs in hEMVEC, the presence of MT3-MMP protein on 
endometrial endothelial cells and the inhibition of capillary tube formation by inhibiting 
MT3-MMP are strongly in favour of a contribution of MT3-MMP in capillary-like tube for-
mation by hEMVEC. This was a striking finding, since up to now MT1-MMP was thought 
to be the most important MT-MMP involved in angiogenesis [Pepper 2001; Seiki, Yana 
2003; Sounni et al., 2002; Stetler-Stevenson 1999].
Certainly, in vitro models comprise several limitations. For instance, our model uses 
fibrin/collagen matrices, whereas the endometrial ECM consists of several proteins, 
among which collagen, and its composition and the presence of fibrin varies during the 
menstrual cycle [Aplin et al., 1988; Bulletti et al., 1988; Iwahashi et al., 1996; Okada et 
al., 2001]. We attempted to mimic endometrial ECM by isolating ECM of cultured en-
dometrial stromal cells (hESC). hEMVEC cultured on fibronectin and on hESC ECM for 
24-96 hours displayed differential gene expression. For example, ECM cultured hEMVEC 
showed markedly induced expression of VE-cadherin, fibronectin, and SPARC (inhibits 
proliferation of endothelial cells). Alternatively, the MT-MMPs, TIMPs, uPA, uPAR, PAI-1 
and CD31 showed less than 2-fold (re)inductions. Thus, the gene expressions of the 
proteases of interest were not considerably changed by culturing on fibronectin.
Only by a combination of mechanistic in vitro and observational in vivo or in situ studies, 
an overall picture can emerge. In view of the proposed angiogenic involvement of MT3-
MMP, we were interested whether MT3-MMP was expressed in human endometrium 
in vivo. All MT-MMPs were expressed in human endometrium. The elevated expression 
of MT-MMP antigens during the late secretory and menstrual phase indicates a role in 
the shedding process during menstruation [Lockwood et al., 1998; Salamonsen, Woolley 
1996; Zhang et al., 2000]. Several MT-MMPs also showed a reduced expression during 
the receptive window, probably under the influence of steroidal hormones, which sug-
gest a contribution to the generation of a stable environment in preparation for embry-
onic implantation.
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With regard to the endothelium, MT2-, MT3-, and MT4-MMP, but not MT1-MMP, were 
expressed by in vivo endothelial cells. The endothelial expression of MT3-MMP and the 
consistent absence of endothelial MT1-MMP are in accordance with previous in vivo 
and in vitro work, but no data regarding the cellular expression of MT3- and MT4-MMP 
have been reported prior [Zhang et al., 2000; Maatta et al., 2000]. Strikingly, endothelial 
MT2, and MT3-MMPs were expressed during the proliferative and late secretory phase, 
which both display high angiogenic activity [Ferenczy et al., 1979; Goodger, Rogers 1995; 
Morgan et al., 1996; Rogers, Gargett 1998; Smith 2001]. This confirms the suggested 
contribution of MT3-MMP to angiogenesis in vitro. Moreover, MT2-MMP might be an 
additional angiogenic regulator to consider [Hiraoka et al., 1998; Hotary et al., 2000; 
Lafleur et al., 2002]. So overall, the pericellular proteases uPA, MT2- and MT3-MMP, but 
not MT1-MMP, were shown to be involved in endometrial angiogenesis.
contriButors to the forMAtion of first-triMester deciduA
The endometrium transforms during the secretory phase into a well vascularised re-
ceptive tissue in response to oestradiol and progesterone. Influx of uterine NK (uNK) 
cells, decidual remodelling and angiogenesis are dominating features in this stage and 
continue in the presence of fertilisation and implantation. The differential presence of 
hormones, extra-villous trophoblasts, and uNK cells results in the generation of differ-
ent types of decidua; pregnancy-induced hormones are involved in the development 
of decidua parietalis (DP) from the decidual secretory endometrium (DSE), while the 
additional presence of the extra-villous trophoblast (EVT) induces the generation of the 
decidua basalis (DB).
The invasion of immune cells to the implantation site is enormous; from 8% of total 
stromal cells during the menstrual cycle up to 30% during the first-trimester. Approxi-
mately 70 % of these leucocytes are uNK cells and 10% are macrophages [Bulmer et al., 
1991]. Various growth factors and cytokines are expressed by uNK cells, including the 
angiogenic factors and proteases Ang-1, Ang-2, TIE-2, VEGF-c, PlGF, uPA, uPAR and 
MT1-MMP [Al-Atrash et al., 2001; Albertsson et al., 2000; Hanna et al., 2006; Lash et 
al., 2006; Li et al., 2001]. Consequently, an influx of uNK cells and macrophages may 
influence angiogenesis, decidualisation and implantation.
For that reason, we evaluated the presence of these cells in the three types of decidua. 
uNK cells (CD56+) and macrophages (CD68+) were present in DSE, DP and DB. The 
percentage of uNK cells showed an increase in DP and DB compared to DSE, while a 
comparable increase in macrophages did not reach statistical significance.
The foregoing information is summarised in a model, which describes the influences of 
uNK cells, EVT and pregnancy-induced hormones on DSE, DP and DB (Figure 1). This 
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model enables hypothesising about vascular changes that occur independently of tro-
phoblast invasion, and those that are mainly induced by pregnancy-induced hormones 
and/or uNK cells.
VAscuLArisAtion pAtterns in first-triMester deciduA
Vascular adaptation to pregnancy is not well studied in human tissues and as a con-
sequence, the regulation of decidual vascularisation is not clear. In rats, two separate 
mechanisms appear to control endothelial cell proliferation during implantation; a 
maternal control mechanism throughout the endometrium during the first days after 
fertilisation and a second post-implantation mechanism in the vicinity of the embryo 
[Goodger, Rogers 1993]. However, whether human decidual vascular adaptation to im-
plantation is regulated by hormones, immune cells and/or the EVT and which media-
tors are used is unknown. In order to evaluate this, we determined the vascularisation 
 
 
Chapter 9, figure 1 
figure 1. Schematic representation of the contributors to the formation of decidua parietalis and decidua 
basalis out of decidual secretory endometrium in the first-trimester of pregnancy. *) hCG, oestradiol and 
progesterone. DSE and DP express cytokeratin in (open arrows), whereas cytokeratin is also expressed in 
EVT (closed arrows) of DB. Bar =100 µm.
(see figure 5 of chapter 6 in colour figures supplement)
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pattern and expression of angiogenic factors in decidual secretory endometrium (DSE), 
decidua basalis (DB) and decidua parietalis (DP).
Differences in vascularisation pattern, enhanced total vascular surface and luminal 
diameter and reduced vessel density, from decidual secretory endometrium (DSE) to 
decidua parietalis (DP) to decidua basalis (DB). This vascular adaptation appeared to 
occur under influence of pregnancy-induced hormones, uNK cells, and the EVT. The 
reduced vascular density at the implantation site has been described before in rats and 
was suggested to result from oedema [Goodger, Rogers 1993]. However, the vascular 
density still differed after correction for oedema. The increase in luminal diameter may 
represent an adaptation to increased blood flow or may be due to vasodilatation re-
ported to occur prior to infiltration of endovascular trophoblasts [Charnock-Jones 2002; 
Huppertz, Peeters 2005]. Furthermore, increased vessel diameter could also be induced 
by a relatively low oxygen level, which has been shown previously for pregnancies at high 
altitude [Zhang et al., 2002]. The enlargement of the total vascular surface in DB and 
DP has been reported previously and likely is functionally related to the increased blood 
supply required to serve the growing demands of the foetus. [Gibbons, Dzau 1994; Kam 
et al., 1999].
Angiogenic fActors in first-triMester deciduA
The differential vascular pattern in various decidual tissues enlarged our interest in 
vascular regulation. Endometrial vasculature already undergoes expansion during the 
pre-implantation period. Apparently the embryo prepares its implantation site by stimu-
lating angiogenesis before any physical contact between embryo and endometrium has 
been made. We demonstrate that the human blastocyst is able to stimulate in vitro an-
giogenesis via the production of significant amounts of vascular endothelial growth 
factor-A (VEGF-A). Das et al., reported comparable events during rabbit implantation 
[Das et al., 1997a]. In humans, VEGF has been shown to be one of the earliest genes acti-
vated during pre-implantation embryo development [Krussel et al., 2003]. Thus, VEGF-A 
appears to be a crucial contributor to the inception of pregnancy.
We attempted to further reveal whether VEGF-A and other angiogenic factors are media-
tors in the regulation of the described differential vascularisation. in the three types of 
decidua, DSE, DP and DB. VEGF-A was abundantly, but not differentially, expressed in 
all decidual tissues. KDR and flt-1 and VEGF proteins were expressed on endothelium 
of both DB and DP. Together, these findings confirm both the role of VEGF in decidual 
angiogenesis throughout implantation and the hypothesis of VEGF being an important 
factor during implantation.
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Other mediators appeared to play their role more locally at the implantation site. The 
abundant induction of PlGF mRNA and proteins in decidua basalis in general and of 
PlGF and Flt-1 proteins on endothelial cells in particular was remarkable. PlGF, via Flt-1, 
is able to potently induce angiogenesis resulting in mature and stable vessels [Arroyo et 
al., 2004; Carmeliet et al., 2001; Khaliq et al., 1996; Luttun et al., 2002; Torry et al., 1999]. 
These are important features in facilitating and resisting the dramatic increase in blood 
supply at the implantation site to serve the growing demands of the foetus. Furthermore, 
the Ang-2/Ang-1 ratio was elevated in decidua basalis (DB), which suggests that vessel 
destabilisation is favoured over vessel maturation in DB. Overall, the angiopoietins, via 
TIE-2, and PlGF, via Flt-1, appear to be key regulators of the vascular adaptive process 
and may, partially, account for the vascular changes at the site of embryonic implanta-
tion in decidua basalis.
Solely locating numerous angiogenic growth factors in human decidua presents a prob-
lem in understanding the coordination of local events in new vessel growth, as most of 
these factors display differing effects not necessarily related to angiogenesis. It must 
be remembered that the mere presence of a particular growth factor does not indicate 
functional availability and that further studies have to be performed to elucidate vascular 
regulation.
periceLLuLAr proteAses in first-triMester deciduA
Proteolysis is imperative during the adaptation to implantation since trophoblasts, 
uNK cells and endothelial cells require proteolytic activity to migrate. Key regulators 
of proteolysis belong to the family of matrix metalloproteinases (MMPs), in particular 
to the subgroup of membrane-type matrix metalloproteinases (MT-MMPs), and to the 
plasmin/plasminogen system [Alfano et al., 2005; Kindzelskii et al., 2004; Reuning et 
al., 2003]. A synergistic effect of both systems on decidual vascularisation in mice has 
been shown by Solberg et al. MMP inhibition altered the differentiation of the decidua, 
whereas loss of both MMP and uPA/plasmin was necessary to alter decidual vascularisa-
tion and induce embryonic lethality [Solberg et al., 2003]. In light of these observations, 
the PA/plasmin system and MT-MMPs were also evaluated in human decidua.
The expression of various pericellular-acting proteases varied between DSE, DB and DP. 
This differential expression enabled hypothesising about their functions as well as their 
regulation (Figure 1). Regarding their regulation, uPAR and MT1-MMP appeared regu-
lated by pregnancy-induced hormones and/or uNK cells, whereas the presence of uPA, 
MT2-, MT3-, and MT5-MMP appeared regulated by the extra-villous trophoblast.
Possible decidual functions of the proteases may involve trophoblast invasion, immune 
cell migration, and /or vascularisation. All proteases were expressed by the EVT, which 
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suggests involvement in trophoblast invasion. Whether the proteases are involved in 
immune cell migration could not be answered from our data and is neither supported 
nor contradicted by the equal presence of immune cells in DB and DP. However, the 
expression of proteases by stromal decidual cells (our finding) and uNK cells enables 
both autocrine and paracrine influences on immune cell infiltration [Albertsson et al., 
2000; Kim et al., 2000].
An interesting observation came into view with regard to their possible role in vasculari-
sation. Endothelial and perivascular smooth muscle cell MT2- and MT3-MMP antigens 
were less abundantly present in DP and DB as compared to DSE. The endothelial amount 
of these MT-MMPs correlated well with the vessel density and correlated inversely with 
the luminal surface of vascular structures. This differential MT2- and MT3-MMP expres-
sion, together with the fact that MT2- and MT3-MMP are likely candidates for regulation 
of angiogenesis, suggests a role for MT2- and MT3-MMP in the regulation of vascularisa-
tion at the implantation site in vivo. Their reduced endothelial expression might indicate 
a control mechanism which prevents too vigorous endothelial migration and thereby too 
fast vascular remodelling. This has not been described previously. Whether MT-MMPs 
act as crucial contributors, or merely as trivial bystanders, to implantation remains to 
be elucidated.
Angiogenesis, proteAses And Angiogenic fActors in LAte first-
triMester pregnAncy
As gestation progresses, vascular adaptation continues and is represented by decreased 
vessel density and a non-significant increased luminal surface in DB and DP. These 
vascular changes correlated with decreased total and endothelial expression of MT1-, 
MT2- and MT3-MMP proteins, whereas endothelial expression of PlGF and VEGF was in-
creased in late first-trimester. The increased levels of growth factor and decreased levels 
of proteases in endothelial cells at the implantation site appear contradictive. Possibly, 
the regulatory mechanisms alter as gestation proceeds, perhaps under the influence 
of changing concentrations of hormones. The observed induced endothelial VEGF and 
PlGF might be correlated to the enhanced vascular remodelling, whereas the reduced 
endothelial MT-MMP expression might control vascular infiltration. Furthermore, the 
reduced overall MT-MMP expression might function in controlling a too destructive 
infiltration of EVT.
C
ha
pt
er
 9
156
Angiogenesis, proteAses, Angiogenic fActors And iMMune ceLLs in 
MiscArriAge
Vascularised, decidua is important for implantation and disturbances in vascular de-
velopment may play a role in the pathogenesis of miscarriages. Few studies have ad-
dressed this hypothesis; higher decidual vessel density and differential expression of 
VEGF and its receptors were correlated with miscarriages [Vailhe et al., 1999; Vuorela 
et al., 2000]. Additionally, differential MMP and TIMP expression has been detected in 
receptive endometrium of recurrent miscarriage patients [Inagaki et al., 2003b, Jokimaa 
et al., 2002].
We demonstrated the importance of vascular remodelling for implantation. The occur-
rence of miscarriage was associated with altered vascularisation: significant decreased 
vessel density and increased luminal surface in DB and DP in decidua of miscarriages. 
The vascular differences correlated with the differential expression of angiogenic factors 
and proteases at the implantation site of miscarriages. Furthermore, the endothelial 
antigen expression of Flt1, KDR and MT2- and MT5-MMP was enhanced in DP and DB 
of miscarriages. Surprisingly, PlGF, the most regulated factor in uncomplicated first-
trimester decidua, appeared not to be involved in the pathogenesis of missed abortions. 
Overall, more angiogenic activity generated by angiogenic growth factors as well as pro-
teases, appeared to be generated in decidua of miscarriages.
The altered vascularisation and expression of angiogenic factors in miscarriages must 
have an embryonic or a maternal origin. The first category remains fairly hypothetical and 
might include genetical modifications, like polymorphisms and mutations, which pos-
sibly result in changed expression of angiogenic factors. These DNA variations are not 
detectable by conventional karyotyping techniques and therefore performing karyotyping 
would not have helped clarify this hypothesis. In addition, previously no differences in 
the number of leucocytes, in uNK cells and macrophages, and in decidual architecture 
were previously detected between chromosomally normal and abnormal pregnancies 
[Greenwold et al., 2003; Quack et al., 2001; Shimada et al., 2006]. Thus, the lack of 
karyotyping will probably not significantly bias our observations.
Maternal-related causes might include a fundamentally disturbed angiogenic reaction 
to fertilisation and implantation. Strikingly, this “miscarriage vascularisation” resembles 
the differences between early and late first-trimester vascularisation, suggesting that 
too fast maturing vasculature is associated with the pathogenesis of miscarriages. The 
pre-maturely ripening may allow maternal blood in the intervillous space too early in the 
development of pregnancy, also demonstrated in vivo by doppler ultrasound imaging 
[Greenwold et al., 2003; Jauniaux, Burton 2005]. The early-onset of maternal circula-
tion could result in increased oxygen levels with subsequent oxidative stress. This could 
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modulate the architecture of vasculature and the expression of peri-cellular proteases 
and angiogenic factors [Burton 1997; Kingdom, Kaufmann 1997; Sharkey et al., 2000].
Another maternal cause might be the altered regulation of oxygen levels, resulting in 
an even more hypoxic situation then during uncomplicated implantation. The rela-
tive “super-hypoxic” situation can induce non-branching angiogenesis and affect the 
expression of various angiogenic factors. These compensatory mechanisms generate 
the needed increase in blood supply, but may occasionally induce disproportionate an-
giogenic activity and set the stage for embryonic loss [Burton 1997, Khaliq et al., 1999; 
Kingdom, Kaufmann 1997; Regnault et al., 2003; Sharkey et al., 2000; Zhang et al., 
2002]. This hypothesis is confirmed by the described increased vascular area and altered 
VEGF expression and Ang-2/Ang-1 ratio, but not by the unchanged PlGF expression in 
miscarriage decidua. A shortcoming of this hypothesis is that the effects of oxygen on 
vascularisation and the expression of angiogenic factors are derived from experiments 
in term placental tissue and whether these effects are true in first-trimester decidua has 
not been described yet.
Conclusions from histo-pathological studies of abortion tissue are often questioned 
since foetal death may occur days before evacuation, allowing post-mortem inflamma-
tion or apoptosis during this “retention time”. Retention time has been reported to 
have no effect on vascularisation [Lisman et al., 2004; Meegdes et al., 1988; Nelen et 
al., 2000], which appears to exclude a contribution of “retention time” to the observed 
vascularisation differences between miscarriages and controls. To analyse whether our 
specimens demonstrated differential inflammatory or apoptotic events in response to 
foetal death, we determined proliferation, apoptosis and the number of immune cells.
Ki67 and active Caspase-3 (aCasp-3) showed similar expression patterns suggesting 
an increased cellular turnover from DSE, to DP to DB in both cases and controls. The 
cases and controls showed equal amount of proliferation and apoptosis, thus indicating 
that increased apoptotic events in the miscarriage samples are unlikely. Comparable 
numbers of uNK cells were demonstrated in DP and DB of cases, but their number 
was significantly increased in DSE. Most reports on the relation of uNK cells to miscar-
riages describe increased uNK cells in receptive endometrium of patients with recurrent 
miscarriages (RM) [Quenby et al., 1999; Tuckerman et al., 2007]. The abundant presence 
of NK cells in our DSE samples may reflect these observations. The difference between 
cases and controls were levelled in DP and DB, possibly by hormone regulated NK cell 
migration to normal values [van den Heuvel et al., 2005b].
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Angiogenic fActors in pre-ecLAMpsiA And foetAL groWth 
restriction
Both pre-eclampsia (PE) and foetal growth restriction (FGR) are extensively studied in 
serum/plasma, third-trimester tissues and also, too a smaller extent, by in vitro models 
[Chung et al., 2004; Eriksson Hagen et al., 2005; Geva et al., 2002; Maynard et al., 2003; 
Sugimoto et al., 2003]. Information about first-trimester molecular and morphological 
events would be very valuable.
Current knowledge suggests that the pathogenesis of PE starts with defective vascular 
remodelling of maternal spiral arteries leading to non-invasion of trophoblasts, placen-
tal insufficiency and ischemia [Luttun, Carmeliet 2003; Zhou et al., 1997]. The diseased 
placenta releases soluble anti-angiogenic factors, like soluble flt-1 (sFlt-1) and endoglin 
(sEng). These factors alter the angiogenic balance, mainly by neutralising VEGF-A and 
PlGF, induce systemic endothelial dysfunction and finally clinical PE [Ahmad, Ahmed 
2004; Clark et al., 1998; Fisher 2004; Hayman et al., 1999; Maynard et al., 2003; Sug-
imoto et al., 2003; Tjoa et al., 2007; Yuan et al., 2005]. FGR, or Foetal growth restriction 
(FGR), has been proposed to be induced by relatively high oxygen levels, which cause 
disturbed expression of angiogenic factors and altered angiogenesis in placental villi 
[Burton 1997; Kingdom, Kaufmann 1997; Regnault et al., 2003]. These relative hyperoxic 
conditions may explain the decreased VEGF and increased PlGF expression found in 
FGR placentas, since both factors are inversely regulated by oxygen [Lyall 1997; Khaliq 
et al., 1999]. Whether the altered oxygen levels also affect decidual angiogenesis is not 
documented, but is likely.
We showed that pre-eclampsia and foetal growth restriction were both associated with 
the induction of angiogenic factors in first-trimester decidua. Unfortunately, the study 
groups are small because of the rarity of the samples. This results in rather high stan-
dard deviations, which prevents significance and makes interpretation of the data dif-
ficult. However, the 10 to 100-fold induction of genes in these small groups promises 
significant differences when groups could be expanded.
The early first-trimester changes in angiogenic factor expression may well occur as a com-
pensatory mechanism, but in turn may unintentionally induce increased non-branching 
angiogenesis, altered decidual and placental vascularisation and insufficiency that result 
in pre-eclampsia and/or foetal growth restriction during late gestation.
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future perspectiVes
This thesis includes studies focussing on angiogenesis and its regulation in human en-
dometrium and decidua and provides new insights into the regulation of endometrial 
and decidual angiogenesis
In human, very little work has been done in relation to decidual angiogenesis apart 
from few studies focussing on the location of numerous angiogenic growth factors. This 
approach presents a problem in understanding the coordination of local events in new 
vessel growth and its controls and limits, as most of these factors display widely differ-
ing effects. It must be remembered that the presence of a growth factor does necessarily 
indicates functional availability. Therefore, observations obtained from these in situ stud-
ies have to be accompanied by in vitro studies in order to confirm and further elucidate 
the mechanisms controlling decidual vascular development. For example, analysing the 
involvement of uNK cells and the role of MT2- and MT3-MMP, but also MT5-MMP, in 
regulating capillary like tube formation in vitro will be very interesting. However, it is es-
sential to optimise the in vitro tube formation model to the “decidual situation” in order 
to obtain valuable results.
The interaction between EVT and vascularisation and the regulation of angiogenic factors 
and proteases by pregnancy-induced hormones, uNK cells and/or the extravillous tro-
phoblast is best studied in vitro. The first item can be studied by performing co-cultures 
of trophoblasts and endothelial cells and for example subsequent gene expression profil-
ing. The latter item is probably best studied by analysing the effect of the three possible 
regulators on separate cell types. In addition, determining the presence of hormone 
receptors is imperative as well. Merely the combination of in vivo and in vitro assays will 
achieve the understanding of human implantation.
Additionally, the interesting regulatory effects of hypoxia on decidual vascularisation 
must be further elucidated. The oxygen level in the different types of first-trimester de-
cidua, DSE, DP and DB, has to be established and the regulation of angiogenic factors 
and proteases in first-trimester tissues by oxygen has to be determined. This information 
will contribute to a better understanding of oxygen mechanisms in both physiologic 
and pathologic pregnancies. Moreover, new morphological imaging as well as new ul-
trasound techniques and measurements hopefully will allow quantification of altered 
angiogenesis and blood flow in physiologic and complicated first-trimester pregnancies 
and pregnancies complicated by miscarriage, PE and FGR.
Another promising future research subject is the role of endothelial progenitor cells 
during pregnancy. Endothelial progenitor cells are mobilised from the bone marrow by 
oestrogen and are proposed to play an important role in the regulation and maintenance 
of vasculature during pregnancy. Their increased mobilisation, probably via ischemia, 
may underlie pre-eclampsia [Robb et al., 2007].
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Finally, angiogenesis and its regulation in endometrium and decidua is a fascinating re-
search topic. Angiogenesis and various angiogenic factors and proteases appear crucial 
contributors to the inception of pregnancy. The obtained knowledge adds to a better 
understanding of physiologic and pathologic conditions regarding menstruation and 
pregnancy.
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Angiogenesis and pericellular proteases in cycling endometrium
•	 Tube formation by endometrial endothelial cells depends on uPA/plasmin and MMPs (ch. 
2).
•	 MT3-MMP is a potential regulator of endometrial angiogenesis in vitro (ch. 2).
•	 MT-MMPs are expressed in endometrium in a cycle-dependent pattern (ch. 3).
•	 MT2- and MT3-MMP appear associated with endometrial angiogenesis in vivo, which is a 
confirmation of earlier in vitro data (ch. 3).
contributors to the formation of first-trimester decidua
•	 Pregnancy induced hormones, i.e. oestradiol, progesterone and hCG, uterine NK cells and 
the extra-villous trophoblast are the main regulators of decidual development (ch. 5, 6).
Vascularisation patterns in first-trimester decidua
•	 The extra-villous trophoblast (EVT), the pregnancy-induced hormones (oestradiol, 
progesterone and hCG), and uterine NK cells contribute to vascular regulation (ch. 5).
•	 Vasculature at the implantation site displays fewer vessels with greater circumference and 
an enlarged total vascular area (ch. 5).
Angiogenic factors in first-trimester decidua
•	 The human embryo is able to stimulate decidual angiogenesis via VEGF-A (ch. 4).
•	 VEGF-A is probably involved in vascularisation in all decidual tissues (ch. 5).
•	 PlGF, via Flt-1, and the angiopoietins appear to be related to decidual angiogenesis at the 
implantation site (ch. 5).
pericellular proteases in first-trimester decidua
•	 The pericellular proteases, uPA (and uPAR), MT1-, MT2-, MT3- and MT5-MMP were 
differentially regulated by the EVT, pregnancy-induced hormones, and uterine NK cells (ch. 
6).
•	 All MT-MMPs might be involved in trophoblast and uNK cell invasion, whereas MT2- and 
MT3-MMP also appear to contribute to decidual vascularisation (ch. 6).
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Angiogenesis, proteases and angiogenic factors in late first-trimester pregnancy
•	 Decidual vascularisation is altered as gestation progresses, showing less but larger vessels 
(ch. 5).
•	 This altered vascularisation correlated with elevated expression of VEGF and PlGF and 
decreased expression of MT1, MT2- and MT3-MMP in endothelium and in general (ch. 
5/6).
Vascularisation and miscarriage, pre-eclampsia and foetal growth restriction
•	 Decidual vascularisation appears to adapt too rapidly to embryonic implantation in 
miscarriage (ch. 7).
•	 The disturbed vascular development correlated with differential expression of angiogenic 
factors and proteases (ch. 7).
•	 Altered expression of angiogenic factors in first-trimester decidua appears correlated with 
the pathogenesis of pre-eclampsia of foetal growth retardation later in pregnancy (ch. 8).
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suMMAry
Endometrial angiogenesis is indispensable for the formation of a richly vascularised re-
ceptive endometrium and decidua. The endometrium is a unique tissue which undergoes 
rapid remodelling during each menstrual cycle. During the secretory phase endometrial 
receptivity is enhanced by stimulation of oestradiol and progesterone. This process is 
called pre-decidualisation. By secretion of prostaglandin, cytokines and hCG the blas-
tocyst will further induce decidualisation of the endometrium at the implantation site, 
and eventually throughout the endometrium. Vascularisation during decidualisation 
and in the decidua is of importance for the success of the embryo-maternal interaction. 
Disturbances in vascular development may play an important role in pathologies during 
pregnancy. For instance, early pregnancy wastage, pre-eclampsia (PE) and foetal growth 
restriction (FGR) are disorders associated with impaired angiogenesis.
Angiogenesis is a multi-step process involving degradation of the basal membrane, 
activation, migration and proliferation of endothelial cells and finally the formation of 
capillaries and the recruitment of pericellular smooth muscle cells. Numerous factors 
are involved in these processes, e.g. vascular endothelial growth factor (VEGF), pla-
cental growth factor (PlGF), angiopoietins and proteases, each of which can regulate 
the process in different ways. Pericellular proteolysis plays an important role in angio-
genesis being required for endothelial cell migration, invasion and tube formation. Key 
regulators of proteolysis belong to the family of matrix metalloproteinases (MMPs), in 
particular to the subgroup of membrane-type matrix metalloproteinases (MT-MMPs), 
and to the plasmin/plasminogen system. However, neither the timing of vascular growth 
during the menstrual cycle and implantation, nor the mechanisms by which vessels are 
formed are currently completely understood.
In chapter 2 we studied the expression of MMPs and urokinase-type plasminogen 
activator (uPA) by human endometrial microvascular endothelial cells (hEMVEC) and 
their involvement in the formation of capillary tubes. We demonstrated that both uPA/
plasmin and MMPs, expressed by hEMVEC, contribute to the invasion and tubular 
structure formation of hEMVEC in 3D fibrin matrices. MT1-, MT2- and MT3-MMP are 
known inducers of capillary-tube formation and their mRNA levels increase during tube 
formation in vitro. Experiments with overexpression of MMP inhibitors (tissue inhibitor 
of matrix metalloproteinases (TIMP) -1 and -3), which are also expressed by endometrial 
endothelial cells in vivo, indicated that hEMVEC utilise a unique pattern of MT-MMPs 
during angiogenesis compared to endothelial cells originating from other tissues. The 
relative high expression of MT3-MMP mRNA in hEMVEC, the presence of MT3-MMP 
protein on endometrial endothelial cells and the inhibition of capillary tube formation by 
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inhibiting MT3-MMP are strongly in favour of a contribution of MT3-MMP in capillary-
like tube formation by hEMVEC. This was a striking finding, since up to now MT1-MMP 
was thought to be the most important MT-MMP involved in angiogenesis.
Although membrane-type-3 metalloproteinase (MT3-MMP) appeared associated with 
endometrial capillary-like tube formation in vitro, the involvement of MT-MMPs with 
endometrial angiogenesis in vivo is unknown. chapter 3 describes the presence of MT-
MMPs (MT1-MMP to MT6-MMP) in human endometrium and their correlation with 
endometrial neovascularisation. The various MT-MMP antigens were expressed in 
the various cell types of the endometrium. Their presence was decreased during the 
early secretory phase, which might suggest a contribution to the generation of a stable 
environment in preparation for embryonic implantation. Only MT2-, MT3- and MT4-
MMP antigens were expressed by endothelial cells. Strikingly, this vascular expression 
of MT2- MT3- and MT4-MMP correlated with angiogenic episodes of the cycle. These 
findings support earlier in vitro data on the regulatory role of MT3-MMP in endometrial 
angiogenesis. Additionally, MT2-MMP appears to be associated with endometrial neo-
vascularisation as well.
Whereas the previous chapters concentrate on endometrial angiogenesis, chapters 4-8 
focus on decidual angiogenesis. We demonstrated in chapter 4 that the human blasto-
cyst is able to stimulate in vitro angiogenesis via the production of significant amounts 
of vascular endothelial growth factor A (VEGF-A). This inducing effect was counteracted 
by adding soluble VEGF-R1 (flt-1). Other mediators, which have been described as pro-
duced by the early embryo/trophoblast, had no effect on tube formation by hEMVEC. 
This confirmed the hypothesis that VEGF-A plays a key role during early pregnancy and 
supports the finding that VEGF-A expression is reduced in trophoblastic tissue and in 
maternal endometrium of recurrent miscarriage cases.
chapter 5 evaluates vascular adaptation to implantation by studying vascularisation and 
angiogenic factors in decidual secretory endometrium (DSE) decidua parietalis (DP), and 
basalis (DB) of first-trimester pregnancies. The vascularisation pattern differed among 
the three tissues, for example an enhanced vascular and luminal surface and reduced 
vessel density were found at the implantation site. This raised questions regarding the 
regulation of decidual vascularisation. Comparing the three tissues provided informa-
tion about the regulation of vascularisation and showed that both pregnancy-induced 
hormones and extra-villous trophoblast (EVT) influenced vascularisation.
The observed vascular differences were also correlated to the differential expression of 
angiogenic factors. VEGF-A mRNAs and proteins were abundantly, but not differentially, 
expressed in all decidual tissues and KDR, flt-1 and VEGF-A proteins were expressed on 
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endothelium of both DB and DP. These findings suggest a role for VEGF-A in supporting 
decidual angiogenesis throughout implantation and further confirm the hypothesis of 
VEGF-A being an important factor during implantation.
Other mediators, like PlGF and the angiopoietins, appeared to have a specific role at the 
implantation site. These factors may, partially, account for the vascular changes at the 
site of embryonic implantation in decidua basalis.
Proteolysis is essential for decidual development during embryonic implantation. There-
fore, the decidual expression of pericellular proteases was studied in chapter 6. The 
expression of MT-MMPs and urokinase/urokinase receptor (uPA/uPAR) varied between 
decidua basalis (DB), decidua parietalis (DP) and decidual secretory endometrium 
(DSE). This enabled hypothesising about their regulation by pregnancy-induced hor-
mones, immune cells and/or the extra-villous trophoblast (EVT) and their relationship 
with decidual remodelling, trophoblast invasion and vascularisation. uPAR and MT1-
MMP appeared to be regulated by pregnancy-induced hormones and uPA, MT2-, MT3-, 
and MT5-MMP by EVT. All proteases were expressed by the EVT themselves and might 
be involved in trophoblast invasion. Furthermore, MT2- and MT3-MMP may also regu-
late vascularisation at the implantation site.
Additionally, decidual vascularisation and its regulation were compared between early 
and late first-trimester in chapter 5 and 6. As gestation progresses, vascular adapta-
tion continues and is represented by decreased vessel density and a non-significant in-
creased luminal surface in DB and DP. These vascular changes correlated with increased 
endothelial expression of PlGF and VEGF-A in late first-trimester. Also, decreased total 
and endothelial expression of MT1-, MT2- and MT3-MMP proteins were observed in later 
gestation, which might function in controlling a too destructive infiltration of endothelial 
cells and extra-villous trophoblasts.
chapter 7 describes vascular adaptation to implantation in missed abortions. A sig-
nificant decreased vessel density and increased luminal surface was demonstrated in 
DB and DP in decidua of miscarriages. Strikingly, these differences in vascularisation 
patterns resemble the differences between early and late first-trimester vascularisation, 
suggesting that too fast maturing vasculature is associated with the pathogenesis of 
miscarriages.
The vascular differences between missed abortions and controls correlated with the 
differential expression of angiogenic factor, showing an induction of VEGF-A, VEGF-
receptor-1 and -2 (flt-1and KDR), the angiopoietins Ang-1 and Ang-2, angiopoietin re-
ceptor TIE-2, MT2-and MT5-MMP and reduction of MT3-MMP at the implantation site. 
Furthermore, the endothelial expression of flt1, KDR, MT2- and MT5-MMP antigens were 
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enhanced in DP and DB of missed abortions cases. Surprisingly, placental growth factor 
(PlGF), the most regulated factor in uncomplicated first-trimester decidua, appears not 
to be involved in the pathogenesis of missed abortions.
Differential inflammatory or apoptotic events, in response to foetal death, were excluded 
in our specimens, since cases and controls showed equal amounts of proliferation and 
apoptosis and comparable numbers of uNK cells in DP and DB. However, uterine natu-
ral killer (uNK) cells numbers were significantly increased in DSE. Most reports on the 
relation of uNK cells to miscarriages describe increased numbers of uNK cells in recep-
tive endometrium of patients with recurrent miscarriages (RM). The abundant presence 
of uNK cells in our DSE samples may reflect these observations.
Current knowledge suggests that the pathogenesis of pre-eclampsia (PE) includes de-
fective vascular remodelling of maternal spiral arteries, non-invasion of trophoblasts, 
placental insufficiency and ischemia and that foetal growth restriction (FGR) has been 
proposed to originate from defective angiogenic factor expression and angiogenesis in 
placental villi in response to relatively high oxygen levels.
Whether decidual angiogenesis is also affected was studied in chapter 8. We showed 
the differential mRNA expression of various angiogenic factors in first-trimester decidua 
of third-trimester PE and FGR patients compared to matched controls. The expression 
of VEGF-A, PlGF, KDR, Ang-1, Ang-2 and TIE-2 appeared unregulated in FGR cases and 
PlGF, Ang-1 and TIE-2 appeared upregulated in PE cases. Significance was not reached, 
which is probably due to the large inter-individual variation. This is rather normal for a 
pilot study but restricts data interpretation. However, the 10- to 100-fold gene induction 
in these small groups promises significant differences in expanded groups. The early 
first-trimester changes in angiogenic factor expression may well occur as a compensa-
tory mechanism, but in turn may unintentionally induce increased non-branching angio-
genesis, altered decidual and placental vascularisation and insufficiency that result in PE 
and/or FGR during late gestation.
In chapter 9 the results of the studies of this thesis are discussed. The obtained 
knowledge generated through this thesis adds to a better understanding of physiologic 
and pathologic conditions regarding menstruation and pregnancy. Additionally, recom-
mendations for future research are given. chapter 10 provides a final conclusion.
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sAMenVAtting
Angiogenese is essentieel voor het ontstaan van een zwangerschap, omdat het zorgt 
voor het ontstaan van een rijk gevasculariseerd en receptief endometrium dat toegan-
kelijk is voor implantatie van de blastocyst. Het endometrium is een uniek weefsel, dat 
gedurende elke menstruele cyclus enorme veranderingen doormaakt. De receptiviteit 
van het endometrium wordt gedurende de secretoire fase van de cyclus gestimuleerd 
door progesteron en oestradiol. Dit proces wordt pre-decidualisatie genoemd. De blas-
tocyst zal daarna op de plaats van implantatie verdere decidualisatie induceren door het 
lokaal uitscheiden van prostaglandinen, cytokinen en hCG. Uiteindelijk zal het gehele en-
dometrium decidualiseren. Dit wordt gekarakteriseerd door oedeem en de extravasatie 
van macromoleculen ter bevordering van de receptiviteit. Daarnaast is voldoende vas-
cularisatie belangrijk voor het succes van de implantatie. Verstoringen in de vasculaire 
ontwikkeling lijken een rol te spelen bij het ontstaan van zwangerschapscomplicaties, 
zoals miskraam, pre-eclampsie (PE) en intrauteriene groeivertraging (IUGR).
Angiogenese is een proces dat uit verschillende stappen bestaat, te weten degradatie 
van de basaalmembraan; activatie, migratie en proliferatie van endotheelcellen; en 
uiteindelijk de formatie van capillairen en het aantrekken van peri-vasculaire gladde 
spiercellen. Verschillende factoren zijn betrokken bij de regulatie van deze processen, 
zoals vascular endothelial growth factor (VEGF-A), placental growth factor (PlGF), an-
giopoietinen en proteases. Daarnaast speelt peri-cellulaire proteolyse een belangrijke 
rol in het angiogenese proces. Het is noodzakelijk voor endotheelcel-migratie, -invasie 
en capillairvorming. Belangrijke regulatoren van proteolyse zijn het plasminogeen acti-
vator/plasmine systeem, met onder meer urokinase (uPA) en zijn receptor (uPAR), en 
de matrix metalloproteinases (MMPs), in het bijzonder de membraangebonden MMPs 
(MT-MMP’s).
Zowel de manier waarop nieuwe vaten worden gevormd als de timing van vasculaire 
groei in de menstruele cyclus en de embryonale implantatie, zijn tot op heden groten-
deels onbekend.
In hoofdstuk 2 wordt de expressie van MMP’s en uPA door humane endometriale 
micro-vasculaire endotheelcellen (hEMVEC) en hun betrokkenheid bij de vorming van 
capillairen in vitro bestudeerd. Zowel uPA als MMP’s blijken een rol te spelen bij het tot 
stand komen van capillairen door hEMVEC. Naast uPA werden verschillende MMP’s 
aangetroffen in deze cellen.
Het is bekend dat MT1-MMP, MT2-MMP, en MT3-MMP angiogenese kunnen induce-
ren, en dat hun mRNA niveau stijgt tijdens capillairvorming in vitro. Een experiment dat 
gebruikmaakt van twee MMP-remmers (tissue inhibitor of matrix metalloproteinases 
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(TIMP-1 en -3)) toonde aan dat hEMVEC een unieke set MT-MMPs voor angiogenese 
gebruiken in vergelijking met endotheelcellen uit andere weefsels. De relatief hoge ex-
pressie van MT3-MMP mRNA in hEMVEC, de aanwezigheid van MT3-MMP eiwitten op 
endometrium endotheelcellen en de remming van capillairvorming door anti-MT3-MMP 
wezen allen op een rol van MT3-MMP in endometrium angiogenese. Dit was een verras-
sende observatie, aangezien tot op heden MT1-MMP als de belangrijkste MT-MMP in 
angiogenese werd beschouwd.
MT3-MMP lijkt dus geassocieerd met endometriale capillairvorming in vitro, maar het 
is onduidelijk of dit ook in vivo het geval is. hoofdstuk 3 beschrijft de expressie van MT-
MMP’s en hun correlatie met vascularisatie in humaan endometrium. Alle MT-MMP’s 
werden aangetoond in diverse celtypen in het endometrium en waren verminderd aan-
wezig tijdens de vroege secretoire fase van de cyclus. Dit wijst op een bijdrage van MT-
MMP’s aan de stabilisatie van het endometrium in voorbereiding op de embryonale 
implantatie. Alleen MT2-, MT3- en MT4-MMP antigenen kwamen tot expressie in endo-
theelcellen. Deze vasculaire expressie correleerde met angiogene perioden gedurende 
de menstruele cyclus. Deze bevindingen ondersteunen eerdere data met betrekking tot 
de rol van MT3-MMP in endometrium angiogenese. Bovendien lijkt MT2-MMP ook ge-
associeerd met neovascularisatie in humaan endometrium.
De eerste hoofdstukken beschrijven angiogenese in het endometrium, maar de hoofd-
stukken 4 t/m 8 richten zich op angiogenese in humaan first-trimester decidua. Diermo-
dellen tonen aan dat het embryo zijn implantatie voorbereidt door het stimuleren van 
angiogenese, voordat sprake is van fysiek contact tussen embryo en endometrium. In 
hoofdstuk 4 wordt aangetoond dat de humane blastocyst in staat is tot het stimuleren 
van in vitro angiogenese door de productie van significante hoeveelheden VEGF-A. Dit ef-
fect kon worden geremd door toevoeging van oplosbaar flt-1. Eerder werd al aangetoond 
dat VEGF-A één van de eerste genen is die geactiveerd wordt tijdens de embryonale ont-
wikkeling in de pre-implantatie periode. De hypothese dat VEGF-A een sleutelrol vervult 
bij het tot stand komen van een jonge zwangerschap wordt verder bevestigd door de 
observatie dat de VEGF-A expressie in trofoblastweefsel verminderd is in endometrium 
van patiënten met herhaalde miskramen.
hoofdstuk 5 bestudeert de aan implantatie gerelateerde vasculaire veranderingen. 
Daartoe werden het vaatpatroon en de expressie van angiogene factoren bepaald in 1e 
trimester deciduaal secretoir endometrium (DSE), decidua pariëtalis (DP), en decidua 
basalis (DB). Deze deciduale weefsels toonden een verschillend vaatpatroon. Zo toonde 
decidua basalis, de plaats van implantatie, een toegenomen totale vasculaire opper-
vlakte in vergelijking met DP en DSE.
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Het vergelijken van de drie weefsels toonde dat zowel zwangerschapsgeïnduceerde hor-
monen als de extravilleuze trofoblast (EVT) vascularisatie beïnvloeden. Welke mediato-
ren betrokken zijn bij de regulatie van deze vasculaire veranderingen in de verschillende 
typen decidua werd bestudeerd in hoofdstuk 5. VEGF-A mRNA en proteïnen kwamen 
uitbundig tot expressie in alle typen decidua. VEGF-A proteïnen zowel als de receptoren 
voor VEGF-A, KDR en flt-1, werden aangetroffen op endotheelcellen in zowel DB als 
DP. VEGF lijkt dus angiogenese te ondersteunen in alle onderzochte decidua-typen. Dit 
bevestigt wederom de hypothese dat VEGF-A een belangrijke rol speelt in het implanta-
tieproces.
Andere mediatoren, zoals placental growth factor (PlGF) en de angiopoietinen, kwamen 
verhoogd tot expressie in decidua basalis (DB). Zij lijken dus specifiek een rol te spelen 
bij vascularisatie op de plaats van implantatie en zijn dus mogelijk medeverantwoorde-
lijk voor de vasculaire veranderingen in decidua basalis.
Proteolyse is belangrijk voor de ontwikkeling van decidua. De expressie van pericellulaire 
proteases in decidua werd daarom bestudeerd in hoofdstuk 6. Ook de regulatie door 
zwangerschapshormonen, immuuncellen en de EVT, en de relatie tot trofoblastinvasie 
en vascularisatie werden beschreven. De drie typen decidua toonden verschillende hoe-
veelheden MT-MMPs, urokinase-type plasminogeen activator (uPA) en uPA receptor 
(uPAR). MT1-MMP en uPAR bleken gereguleerd te worden door zwangerschapshormo-
nen; uPA, MT2-, MT3- en MT5-MMP door EVT. Alle proteases kwamen tot expressie in 
EVT en spelen mogelijk een rol bij trofoblastinvasie. Daarnaast lijken MT2- en MT3-MMP 
ook de vascularisatie te reguleren in decidua basalis.
In hoofdstuk 5 en 6 wordt vascularisatie vergeleken in vroege en late 1e trimester zwan-
gerschappen. Naarmate de zwangerschap vordert worden de aan implantatie gerela-
teerde vasculaire veranderingen steeds duidelijker, zoals een verminderde vaatdichtheid 
en een verhoging van lumen-oppervlakte in DB en DP. De veranderingen in het vaatbed 
correleren met een verhoogde expressie van PlGF en VEGF-A in endotheelcellen. Verder 
bleken de expressies van MT1-, MT2- en MT3-MMP in verschillende celtypen, inclusief 
endotheelcellen, verminderd in de late 1e trimester groep. Dit heeft mogelijk een functie 
in het controleren van de destructieve infiltratie van endotheel- en trofoblastcellen.
hoofdstuk 7 beschrijft de vasculaire aanpassingen aan implantatie in missed abortions 
(MA) in vergelijking met ongecompliceerde zwangerschappen. Een significant afgeno-
men vaatdichtheid en lumen-oppervlakte werden aangetoond in DB en DP van missed 
abortions. De verschillen in vaatpatronen tussen MA en controles zijn vergelijkbaar met 
de gevonden verschillen tussen vroege en late first-trimester zwangerschappen. Dit kan 
duiden op het te vroeg uitrijpen van het vaatbed in MA.
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De verschillen op vasculair gebied correleren met verschillende expressie van angiogene 
factoren. MA decidua toonde een verhoogde expressie van VEGF-A, VEGF receptor-1 en 
-2 (flt-1, KDR), de angiopoietinen Ang-1 and Ang-2, angiopoietine receptor TIE-2 MT2- en 
MT3-MMP en verlaagde expressie van MT3-MMP in decidua basalis. Verder bleek de 
expressie van flt-1, KDR, MT2- en MT5-MMP verhoogd in endotheelcellen in DB en DP 
van MA. PlGF, de meest gereguleerde factor in ongecompliceerde zwangerschappen, 
lijkt niet betrokken bij de pathogenese van MA.
De mogelijkheid dat de verschillen tussen beide groepen veroorzaakt worden door ont-
steking en apoptose in reactie op foetale dood lijkt verworpen te kunnen worden. De 
missed abortion en de controle groep tonen namelijk vergelijkbare apoptose-, prolife-
ratie- en ontstekingsparameters. Alleen het aantal uNK cellen in DSE was significant 
verhoogd in missed abortions. Enkele publicaties over de relatie van uNK cellen met 
miskramen wijzen op een verhoogd aantal uNK cellen in receptief endometrium van 
patiënten met herhaalde miskramen. De verhoogde aanwezigheid van NK cellen in DSE 
zou dit kunnen weerspiegelen.
Recente inzichten suggereren dat pre-eclampsie is geassocieerd met verstoorde re-
modellering van maternale spiraalarteriën, gevolgd door non-invasie van trofoblasten, 
placenta-insufficiëntie en ischemie. Intrauteriene groeivertraging (IUGR) lijkt te worden 
veroorzaakt door relatieve hyperoxie, gevolgd door angiogenese en expressie van angio-
gene factoren in villi. Of ook deciduale angiogenese een rol speelt, wordt onderzocht in 
hoofdstuk 8. De expressie van angiogene factoren in 1e trimester decidua van uiteinde-
lijke PE en IUGR patiënten is vergeleken met de expressie in decidua van een gematchte 
controlegroep. De expressie van VEGF-A, PlGF, KDR, Ang-1, Ang-2 en TIE-2 was verhoogd 
in IUGR, en de expressie van PlGF, Ang-1 en TIE-2 was verhoogd in PE. Vanwege de grote 
inter-individuele verschillen in deze pilot-studie zijn de bevindingen niet significant. Dit 
bemoeilijkt de interpretatie, echter de 10-100-maal inductie doet significante verschillen 
verwachten bij grotere groepen. De 1e trimester verschuivingen in de expressie van angi-
ogene factoren lijken te functioneren als een compensatiemechanisme. Dit verstoorde 
expressiepatroon kan tegelijkertijd non-branching angiogenese veroorzaken, met ver-
stoorde deciduale vascularisatie en PE en IUGR in een later trimester tot gevolg.
In hoofdstuk 9 worden de resultaten van deze thesis bediscussieerd, en worden aanbe-
velingen gedaan voor toekomstig onderzoek. hoofdstuk 10 geeft beknopt de conclusies 
van deze thesis weer.
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Ang-1  Angiopoietin-1
Ang-2  Angiopoietin-2
ANOVA  Analysis of Variance
APLA  Abortus Provocatus Lege Artis
BP  Blood pressure
cDNA  complementary DNA
CSF-1  Colony stimulating factor-1
Ct  Cycle threshold
CVS  Chorion villous sampling
dCt  Difference in Ct values
ΔdCt  Difference in ΔdCt values
DB  Decidua Basalis
DP  Decidua Parietalis
DSE Decidual Secretory Endometrium
EC  Endothelial cell
ECGF  Endothelial cell growth factor
ECM  Extracellular matrix
EGF  Epidermal growth factor
ELISA Enzyme-linked immunosorbent Assay
ER  Estrogen receptor
EP  Early proliferative
ES  Early secretory
EVT  Extra-villous trophoblast
FAM  6-carboxyfluorescein
FGR  Foetal growth restriction
Flt-1 Fms-related Tyrosine Kinase-1 or VEGF-Receptor 1
GA  Gestational age
GAPDH Glycerylaldehyde-3-phosphate dehydrogenase
GPI  Glycosyl-phosphatidylinositol
hCG  Human chorionic gonadotropin
hEEC Human endometrial epithelial cells
HELLP Haemolysis, elevated liver enzymes, low platelets
hEMVEC Human endometrial micro-vascular endothelial cells
hESC Human endometrial stromal cells
hFMVEC Human foreskin microvascular endothelial cells
HPS  Haematoxylin phloxin safrane
HRT  Hormonal replacement therapy
HS  Human serum
IFN  Interferon
IGF  Insulin-like growth factor
IgG  Immunoglobulin
IL  Interleukin
IVF  In vitro fertilisation
KDR Kinase insert Domain Receptor or VEGF-Receptor 2
LIF  Leukaemia inhibitory factor
LP  Late proliferative
LS  Late secretory
M  Menstruation
MAPK Mitogen-activated protein kinase
MMP  Matrix metalloproteinase
mRNA  Messenger ribonucleic acid
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MSI  Mean staining index
MT-MMP Membrane-type matrix metalloproteinase
NBSC  Newborn calf serum
PDGF  Platelet-derived growth factor
PE  Preeclampsia
PI3K  Phosphatidyl-Inositol-3-kinase
PlGF  Placental Growth Factor
PSMC Perivascular smooth muscle cell
SC  Stromal cell
SD Standard deviation
SEM Standard error of mean
S-Flt-1 Soluble Flt-1
SI Staining Index
RT-PCR Real time polymerase chain reaction
TAMRA  tetremethyl-6-carboxyrhodamin
TGF  Transforming growth factor
TIE-2 Tyrosine protein kinase receptor for Ang-1 and Ang-2
TIMP Tissue inhibitor of matrix metalloproteinase
TNF  Tumour Necrosis Factor
tPA Tissue-type plasminogen activator
TSI  Total staining index
VEGF Vascular endothelial growth factor
vWF  Van Willebrand Factor
uNK  Uterine Natural Killer cells
uPA Urokinase-type plasminogen activator
uPAR Urokinase-type plasminogen activator receptor
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De schrijfster van dit proefschrift werd geboren op 15 december 1975 te Dordrecht. Haar 
jeugd bracht zij door in Puttershoek, Zuid-Holland. Na het behalen van het eindexamen 
atheneum aan de Willem van Oranje Scholengemeenschap, te Oud-Beijerland, startte zij 
in 1994 met de studie Biomedische Wetenschappen aan de Universiteit Leiden. In 1996 
werd begonnen met de studie geneeskunde aan dezelfde universiteit. Tijdens de studie 
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zij enkele maanden in Bolgatanga, Ghana, en werkte daar aan een onderzoek naar Oeso-
phagostomum Bifurcum. Tevens was zij betrokken bij het onderzoek naar de rol van het 
immuunsysteem bij herhaalde miskramen, onder leiding van Prof. Dr. F.M. Helmerhorst 
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“We must not forget that when radium was discov-
ered no one knew that it would prove useful in hos-
pitals. The work was one of pure science. And this is 
a proof that scientific work must not be considered 
from a point of view of the direct usefulness of it. 
It must be done for itself, for the beauty of science. 
And then, there is always the chance that a scientific 
discovery may become like the radium.”
By Marie curie (1867 - 1934)
$PMPVS'JHVSFT
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Chapter 1, Figure 3.  
Sprouting
Intussusception
Elongation
Figure 2. Endometrial angiogenesis proceeds by elongation and intussusception rather than by classical 
sprout formation. Adapted from Rogers 1998.
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Chapter 2, Figure 1.  
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figure 1. Capillary-like tube formation by hEMVEC in a fibrin or collagen matrix depends on u-PA and MMP 
activities.
hEMVEC were cultured on top of a three-dimensional fibrin matrix (A,C,D) or 50-50% fibrin/collagen-type-1 
matrix (B,E) and stimulated with VEGF-A (10 ng/mL). A and B: Micrographs taken after 4 days of culturing; 
insets in A and B show details of capillary-like structures. Bar = 300 µm, Bar insets = 100 µm. C: Cross 
section perpendicular to the matrix surface and stained with Hematoxylin-Phloxine-Safran (bar = 50 µm). 
D and E: hEMVEC were cultured with 10 ng/mL VEGF-A (control) in the absence or presence of polyclonal 
anti-u-PA (αuPA, 100 µg/mL), BB94 (5 µg/mL) or a combination of BB94 and anti-u-PA. After 3-5 days 
of culturing, mean tube length was measured by image analysis. The data in panel D are expressed as a 
percentage of VEGF-A-induced tube formation ± SEM of 6 independent experiments of duplicate wells 
performed with 3 different hEMVEC isolations. Panel E represents 3 experiments. ∗: P<0.05 vs. control, #: 
P<0.05 vs. αuPA.
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Chapter 2, Figure 2.  
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Figure 2. hEMVEC express various MMPs and MT-MMPs.
hEMVEC were cultured for 24 h in M199 supplemented with 0.5% HSA (A) or 20% HS (B,C) and were 
not stimulated (control) or stimulated with TNFα (2.5 ng/mL), VEGF-A (10 ng/mL) or PMA (10-8 M), 
as indicated. A: Gelatin zymography of 24 h conditioned medium. (M = ladder) B: MT1-MMP activity in 
cell lysates (mean ± range of two experiments performed in duplicate wells with two different isolations; 
detection limit of the assay 0.2 ng/mL). C: Western blot of MT3-MMP in 24 h conditioned medium. D and 
E: Immunohistochemical analysis of MT3-MMP in endometrial tissue shows the presence of MT3-MMP in 
endothelial cells (D, arrows) and myometrium (E, stars).
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Chapter 3, figure 1 
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Figure 1. Vascularisation pattern in cycling human endometrium.
The vascularisation pattern in human endometrium was determined by image analysis of anti-CD34-
stained sections. Six fields per biopsy were scanned at 100x magnification. A CD34 antigen expression in 
endothelial cells in late proliferative endometrium (bar = 50 µm). B The total vascular surface (mm2/mm2), 
c the number of vessels per mm2 and d the luminal surface (µm2/vessel) were calculated for each sample 
and expressed as mean ± SEM. EP = Early proliferative phase (n=6), LP = Late proliferative phase (n=7), ES 
= Early secretory phase (n=6), LS = Late secretory phase (n=6), M = menstrual phase (n=2); • p<0.01 versus 
EP, ES and LS; # p <0.02 versus EP, ES; ∗ p<0.01 versus ES, LS and M; and $ p<0.05 versus ES, LS and M.
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Chapter 3, figure 2 
A. MT1-MMP 
E. MT3-MMP 
G. MT4-MMP 
H. v WF
I. Lysotracker 
C. MT2-MMP 
B. MT1-MMP + actin
F. MT3-MMP + actin
D. MT2-MMP + actin
figure 2. MT-MMP antigen expressions in hEMVEC.
Endothelial MT-MMP expression was determined by fluorescence microscopy (magnification 40x). The 
expression of MT1-MMP (± actin A, B), MT2-MMP (± actin c,d), MT3-MMP (± actin e,f), MT4-MMP (g), 
von Willebrand Factor in Weibel Palade bodies (h) and Lysotracker in lysosomes (i) in cultured endometrial 
endothelial cells (hEMVEC). The negative control only showed blue staining of the nuclei (not shown). Blue 
= DAPI in nuclei, green = target protein, red = actin or lysotracker.
C
ol
ou
r 
fig
ur
es
218
 
 
 
 
Chapter 3, figure 3 
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figure 3. MT-MMP antigen expressions in endometrial endothelium and other cell types.
The expression of MT-MMP antigens by endometrial endothelial cells was determined by 
immunohistochemistry. A. MT-MMP antigen expressions in endothelial cells expressed per cycle phase as 
mean staining index ± SEM (all p>0.05). The staining index is minimally 0 (no stained cells) and maximally 
9 (>50% strongly stained cells). B. MT1-MMP antigen detected in PSMCs (open arrow) but not in endothelial 
cells (arrows) in late proliferative (LP) endometrium. c. MT2-MMP antigen expression in endothelium in LP 
endometrium (arrow). d. MT3-MMP expression in endothelial cells (arrows) and stromal cells (open arrow) 
in LP endometrium. e. MT4-MMP expression in endothelial cells (arrow) in LP endometrium. f. Negative 
control. Bar = 50 μm.
  = Early proliferative phase (n=6),  = Late proliferative phase (n=7),  = Early secretory phase (n=6),
 = Late secretory phase (n=6),  = menstrual phase (n=6).
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Figure 2, Plaisier et al
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figure 2. Cytokeratin expression and vascularisation in the three decidual tissues.
Differentiation between three decidual tissues was obtained by HPS and anti-cytokeratin staining (top 
panel). DSE and DP expressed cytokeratin only in glandular epithelial cells (closed arrows), whereas 
cytokeratin is also expressed in extra-villous trophoblasts of DB (open arrows). The vascularisation pattern 
in human decidual tissues was determined by image analysis of anti-CD34-stained sections (middle and 
bottom panel). CD34 antigen expression in endothelial cells (arrows) of DSE, DP and DB was compared 
within subjects. Data were analysed using the repeated measures ANOVA. A. The number of vessels per 
mm2, B. the vascular surface per area (mm2/mm2) and c. the luminal surface (μm2/vessel) were calculated 
and expressed as mean ± SEM. ∗ p<0.0001; ♦ p< 0.04. Bar =100 μm.
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Chapter 5 figure 3 figure 3. Protein expression of angiogenic factors in endothelium of early first- trimester decidua.
The protein expression of angiogenic factors was determined in DSE, DP and DB. Friedman test, a non-
parametrical test for paired samples, and the Wilcoxon test were used for statistical analysis. A. Protein 
expression of each angiogenic factor in endothelium was expressed as the mean staining index ± SEM and 
B-h show examples of these expressions. B. Endothelial VEGF expression was not detectable in DB. c. PlGF 
was expressed in epithelium (open arrow) and endothelium (closed arrow) of DB. d. Endothelial KDR 
expression (closed arrow) and stromal KDR expression (open arrow) in DB. e. Endothelial Flt-1 expression 
in DB (arrow) f. Angiopoitein-1 in DB was detected in epithelium (open arrow), but not in stromal and 
endothelial cells (closed arrow). g. Endothelial angiopoietin-2 expression in DB (arrow). h. Endothelial 
TIE-2 expression in DB (arrow).  DSE,   DP,   DB. Bar = 100 µm (except F = 50 µm).
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Chapter 5 figure 4 
figure 4. Protein expression of angiogenic factors in extra-villous trophoblasts (EVT) of early first-trimester 
decidua.
The protein expression of angiogenic factors in EVT in decidua basalis (DB) was studied in serial sections 
stained against cytokeratin and the target protein. A. Protein expression in EVT was expressed as the mean 
staining index ± SEM. B. Cytokeratin (arrows) and c. serial PlGF expression (arrows) in EVT. Bar = 50 μm.
 
Chapter 5 figure 5 
 
 
figure 5. Vascularisation pattern and endothelial protein expression in early versus late first- trimester 
decidu .
The vascularisation pattern in human early (black bars) and late (white bars) first-trimester decidual tissues 
was determined by image analysis of anti-CD34-stained sections. Data were analysed using the repeated 
measures ANOVA. A. The number of vessels per mm2, B. the vascular surface per area (mm2/mm2) and c. 
the luminal surface (μm2/vessel) were expressed as mean ± SEM. VEGF expression was not detectable in 
early first- trimester endothelium of DB (arrow, d), whereas the expression was present in late first- trim. 
endothelium of DB (arrow, e). Early first- trimester and late first- trimester. Bar = 50 μm, ∗ p<0.04.
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Chapter 6 figure 1 
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figure 1. Protein levels of proteases in early first-trimester decidua.
The level of proteases was determined in DSE, DP and DB. A. MT1-MMP antigen was detectable in epithelial 
(open arrow), endothelium (closed arrow) and stromal cells (closed arrowhead) of DSE. B. MT2-MMP 
antigen in epithelium (open arrow), stromal cells (closed arrowhead) and pericytes (open arrowhead) of 
DB. c. Epithelial (open arrow) and stromal (closed arrowhead) MT3-MMP antigen in DB. Pericytes not 
present in this field. d. MT5-MMP antigen in epithelium (open arrow), and only dimly in stromal cells 
(closed arrowheads) of DP. e. uPA antigen in epithelium (open arrow), stromal cells (closed arrowhead) 
and endothelium (closed arrows) in DB. Pericytes not present in this field. f. Epithelial (open arrow), 
endothelial (closed arrows) and stromal cells (closed arrowheads) uPAR protein in DB. A-d,f Bar = 100 
µm, e. Bar = 50 µm.
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Chapter 6 figure 2 
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figure 2. Protein levels of proteases in endothelium of early first-trimester decidua.
A. Presence of protease antigens in endothelium (EC) was expressed as the mean staining index ± SEM and 
B-f show examples of endothelial protease expression. B. Endothelial (arrows) and stromal (arrowheads) 
MT1-MMP was detectable in DB. c. MT2-MMP was detected in endothelium (arrows) of DB. d. Endothelial 
MT3-MMP antigen (arrows) in DSE. e. uPA antigen in endothelium (closed arrows), epithelium (open 
arrow) and stromal cells (arrowhead) in DB f. uPAR in DB was detected in endothelial cells (arrows) and 
stromal cells (arrowheads). B-f. Bar = 50 µm.
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Chapter 6 figure 3 
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figure 3. Protein levels of proteases in villous and extra-villous trophoblasts (EVT) of early first-trimester 
decidua.
The presence of protease antigens in villous and extra-villous trophoblasts in decidua basalis (DB) was 
studied in serial sections stained against cytokeratin and the target protein. A. Immunostaining in syncytio- 
and cytotrophoblasts (synCTB and CTB) was expressed as the mean staining index ± SEM. B. and c. uPAR 
and cytokeratin antigens in serial expression in EVT (closed arrows) and epithelium (open arrows). d. uPA 
antigens in syncytiotrophoblast (open arrow) and not in cytotrophoblast (closed arrow). B-d. Bar = 50 
µm.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 figure 4 
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figure 4. CD56- and CD68- positive cells in early and late first-trimester decidua.
A. CD56-positive cells in decidua, expressed as the mean number of positive cells per total number of 
stromal cells (mean ± SD) B. CD68-positive cells in decidua, expressed as the mean number of positive 
cells per total number of stromal cells (mean ± SD). c. CD56 expression in decidua basalis, bar = 100 µm. 
Blow up shows CD56+ cells (arrows) surrounding a vessel and gland, bar = 50 µm d. CD68-positive cell 
(arrow) in decidua parietalis, bar = 50 µm. e. Negative control, bar = 100 µm. * p<0.05 versus DSE
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Chapter 6 figure 5 
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figure 5. Human first-trimester decidual tissues.
Representation of the influences of immune cells, extra-villous trophoblast and pregnancy-induced 
hormones (*hCG, oestradiol and progesterone) on first-trimester decidual tissues. Differentiation between 
decidual secretory endometrium (DSE), decidua parietalis (DP) and basalis (DB), was obtained by HPS 
and cytokeratin staining. DSE and DP express cytokeratin in glandular epithelium (open arrows), whereas 
cytokeratin is also expressed in EVT (closed arrows) of DB. Bar =100 μm.
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figure 1. Vascularisation pattern in cases and controls.
The vascularisation pattern in decidual tissues of controls (n=16, black bars) and cases (n=11, white bars) 
was determined by image analysis of anti-CD34-stained sections. A. Vessel density (number of vessels per 
mm2), B. the total vascular surface (mm2/mm2) and c. the luminal surface (μm2/vessel) were calculated 
and expressed as mean±SEM. # p<0.05 within controls, ∗ p<0.05 in cases versus controls. The bottom 
panels show examples of vascularisation in decidua parietalis and basalis of cases and controls.
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Plaisier et al
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figure 2. Antigen presence of angiogenic factors and proteases in cases and controls.
Examples of the antigen expression of Ang-1, Flt-1 and MT5-MMP in controls (left site of panel) and cases 
(right site of panel). Ang-1 antigen presence in epithelial cells (open arrow) in DB of controls, compared to 
their presence in stromal (closed arrow), epithelial cells (open arrow) and PSMC (open arrowhead) in DB 
of cases. flt-1 antigen presence in epithelial cells (open arrow) and stromal cells (closed arrow) in DB of 
controls, compared to their elevated presence in DB of cases. No vasculature present in these fileds. M5-
MMp antigens in epithelial cells (open arrow) in DB of controls, compared to their presence in PSMC (open 
arrowhead), endothelial (closed arrowhead), stromal (closed arrow) in DB of cases. negative controls using 
non-immune mouse IgG
1
 (left) and omission of the first antibody (right). All panels bar = 100 μm.
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Figure 3
Plaisier et al
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figure 3. Antigen presence of angiogenic factors and proteases in endothelium in cases and controls.
The protein expression of angiogenic factors and proteases was determined in DSE, DP and DB of cases 
and controls via immunohistochemistry. Examples of the differential endothelial expression (arrowheads) 
of flt-1, KDR and MT2-MMP between cases (right site of panel) and controls (left site of panel) are given. 
flt-1. Elevated flt-1 expression in endothelial cells in DB of cases compared to controls. kdr. Elevated 
KDR expression in endothelial cells in DB of cases compared to controls. Mt2-MMp. Elevated MT2-MMP 
expression in endothelial cells in DB of cases compared to controls. All panels bar = 50 μm.
